{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Merck, in 2022 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  | \n  |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n |   |  |  |  |  |  |  |  | \nNew Jersey | 22-1918501\n(State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.)\n | \n126 East Lincoln Avenue\nRahway | New Jersey | 07065\n(Address of principal executive offices) (zip code)  |  |  |  |  |  |  |  | \n | 2000 Galloping Hill Road,Kenilworth,New Jersey07033 | \n(Former name, former address and former fiscal year, if changed since last report.)  |  |  |  |  |  |  |  | \nSecurities Registered pursuant to Section\u00a012(b) of the Act:\nTitle of each class | Trading Symbol(s) | Name of each exchange on which registered\nCommon Stock ($0.50\u00a0par value) | MRK | New York Stock Exchange\n0.500% Notes due 2024 | MRK 24 | New York Stock Exchange\n1.875% Notes due 2026 | MRK/26 | New York Stock Exchange\n2.500% Notes due 2034 | MRK/34 | New York Stock Exchange\n1.375% Notes due 2036 | MRK 36A | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 | Accelerated filer | \u2610\n |  |  | \nNon-accelerated filer | \u2610 | Smaller reporting company | \u2610\n |  |  | \n |  | Emerging growth company | \u2610  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page No.\nPART I | FINANCIAL INFORMATION | 3\n |  | \nItem 1. | Financial Statements | 3\n | Condensed Consolidated Statement of Income | 3\n | Condensed Consolidated Statement of Comprehensive Income | 3\n | Condensed Consolidated Balance Sheet | 4\n | Condensed Consolidated Statement of Cash Flows | 5\n | Notes to Condensed Consolidated Financial Statements | 6\n |  | \nItem 2. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 30\n |  | \nItem 3. | Quantitative and Qualitative Disclosures about Market Risk | 42\n |  | \nItem 4. | Controls and Procedures | 42\n |  | \n | Cautionary Factors That May Affect Future Results | 43\n |  | \nPART II | OTHER INFORMATION | 43\n |  | \nItem 1. | Legal Proceedings | 43\n |  | \nItem 1A. | Risk Factors | 43\n |  |  |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 44\n |  |  |  | \nItem 6. | Exhibits | 44\n |  | \n | Signatures |  |  | 45  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2022 |  | 2021 |  |  |  | \nSales | $ | 15,901 |  |  | $ | 10,627 |  |  |  |  | \nCosts, Expenses and Other |  |  |  |  |  |  | \nCost of sales | 5,380 |  |  | 3,199 |  |  |  |  | \nSelling, general and administrative | 2,323 |  |  | 2,187 |  |  |  |  | \nResearch and development | 2,576 |  |  | 2,412 |  |  |  |  | \nRestructuring costs | 53 |  |  | 297 |  |  |  |  | \nOther (income) expense, net | 708 |  |  | (455) |  |  |  |  | \n | 11,040 |  |  | 7,640 |  |  |  |  | \nIncome from Continuing Operations Before Taxes | 4,861 |  |  | 2,987 |  |  |  |  | \nTaxes on Income from Continuing Operations | 554 |  |  | 238 |  |  |  |  | \nNet Income from Continuing Operations | 4,307 |  |  | 2,749 |  |  |  |  | \nLess: Net (Loss) Income Attributable to Noncontrolling Interests | (3) |  |  | 4 |  |  |  |  | \nNet Income from Continuing Operations Attributable to Merck\u00a0& Co., Inc. | 4,310 |  |  | 2,745 |  |  |  |  | \nIncome from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | \u2014 |  |  | 434 |  |  |  |  | \nNet Income Attributable to Merck & Co., Inc. | $ | 4,310 |  |  | $ | 3,179 |  |  |  |  | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nIncome from Discontinued Operations | \u2014 |  |  | 0.17 |  |  |  |  | \nNet Income | $ | 1.70 |  |  | $ | 1.26 |  |  |  |  | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nIncome from Discontinued Operations | \u2014 |  |  | 0.17 |  |  |  |  | \nNet Income | $ | 1.70 |  |  | $ | 1.25 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2022 |  | 2021 |  |  |  | \nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,310 |  |  | $ | 3,179 |  |  |  |  | \nOther Comprehensive Income Net of Taxes: |  |  |  |  |  |  | \nNet unrealized gain on derivatives, net of reclassifications | 63 |  |  | 230 |  |  |  |  | \nBenefit plan net gain and prior service credit, net of amortization | 32 |  |  | 81 |  |  |  |  | \nCumulative translation adjustment | (35) |  |  | (299) |  |  |  |  | \n | 60 |  |  | 12 |  |  |  |  | \nComprehensive Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,370 |  |  | $ | 3,191 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\nAssets |  |  | \nCurrent Assets |  |  | \nCash and cash equivalents | $ | 8,556 |  |  | $ | 8,096 | \nShort-term investments | 372 |  |  | \u2014 | \nAccounts receivable (net of allowance for doubtful accounts of $95in 2022and $62in 2021) | 9,828 |  |  | 9,230 | \nInventories (excludes inventories of $2,495in 2022 and $2,194in 2021classified in Other assets - see Note\u00a07) | 5,774 |  |  | 5,953 | \nOther current assets | 6,654 |  |  | 6,987 | \nTotal current assets | 31,184 |  |  | 30,266 | \nInvestments | 316 |  |  | 370 | \nProperty, Plant and Equipment, at cost, net of accumulated depreciation of $18,498in 2022 and $18,192in 2021 | 19,747 |  |  | 19,279 | \nGoodwill | 21,258 |  |  | 21,264 | \nOther Intangibles, Net | 23,022 |  |  | 22,933 | \nOther Assets | 11,141 |  |  | 11,582 | \n | $ | 106,668 |  |  | $ | 105,694 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nLoans payable and current portion of long-term debt | $ | 1,208 |  |  | $ | 2,412 | \nTrade accounts payable | 3,715 |  |  | 4,609 | \nAccrued and other current liabilities | 14,051 |  |  | 13,859 | \nIncome taxes payable | 1,571 |  |  | 1,224 | \nDividends payable | 1,771 |  |  | 1,768 | \nTotal current liabilities | 22,316 |  |  | 23,872 | \nLong-Term Debt | 30,586 |  |  | 30,690 | \nDeferred Income Taxes | 3,071 |  |  | 3,441 | \nOther Noncurrent Liabilities | 9,742 |  |  | 9,434 | \nMerck\u00a0& Co., Inc. Stockholders\u2019 Equity |  |  | \nCommon stock, $0.50par valueAuthorized -6,500,000,000sharesIssued -3,577,103,522shares in 2022 and 2021 | 1,788 |  |  | 1,788 | \nOther paid-in capital | 44,275 |  |  | 44,238 | \nRetained earnings | 56,252 |  |  | 53,696 | \nAccumulated other comprehensive loss | (4,369) |  |  | (4,429) | \n | 97,946 |  |  | 95,293 | \nLess treasury stock, at cost:1,048,727,225shares in 2022 and1,049,499,023shares in 2021 | 57,063 |  |  | 57,109 | \nTotal Merck\u00a0& Co., Inc. stockholders\u2019 equity | 40,883 |  |  | 38,184 | \nNoncontrolling Interests | 70 |  |  | 73 | \nTotal equity | 40,953 |  |  | 38,257 | \n | $ | 106,668 |  |  | $ | 105,694 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31,\n | 2022 |  | 2021\nCash Flows from Operating Activities of Continuing Operations |  |  | \nNet income from continuing operations | $ | 4,307 |  |  | $ | 2,749 | \nAdjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations: |  |  | \nAmortization | 699 |  |  | 514 | \nDepreciation | 421 |  |  | 378 | \nLoss (income) from investments in equity securities, net | 708 |  |  | (574) | \nDeferred income taxes | (338) |  |  | 18 | \nShare-based compensation | 120 |  |  | 111 | \nOther | 143 |  |  | 236 | \nNet changes in assets and liabilities | (1,299) |  |  | (2,192) | \nNet Cash Provided by Operating Activities of Continuing Operations | 4,761 |  |  | 1,240 | \nCash Flows from Investing Activities of Continuing Operations |  |  | \nCapital expenditures | (984) |  |  | (1,082) | \nPurchases of securities and other investments | (372) |  |  | (1) | \nProceeds from sales of securities and other investments | 1 |  |  | 386 | \nOther | 182 |  |  | 11 | \nNet Cash Used in Investing Activities of Continuing Operations | (1,173) |  |  | (686) | \nCash Flows from Financing Activities of Continuing Operations |  |  | \nNet change in short-term borrowings | \u2014 |  |  | 788 | \nPayments on debt | (1,250) |  |  | (1,153) | \nDividends paid to stockholders | (1,745) |  |  | (1,645) | \nProceeds from exercise of stock options | 12 |  |  | 9 | \nOther | (103) |  |  | (97) | \nNet Cash Used in Financing Activities of Continuing Operations | (3,086) |  |  | (2,098) | \nCash Flows from Discontinued Operations |  |  | \nNet cash provided by operating activities | \u2014 |  |  | 551 | \nNet cash used in investing activities | \u2014 |  |  | (52) | \nNet Cash Flows Provided by Discontinued Operations | \u2014 |  |  | 499 | \nEffect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | (55) |  |  | (97) | \nNet Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash | 447 |  |  | (1,142) | \nCash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of$71and $103at January 1, 2022 and 2021, respectively, included in Other current assets) | 8,167 |  |  | 8,165 | \nLess: Cash and cash equivalents related to discontinued operations | \u2014 |  |  | 141 | \nCash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $58and $42at March\u00a031, 2022 and 2021, respectively, included in Other current assets) | $ | 8,614 |  |  | $ | 6,882 |   |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, |  | \n($ in millions) |  | 2021\nSales |  | $ | 1,453 |  |  | \nCosts, Expenses and Other |  |  |  | \nCost of sales |  | 471 |  |  | \nSelling, general and administrative |  | 446 |  |  | \nResearch and development |  | 53 |  |  | \nRestructuring costs |  | 1 |  |  | \nOther (income) expense, net |  | 7 |  |  | \n |  | 978 |  |  | \nIncome from discontinued operations before taxes |  | 475 |  |  | \nTax provision |  | 38 |  |  | \nIncome from discontinued operations, net of taxes |  | 437 |  |  | \nLess: Income of discontinued operations attributable to noncontrolling interests |  | 3 |  |  | \n |  | $ | 434 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nAlliance revenue - Lynparza | $ | 266 |  |  | $ | 228 |  |  |  |  | \nAlliance revenue - Koselugo | 9 |  |  | 5 |  |  |  |  | \nTotal alliance revenue | $ | 275 |  |  | $ | 233 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 299 |  |  | 42 |  |  |  |  | \nSelling, general and administrative | 44 |  |  | 40 |  |  |  |  | \nResearch and development | 26 |  |  | 29 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021 |  |  |  | \nReceivables from AstraZeneca included inOther current assets | $ | 275 |  |  | $ | 271 |  |  |  |  | \nPayables to AstraZeneca included inTrade accounts payableandAccrued and other current liabilities(2) | 190 |  |  | 415 |  |  |  |  | \nPayables to AstraZeneca included inOther Noncurrent Liabilities(2) | 600 |  |  | \u2014 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nAlliance revenue - Lenvima | $ | 227 |  |  | $ | 130 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 53 |  |  | 47 |  |  |  |  | \nSelling, general and administrative | 31 |  |  | 23 |  |  |  |  | \nResearch and development | 57 |  |  | 64 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021 |  |  |  | \nReceivables from Eisai included inOther current assets | $ | 241 |  |  | $ | 200 |  |  |  |  | \nPayables to Eisai included inAccrued and other current liabilities(2) | 325 |  |  | 625 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nAlliance revenue - Adempas/Verquvo | $ | 72 |  |  | $ | 74 |  |  |  |  | \nNet sales of Adempas recorded by Merck | 61 |  |  | 55 |  |  |  |  | \nNet sales of Verquvo recorded by Merck | 3 |  |  | \u2014 |  |  |  |  | \nTotal sales | $ | 136 |  |  | $ | 129 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 50 |  |  | 208 |  |  |  |  | \nSelling, general and administrative | 23 |  |  | 17 |  |  |  |  | \nResearch and development | 17 |  |  | 7 |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021 |  |  |  | \nReceivables from Bayer included inOther current assets | $ | 129 |  |  | $ | 114 |  |  |  |  | \nPayables to Bayer included inAccrued and other current liabilities(2) | 74 |  |  | 472 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nLagevriosales | $ | 3,247 |  |  | $ | \u2014 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 1,724 |  |  | 46 |  |  |  |  | \nSelling, general and administrative | 34 |  |  | 3 |  |  |  |  | \nResearch and development | 6 |  |  | 42 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021 |  |  |  | \nPayables to Ridgeback included inAccrued and other current liabilities(2) | $ | 1,568 |  |  | $ | 283 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, 2022 |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  |  |  |  |  |  |  | \nCost of sales | $ | \u2014 |  |  | $ | 18 |  |  | $ | 28 |  |  | $ | 46 |  |  |  |  |  |  |  |  | \nSelling, general and administrative | \u2014 |  |  | 4 |  |  | 17 |  |  | 21 |  |  |  |  |  |  |  |  | \nResearch and development | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 |  |  |  |  |  |  |  |  | \nRestructuring costs | 26 |  |  | \u2014 |  |  | 27 |  |  | 53 |  |  |  |  |  |  |  |  | \n | $ | 26 |  |  | $ | 29 |  |  | $ | 72 |  |  | $ | 127 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, 2021 |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  |  |  |  |  |  |  | \nCost of sales | $ | \u2014 |  |  | $ | 10 |  |  | $ | 17 |  |  | $ | 27 |  |  |  |  |  |  |  |  | \nSelling, general and administrative | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 3 |  |  |  |  |  |  |  |  | \nResearch and development | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 |  |  |  |  |  |  |  |  | \nRestructuring costs | 229 |  |  | \u2014 |  |  | 68 |  |  | 297 |  |  |  |  |  |  |  |  | \n | $ | 229 |  |  | $ | 20 |  |  | $ | 85 |  |  | $ | 334 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nRestructuring reserves January\u00a01, 2022 | $ | 596 |  |  | $ | \u2014 |  |  | $ | 41 |  |  | $ | 637 | \nExpense | 26 |  |  | 29 |  |  | 72 |  |  | 127 | \n(Payments) receipts, net | (68) |  |  | \u2014 |  |  | (45) |  |  | (113) | \nNon-cash activity | \u2014 |  |  | (29) |  |  | (39) |  |  | (68) | \nRestructuring reserves March\u00a031, 2022(1) | $ | 554 |  |  | $ | \u2014 |  |  | $ | 29 |  |  | $ | 583 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income(1) |  | Amount of Pretax (Gain) Loss Recognized inOther (income) expense, netfor Amounts Excluded from Effectiveness Testing\n | Three Months Ended March 31, |  |  |  | Three Months Ended March 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  |  |  | 2022 |  | 2021 |  |  |  | \nNet Investment Hedging Relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | $ | (16) |  |  | $ | (25) |  |  |  |  |  |  | $ | (1) |  |  | $ | (4) |  |  |  |  | \nEuro-denominated notes | (53) |  |  | (166) |  |  |  |  |  |  | \u2014 |  |  | \u2014 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022\n($ in millions) | Par Value of Debt |  | Number of Interest Rate Swaps Held |  | Total Swap Notional Amount\n2.40% notes due 2022 | $ | 1,000 |  |  | 4 |  |  | $ | 1,000 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Carrying Amount of Hedged Liabilities |  | Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount\n($ in millions) | March 31, 2022 |  | December 31, 2021 |  | March 31, 2022 |  | December 31, 2021\nBalance Sheet Line Item in which Hedged Item is Included |  |  |  |  |  |  | \nLoans payable and current portion of long-term debt | $ | 1,003 |  |  | $ | 2,263 |  |  | $ | 4 |  |  | $ | 13 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31, 2022 |  | December 31, 2021\n |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional\n($ in millions) |  | Asset |  | Liability |  | Asset |  | Liability | \nDerivatives Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts | Other current assets | $ | 4 |  |  | $ | \u2014 |  |  | $ | 1,000 |  |  | $ | 14 |  |  | $ | \u2014 |  |  | $ | 2,250 | \nForeign exchange contracts | Other current assets | 341 |  |  | \u2014 |  |  | 7,429 |  |  | 271 |  |  | \u2014 |  |  | 6,778 | \nForeign exchange contracts | Other Assets | 46 |  |  | \u2014 |  |  | 1,595 |  |  | 43 |  |  | \u2014 |  |  | 1,551 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 21 |  |  | 1,060 |  |  | \u2014 |  |  | 24 |  |  | 1,623 | \nForeign exchange contracts | Other Noncurrent Liabilities | \u2014 |  |  | 1 |  |  | 9 |  |  | \u2014 |  |  | 1 |  |  | 43 | \n |  | $ | 391 |  |  | $ | 22 |  |  | $ | 11,093 |  |  | $ | 328 |  |  | $ | 25 |  |  | $ | 12,245 | \nDerivatives Not Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Other current assets | $ | 288 |  |  | $ | \u2014 |  |  | $ | 12,466 |  |  | $ | 221 |  |  | $ | \u2014 |  |  | $ | 10,073 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 219 |  |  | 7,700 |  |  | \u2014 |  |  | 96 |  |  | 10,640 | \n |  | $ | 288 |  |  | $ | 219 |  |  | $ | 20,166 |  |  | $ | 221 |  |  | $ | 96 |  |  | $ | 20,713 | \n |  | $ | 679 |  |  | $ | 241 |  |  | $ | 31,259 |  |  | $ | 549 |  |  | $ | 121 |  |  | $ | 32,958 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\n($ in millions) | Asset |  | Liability |  | Asset |  | Liability\nGross amounts recognized in the condensed consolidated balance sheet | $ | 679 |  |  | $ | 241 |  |  | $ | 549 |  |  | $ | 121 | \nGross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet | (191) |  |  | (191) |  |  | (110) |  |  | (110) | \nCash collateral received | (220) |  |  | \u2014 |  |  | (164) |  |  | \u2014 | \nNet amounts | $ | 268 |  |  | $ | 50 |  |  | $ | 275 |  |  | $ | 11 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |  |  |  |  |  |  |  |  | \nFinancial Statement Line Items in which Effects of Fair Value or Cash FlowHedges are Recorded | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss) |  |  |  |  |  | \n | $ | 15,901 |  |  | $ | 10,627 |  |  | $ | 708 |  |  | $ | (455) |  |  | $ | 60 |  |  | $ | 12 |  |  |  |  |  |  |  |  |  |  |  |  | \n(Gain) loss on fair value hedging relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHedged items | \u2014 |  |  | \u2014 |  |  | (10) |  |  | (11) |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nDerivatives designated as hedging instruments | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nImpact of cash flow hedging relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 148 |  |  | 180 |  |  |  |  |  |  |  |  |  |  |  |  | \nIncrease (decrease) inSalesas a result ofAOCLreclassifications | 67 |  |  | (112) |  |  | \u2014 |  |  | \u2014 |  |  | (67) |  |  | 112 |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOther (income) expense, neton derivatives | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of loss recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Amount of Derivative Pretax (Gain) Loss Recognized in Income\n |  |  | Three Months Ended March 31, |  |  |  | \n($ in millions) |  |  | 2022 |  | 2021 |  |  |  | \nDerivatives Not Designated as Hedging Instruments | Income Statement Caption |  |  |  |  |  |  |  | \nForeign exchange contracts(1) | Other (income) expense, net |  | $ | 28 |  |  | $ | 50 |  |  |  |  | \nForeign exchange contracts(2) | Sales |  | (2) |  |  | (4) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\n | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue |  | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue\n($ in millions) | Gains |  | Losses |  | Gains |  | Losses | \nCommercial paper | $ | 372 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 372 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nU.S. government and agency securities | 75 |  |  | \u2014 |  |  | \u2014 |  |  | 75 |  |  | 80 |  |  | \u2014 |  |  | \u2014 |  |  | 80 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 | \nForeign government bonds | 3 |  |  | \u2014 |  |  | \u2014 |  |  | 3 |  |  | 2 |  |  | \u2014 |  |  | \u2014 |  |  | 2 | \nTotal debt securities | $ | 454 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 454 |  |  | $ | 86 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 86 | \nPublicly traded equity securities(1) |  |  |  |  |  |  | 1,397 |  |  |  |  |  |  |  |  | 1,647 | \nTotal debt and publicly traded equity securities |  |  |  |  |  |  | $ | 1,851 |  |  |  |  |  |  |  |  | $ | 1,733 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair Value Measurements Using |  | Fair Value Measurements Using\n | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |  | Total\n($ in millions) | March 31, 2022 |  | December 31, 2021\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCommercial paper | $ | \u2014 |  |  | $ | 372 |  |  | $ | \u2014 |  |  | $ | 372 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nForeign government bonds | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 2 | \nPublicly traded equity securities | 313 |  |  | \u2014 |  |  | \u2014 |  |  | 313 |  |  | 368 |  |  | \u2014 |  |  | \u2014 |  |  | 368 | \n | 313 |  |  | 375 |  |  | \u2014 |  |  | 688 |  |  | 368 |  |  | 2 |  |  | \u2014 |  |  | 370 | \nOther assets(1) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | 75 |  |  | \u2014 |  |  | \u2014 |  |  | 75 |  |  | 80 |  |  | \u2014 |  |  | \u2014 |  |  | 80 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 | \nPublicly traded equity securities | 1,084 |  |  | \u2014 |  |  | \u2014 |  |  | 1,084 |  |  | 1,279 |  |  | \u2014 |  |  | \u2014 |  |  | 1,279 | \n | 1,163 |  |  | \u2014 |  |  | \u2014 |  |  | 1,163 |  |  | 1,363 |  |  | \u2014 |  |  | \u2014 |  |  | 1,363 | \nDerivative assets(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 433 |  |  | \u2014 |  |  | 433 |  |  | \u2014 |  |  | 351 |  |  | \u2014 |  |  | 351 | \nPurchased currency options | \u2014 |  |  | 242 |  |  | \u2014 |  |  | 242 |  |  | \u2014 |  |  | 184 |  |  | \u2014 |  |  | 184 | \nInterest rate swaps | \u2014 |  |  | 4 |  |  | \u2014 |  |  | 4 |  |  | \u2014 |  |  | 14 |  |  | \u2014 |  |  | 14 | \n | \u2014 |  |  | 679 |  |  | \u2014 |  |  | 679 |  |  | \u2014 |  |  | 549 |  |  | \u2014 |  |  | 549 | \nTotal assets | $ | 1,476 |  |  | $ | 1,054 |  |  | $ | \u2014 |  |  | $ | 2,530 |  |  | $ | 1,731 |  |  | $ | 551 |  |  | $ | \u2014 |  |  | $ | 2,282 | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nContingent consideration | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 572 |  |  | $ | 572 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 777 |  |  | $ | 777 | \nDerivative liabilities(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 240 |  |  | \u2014 |  |  | 240 |  |  | \u2014 |  |  | 120 |  |  | \u2014 |  |  | 120 | \nWritten currency options | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 | \n | \u2014 |  |  | 241 |  |  | \u2014 |  |  | 241 |  |  | \u2014 |  |  | 121 |  |  | \u2014 |  |  | 121 | \nTotal liabilities | $ | \u2014 |  |  | $ | 241 |  |  | $ | 572 |  |  | $ | 813 |  |  | $ | \u2014 |  |  | $ | 121 |  |  | $ | 777 |  |  | $ | 898 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021\nFair value January 1 | $ | 777 |  |  | $ | 841 | \nChanges in estimated fair value(1) | (84) |  |  | (13) | \nPayments | (119) |  |  | \u2014 | \nOther | (2) |  |  | (12) | \nFair value March 31(2)(3) | $ | 572 |  |  | $ | 816 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021\nFinished goods | $ | 1,772 |  |  | $ | 1,747 | \nRaw materials and work in process | 6,365 |  |  | 6,220 | \nSupplies | 209 |  |  | 196 | \nTotal (approximates current cost) | 8,346 |  |  | 8,163 | \nDecrease to LIFO cost | (77) |  |  | (16) | \n | $ | 8,269 |  |  | $ | 8,147 | \nRecognized as: |  |  | \nInventories | $ | 5,774 |  |  | $ | 5,953 | \nOther assets | 2,495 |  |  | 2,194 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at January 1, 2021 | 3,577 |  | $ | 1,788 |  | $ | 39,588 |  | $ | 47,362 |  | $ | (6,634) |  | 1,047 |  | $ | (56,787) |  | $ | 87 |  | $ | 25,404 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 3,179 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3,179 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 12 |  | \u2014 |  | \u2014 |  | \u2014 |  | 12 | \nCash dividends declared on common stock ($0.65per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,653) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,653) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 25 |  | \u2014 |  | \u2014 |  | (1) |  | 65 |  | \u2014 |  | 90 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 7 |  | 7 | \nBalance at March 31, 2021 | 3,577 |  | $ | 1,788 |  | $ | 39,613 |  | $ | 48,888 |  | $ | (6,622) |  | 1,046 |  | $ | (56,722) |  | $ | 94 |  | $ | 27,039 | \nBalance at January 1, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,238 |  | $ | 53,696 |  | $ | (4,429) |  | 1,049 |  | $ | (57,109) |  | $ | 73 |  | $ | 38,257 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 4,310 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 4,310 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 60 |  | \u2014 |  | \u2014 |  | \u2014 |  | 60 | \nCash dividends declared on common stock ($0.69per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,754) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,754) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 37 |  | \u2014 |  | \u2014 |  | \u2014 |  | 46 |  | \u2014 |  | 83 | \nNet loss attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (3) |  | (3) | \nBalance at March 31, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,275 |  | $ | 56,252 |  | $ | (4,369) |  | 1,049 |  | $ | (57,063) |  | $ | 70 |  | $ | 40,953 |   |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  |  |  |  | \n |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2022 |  | 2021 |  |  |  | \n($ in millions) | U.S. |  | International |  | U.S. |  | International |  |  |  |  |  |  |  | \nService cost | $ | 99 |  |  | $ | 75 |  |  | $ | 100 |  |  | $ | 92 |  |  |  |  |  |  |  |  | \nInterest cost | 103 |  |  | 38 |  |  | 96 |  |  | 29 |  |  |  |  |  |  |  |  | \nExpected return on plan assets | (196) |  |  | (101) |  |  | (188) |  |  | (104) |  |  |  |  |  |  |  |  | \nAmortization of unrecognized prior service credit | (8) |  |  | (4) |  |  | (10) |  |  | (4) |  |  |  |  |  |  |  |  | \nNet loss amortization | 56 |  |  | 25 |  |  | 85 |  |  | 41 |  |  |  |  |  |  |  |  | \nTermination benefits | \u2014 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nCurtailments | 3 |  |  | \u2014 |  |  | 7 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nSettlements | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  | \n | $ | 58 |  |  | $ | 33 |  |  | $ | 91 |  |  | $ | 54 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nService cost | $ | 12 |  |  | $ | 13 |  |  |  |  | \nInterest cost | 11 |  |  | 11 |  |  |  |  | \nExpected return on plan assets | (21) |  |  | (20) |  |  |  |  | \nAmortization of unrecognized prior service credit | (25) |  |  | (25) |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n | $ | (23) |  |  | $ | (21) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nInterest income | $ | (7) |  |  | $ | (11) |  |  |  |  | \nInterest expense | 243 |  |  | 200 |  |  |  |  | \nExchange losses | 39 |  |  | 41 |  |  |  |  | \nLoss (income) from investments in equity securities, net(1) | 708 |  |  | (574) |  |  |  |  | \nNet periodic defined benefit plan (credit) cost other than service cost | (121) |  |  | (89) |  |  |  |  | \nOther, net | (154) |  |  | (22) |  |  |  |  | \n | $ | 708 |  |  | $ | (455) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ and shares in millions except per share amounts) | 2022 |  | 2021 |  |  |  | \nNet Income from Continuing Operations Attributable to Merck\u00a0& Co., Inc. | $ | 4,310 |  |  | $ | 2,745 |  |  |  |  | \nIncome from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | \u2014 |  |  | 434 |  |  |  |  | \nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,310 |  |  | $ | 3,179 |  |  |  |  | \nAverage common shares outstanding | 2,528 |  |  | 2,531 |  |  |  |  | \nCommon shares issuable(1) | 9 |  |  | 10 |  |  |  |  | \nAverage common shares outstanding assuming dilution | 2,537 |  |  | 2,541 |  |  |  |  | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nIncome from Discontinued Operations | \u2014 |  |  | 0.17 |  |  |  |  | \nNet Income | $ | 1.70 |  |  | $ | 1.26 |  |  |  |  | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nIncome from Discontinued Operations | \u2014 |  |  | 0.17 |  |  |  |  | \nNet Income | $ | 1.70 |  |  | $ | 1.25 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance January 1, 2021, net of taxes | $ | (266) |  |  | $ | (4,540) |  |  | $ | (1,828) |  |  | $ | (6,634) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 180 |  |  | (4) |  |  | (211) |  |  | (35) | \nTax | (38) |  |  | (1) |  |  | (88) |  |  | (127) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 142 |  |  | (5) |  |  | (299) |  |  | (162) | \nReclassification adjustments, pretax | 111 |  | (1) | 87 |  | (2) | \u2014 |  |  | 198 | \nTax | (23) |  |  | (1) |  |  | \u2014 |  |  | (24) | \nReclassification adjustments, net of taxes | 88 |  |  | 86 |  |  | \u2014 |  |  | 174 | \nOther comprehensive income (loss), net of taxes | 230 |  |  | 81 |  |  | (299) |  |  | 12 | \nBalance March 31, 2021, net of taxes | $ | (36) |  |  | $ | (4,459) |  |  | $ | (2,127) |  |  | $ | (6,622) | \nBalance January 1, 2022, net of taxes | $ | 144 |  |  | $ | (2,743) |  |  | $ | (1,830) |  |  | $ | (4,429) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 148 |  |  | 1 |  |  | (18) |  |  | 131 | \nTax | (31) |  |  | (2) |  |  | (17) |  |  | (50) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 117 |  |  | (1) |  |  | (35) |  |  | 81 | \nReclassification adjustments, pretax | (68) |  | (1) | 45 |  | (2) | \u2014 |  |  | (23) | \nTax | 14 |  |  | (12) |  |  | \u2014 |  |  | 2 | \nReclassification adjustments, net of taxes | (54) |  |  | 33 |  |  | \u2014 |  |  | (21) | \nOther comprehensive income (loss), net of taxes | 63 |  |  | 32 |  |  | (35) |  |  | 60 | \nBalance March 31, 2022, net of taxes | $ | 207 |  |  | $ | (2,711) |  |  | $ | (1,865) |  |  | $ | (4,369) |   |  |  |  |  |  |  |  |  | \n | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \n($ in millions) | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  |  |  |  |  |  |  |  |  |  |  | \nPharmaceutical: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nKeytruda | $ | 2,779 |  |  | $ | 2,030 |  |  | $ | 4,809 |  |  | $ | 2,181 |  |  | $ | 1,718 |  |  | $ | 3,899 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue - Lynparza(1) | 141 |  |  | 125 |  |  | 266 |  |  | 118 |  |  | 110 |  |  | 228 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue - Lenvima(1) | 156 |  |  | 71 |  |  | 227 |  |  | 85 |  |  | 44 |  |  | 130 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue - Reblozyl(2) | 27 |  |  | 25 |  |  | 52 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nVaccines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | 418 |  |  | 1,042 |  |  | 1,460 |  |  | 313 |  |  | 604 |  |  | 917 |  |  |  |  |  |  |  |  |  |  |  |  | \nProQuad/M-M-RII/Varivax | 371 |  |  | 99 |  |  | 470 |  |  | 333 |  |  | 117 |  |  | 449 |  |  |  |  |  |  |  |  |  |  |  |  | \nRotaTeq | 175 |  |  | 41 |  |  | 216 |  |  | 118 |  |  | 41 |  |  | 158 |  |  |  |  |  |  |  |  |  |  |  |  | \nPneumovax23 | 118 |  |  | 55 |  |  | 173 |  |  | 73 |  |  | 99 |  |  | 171 |  |  |  |  |  |  |  |  |  |  |  |  | \nVaqta | 29 |  |  | 7 |  |  | 36 |  |  | 25 |  |  | 9 |  |  | 34 |  |  |  |  |  |  |  |  |  |  |  |  | \nHospital Acute Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBridion | 195 |  |  | 199 |  |  | 395 |  |  | 167 |  |  | 173 |  |  | 340 |  |  |  |  |  |  |  |  |  |  |  |  | \nPrevymis | 40 |  |  | 54 |  |  | 94 |  |  | 35 |  |  | 47 |  |  | 82 |  |  |  |  |  |  |  |  |  |  |  |  | \nPrimaxin | 1 |  |  | 58 |  |  | 58 |  |  | \u2014 |  |  | 65 |  |  | 65 |  |  |  |  |  |  |  |  |  |  |  |  | \nNoxafil | 10 |  |  | 48 |  |  | 57 |  |  | 15 |  |  | 52 |  |  | 67 |  |  |  |  |  |  |  |  |  |  |  |  | \nCancidas | 1 |  |  | 52 |  |  | 53 |  |  | 3 |  |  | 55 |  |  | 57 |  |  |  |  |  |  |  |  |  |  |  |  | \nDificid | 49 |  |  | 3 |  |  | 52 |  |  | 25 |  |  | 2 |  |  | 27 |  |  |  |  |  |  |  |  |  |  |  |  | \nInvanz | 1 |  |  | 52 |  |  | 52 |  |  | 4 |  |  | 52 |  |  | 57 |  |  |  |  |  |  |  |  |  |  |  |  | \nZerbaxa | 18 |  |  | 12 |  |  | 30 |  |  | (2) |  |  | (6) |  |  | (8) |  |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue - Adempas/Verquvo(3) | 71 |  |  | 1 |  |  | 72 |  |  | 68 |  |  | 6 |  |  | 74 |  |  |  |  |  |  |  |  |  |  |  |  | \nAdempas | \u2014 |  |  | 61 |  |  | 61 |  |  | \u2014 |  |  | 55 |  |  | 55 |  |  |  |  |  |  |  |  |  |  |  |  | \nVirology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLagevrio | 1,523 |  |  | 1,723 |  |  | 3,247 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nIsentress/IsentressHD | 61 |  |  | 97 |  |  | 158 |  |  | 71 |  |  | 138 |  |  | 209 |  |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBelsomra | 20 |  |  | 48 |  |  | 69 |  |  | 18 |  |  | 61 |  |  | 79 |  |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSimponi | \u2014 |  |  | 186 |  |  | 186 |  |  | \u2014 |  |  | 214 |  |  | 214 |  |  |  |  |  |  |  |  |  |  |  |  | \nRemicade | \u2014 |  |  | 61 |  |  | 61 |  |  | \u2014 |  |  | 85 |  |  | 85 |  |  |  |  |  |  |  |  |  |  |  |  | \nDiabetes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nJanuvia | 325 |  |  | 454 |  |  | 779 |  |  | 348 |  |  | 461 |  |  | 809 |  |  |  |  |  |  |  |  |  |  |  |  | \nJanumet | 63 |  |  | 391 |  |  | 454 |  |  | 84 |  |  | 401 |  |  | 486 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther pharmaceutical(4) | 181 |  |  | 339 |  |  | 520 |  |  | 212 |  |  | 341 |  |  | 554 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal Pharmaceutical segment sales | 6,773 |  |  | 7,334 |  |  | 14,107 |  |  | 4,294 |  |  | 4,944 |  |  | 9,238 |  |  |  |  |  |  |  |  |  |  |  |  | \nAnimal Health: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLivestock | 171 |  |  | 661 |  |  | 832 |  |  | 157 |  |  | 662 |  |  | 819 |  |  |  |  |  |  |  |  |  |  |  |  | \nCompanion Animals | 302 |  |  | 348 |  |  | 650 |  |  | 280 |  |  | 319 |  |  | 599 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal Animal Health segment sales | 473 |  |  | 1,009 |  |  | 1,482 |  |  | 437 |  |  | 981 |  |  | 1,418 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal segment sales | 7,246 |  |  | 8,343 |  |  | 15,589 |  |  | 4,731 |  |  | 5,925 |  |  | 10,656 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther(5) | 93 |  |  | 220 |  |  | 312 |  |  | 59 |  |  | (88) |  |  | (29) |  |  |  |  |  |  |  |  |  |  |  |  | \n | $ | 7,339 |  |  | $ | 8,563 |  |  | $ | 15,901 |  |  | $ | 4,790 |  |  | $ | 5,837 |  |  | $ | 10,627 |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nUnited States | $ | 7,339 |  |  | $ | 4,790 |  |  |  |  | \nEurope, Middle East and Africa | 4,359 |  |  | 3,237 |  |  |  |  | \nChina | 1,143 |  |  | 721 |  |  |  |  | \nJapan | 989 |  |  | 629 |  |  |  |  | \nAsia Pacific (other than China and Japan) | 930 |  |  | 575 |  |  |  |  | \nLatin America | 607 |  |  | 500 |  |  |  |  | \nOther | 534 |  |  | 175 |  |  |  |  | \n | $ | 15,901 |  |  | $ | 10,627 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nSegment profits: |  |  |  |  |  |  | \nPharmaceutical segment | $ | 9,501 |  |  | $ | 6,589 |  |  |  |  | \nAnimal Health segment | 585 |  |  | 572 |  |  |  |  | \nTotal segment profits | 10,086 |  |  | 7,161 |  |  |  |  | \nOther profits | 194 |  |  | (50) |  |  |  |  | \nUnallocated: |  |  |  |  |  |  | \nInterest income | 7 |  |  | 11 |  |  |  |  | \nInterest expense | (243) |  |  | (200) |  |  |  |  | \nAmortization | (699) |  |  | (514) |  |  |  |  | \nDepreciation | (378) |  |  | (340) |  |  |  |  | \nResearch and development | (2,446) |  |  | (2,305) |  |  |  |  | \nRestructuring costs | (53) |  |  | (297) |  |  |  |  | \nOther unallocated, net | (1,607) |  |  | (479) |  |  |  |  | \n | $ | 4,861 |  |  | $ | 2,987 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nUnited States | $ | 7,339 |  |  | $ | 4,790 |  |  | 53 | % |  | 53 | % |  |  |  |  |  |  |  | \nInternational | 8,563 |  |  | 5,837 |  |  | 47 | % |  | 52 | % |  |  |  |  |  |  |  | \nTotal | $ | 15,901 |  |  | $ | 10,627 |  |  | 50 | % |  | 52 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nKeytruda | $ | 4,809 |  |  | $ | 3,899 |  |  | 23 | % |  | 27 | % |  |  |  |  |  |  |  | \nAlliance Revenue - Lynparza(1) | 266 |  |  | 228 |  |  | 17 | % |  | 20 | % |  |  |  |  |  |  |  | \nAlliance Revenue-Lenvima(1) | 227 |  |  | 130 |  |  | 75 | % |  | 77 | % |  |  |  |  |  |  |  |   |  |  |  |  | \nDate | Approval\nJanuary 2022 | European Commission (EC) approval as monotherapy for the adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions based on the KEYNOTE-564 trial.\nFebruary 2022 | Japan Ministry of Health, Labour and Welfare approval of the combination ofKeytrudaplus Lenvima for radically unresectable or metastatic RCC based on the CLEAR (Study 307)/KEYNOTE-581 trial.\nFebruary 2022 | Japan Pharmaceuticals and Medical Devices Agency approval for the treatment of adult patients with advanced or recurrent TMB-H solid tumors that have progressed after chemotherapy (limited to use when difficult to treat with standard of care) based on the KEYNOTE-158 trial.\nMarch 2022 | U.S. Food and Drug Administration (FDA) approval as a single agent for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation based on the KEYNOTE-158 trial (Cohorts D & K).\nApril 2022 | EC approval in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in certain adults whose tumors express PD-L1 based on the KEYNOTE-826 trial.\nApril 2022 | EC approval as monotherapy for the treatment of certain patients with unresectable or metastatic MSI-H/dMMR colorectal, gastric, small intestine or biliary cancer, as well as advanced or recurrent MSI-H/dMMR endometrial cancer based on data from KEYNOTE-164 and KEYNOTE-158.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | $ | 1,460 |  |  | $ | 917 |  |  | 59 | % |  | 60 | % |  |  |  |  |  |  |  | \nProQuad | 162 |  |  | 165 |  |  | (2) | % |  | (1) | % |  |  |  |  |  |  |  | \nM-M-RII | 103 |  |  | 80 |  |  | 29 | % |  | 31 | % |  |  |  |  |  |  |  | \nVarivax | 204 |  |  | 204 |  |  | \u2014 | % |  | 1 | % |  |  |  |  |  |  |  | \nRotaTeq | 216 |  |  | 158 |  |  | 36 | % |  | 38 | % |  |  |  |  |  |  |  | \nPneumovax 23 | 173 |  |  | 171 |  |  | 1 | % |  | 3 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nBridion | $ | 395 |  |  | $ | 340 |  |  | 16 | % |  | 20 | % |  |  |  |  |  |  |  | \nZerbaxa | 30 |  |  | (8) |  |  | * |  | * |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nAlliance Revenue - Adempas/Verquvo(1) | $ | 72 |  |  | $ | 74 |  |  | (3) | % |  | (3) | % |  |  |  |  |  |  |  | \nAdempas | 61 |  |  | 55 |  |  | 11 | % |  | 20 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nLagevrio | $ | 3,247 |  |  | $ | \u2014 |  |  | \u2014 |  | \u2014 |  |  |  |  |  |  |  | \nIsentress/Isentress HD | 158 |  |  | 209 |  |  | (24) | % |  | (21) | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nJanuvia/Janumet | $ | 1,233 |  |  | $ | 1,295 |  |  | (5) | % |  | (1) | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nLivestock | $ | 832 |  |  | $ | 819 |  |  | 2 | % |  | 7 | % |  |  |  |  |  |  |  | \nCompanion Animal | 650 |  |  | 599 |  |  | 9 | % |  | 13 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  | \nCost of sales | $ | 5,380 |  |  | $ | 3,199 |  |  | 68 | % |  |  |  |  |  | \nSelling, general and administrative | 2,323 |  |  | 2,187 |  |  | 6 | % |  |  |  |  |  | \nResearch and development | 2,576 |  |  | 2,412 |  |  | 7 | % |  |  |  |  |  | \nRestructuring costs | 53 |  |  | 297 |  |  | (82) | % |  |  |  |  |  | \nOther (income) expense, net | 708 |  |  | (455) |  |  | * |  |  |  |  |  | \n | $ | 11,040 |  |  | $ | 7,640 |  |  | 45 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSegment Profits |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nPharmaceutical segment profits | $ | 9,501 |  |  | $ | 6,589 |  |  |  |  | \nAnimal Health segment profits | 585 |  |  | 572 |  |  |  |  | \nOther | (5,225) |  |  | (4,174) |  |  |  |  | \nIncome from Continuing Operations Before Taxes | $ | 4,861 |  |  | $ | 2,987 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions except per share amounts) | 2022 |  | 2021 |  |  |  | \nIncome from continuing operations before taxes as reported under GAAP | $ | 4,861 |  |  | $ | 2,987 |  |  |  |  | \nIncrease (decrease) for excluded items: |  |  |  |  |  |  | \nAcquisition and divestiture-related costs | 637 |  |  | 497 |  |  |  |  | \nRestructuring costs | 127 |  |  | 334 |  |  |  |  | \nLoss (income) from investments in equity securities, net | 684 |  |  | (561) |  |  |  |  | \nOther items: |  |  |  |  |  |  | \nCharge for the discontinuation of COVID-19 development programs | \u2014 |  |  | 188 |  |  |  |  | \nNon-GAAP income from continuing operations before taxes | 6,309 |  |  | 3,445 |  |  |  |  | \nTaxes on income from continuing operations as reported under GAAP | 554 |  |  | 238 |  |  |  |  | \nEstimated tax benefit on excluded items(1) | 329 |  |  | 48 |  |  |  |  | \nNet tax benefit from the settlement of certain federal income tax matters | \u2014 |  |  | 208 |  |  |  |  | \nNon-GAAP taxes on income from continuing operations | 883 |  |  | 494 |  |  |  |  | \nNon-GAAP net income from continuing operations | 5,426 |  |  | 2,951 |  |  |  |  | \nLess: Net (loss) income attributable to noncontrolling interests as reported under GAAP | (3) |  |  | 4 |  |  |  |  | \nNon-GAAP net income from continuing operations attributable to Merck\u00a0& Co., Inc. | $ | 5,429 |  |  | $ | 2,947 |  |  |  |  | \nEPS assuming dilution from continuing operations as reported under GAAP | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nEPS difference | 0.44 |  |  | 0.08 |  |  |  |  | \nNon-GAAP EPS assuming dilution from continuing operations | $ | 2.14 |  |  | $ | 1.16 |  |  |  |  |   |  |  |  |  |  |  |  | \nPhase 2\nCancerMK-0482(3)Non-Small-Cell LungMK-1026 (nemtabrutinib)Hematological MalignanciesMK-1308 (quavonlimab)(2)Non-Small-Cell LungMK-1308A (quavonlimab+pembrolizumab)Advanced Solid TumorsColorectalHepatocellularMelanomaSmall-Cell LungMK-2140 (zilovertamab vedotin)BreastHematological MalignanciesNon-Small-Cell LungSolid TumorsMK-3475KeytrudaAdvanced Solid TumorsMK-4280 (favezelimab)(2)Hematological MalignanciesNon-Small-Cell LungMK-4280A (favezelimab+pembrolizumab)Renal CellSmall-Cell LungMK-4830(2)ColorectalNon-Small-Cell LungRenal CellSmall-Cell LungMK-5890(3)Non-Small-Cell LungSmall-Cell Lung | CancerMK-6440 (ladiratuzumab vedotin)(1)(3)BreastEsophagealGastricHead and NeckMelanomaNon-Small-Cell LungProstateSmall-Cell LungMK-6482Welireg(3)BiliaryColorectalHepatocellularPancreaticRare cancersVon Hippel-Lindau Disease-Associated Tumors (EU)MK-7119 Tukysa(1)Advanced Solid TumorsBiliaryBladderCervicalColorectalEndometrialGastricNon-Small-Cell LungMK-7339 Lynparza(1)(3)Advanced Solid TumorsMK-7684 (vibostolimab)(2)MelanomaMK-7684A (vibostolimab+pembrolizumab)BiliaryBreastCervicalEndometrialEsophagealHead and NeckHematological MalignanciesHepatocellularProstate | CancerMK-7902 Lenvima(1)(2)BiliaryGlioblastomaPancreaticProstateSmall-Cell LungV937BreastCutaneous Squamous CellHead and NeckMelanomaSolid TumorsCardiovascularMK-2060Chikungunya Virus VaccineV184HIV-1 InfectionMK-8591B (islatravir+MK-8507)(4)MK-8591D (islatravir+lenacapavir)(1)(4)HypercholesterolemiaMK-0616Nonalcoholic Steatohepatitis (NASH)MK-3655MK-6024Overgrowth SyndromeMK-7075 (miransertib)Pneumococcal Vaccine AdultV116Pulmonary Arterial HypertensionMK-5475SchizophreniaMK-8189Treatment Resistant DepressionMK-1942  |  |  |  |  |  |  |  | \nPhase 3 (Phase 3 entry date) | Under Review\nAntiviral COVID-19MK-4482Lagevrio(U.S.) (May 2021)(1)(5)CancerMK-1308A (quavonlimab+pembrolizumab)Renal Cell (April 2021)MK-3475KeytrudaBiliary (September 2019)Cutaneous Squamous Cell (August 2019) (EU)Gastric (May 2015) (EU)Hepatocellular (May 2016) (EU)Mesothelioma (May 2018)Ovarian (December 2018)Prostate (May 2019)Small-Cell Lung (May 2017)MK-3475 (pembrolizumab subcutaneous)Non-Small-Cell Lung (August 2021)MK-4280A (favezelimab+pembrolizumab)Colorectal (November 2021)MK-6482Welireg(3)Renal Cell (February 2020)MK-7119 Tukysa(1)Breast (October 2019)MK-7339 Lynparza(1)(3)Colorectal (August 2020)Non-Small-Cell Lung (June 2019)Small-Cell Lung (December 2020)MK-7684A (vibostolimab+pembrolizumab)Non-Small-Cell Lung (April 2021)Small-Cell Lung (March 2022)MK-7902 Lenvima(1)(2)Colorectal (April 2021)Esophageal (July 2021)Gastric (December 2020)Head and Neck (February 2020)Melanoma (March 2019)Non-Small-Cell Lung (March 2019)HIV-1 InfectionMK-8591A (doravirine+islatravir) (February 2020)(4)HIV-1 PreventionMK-8591 (islatravir) (February 2021)(4)Pulmonary Arterial HypertensionMK-7962 (sotatercept) (January 2021)Respiratory Syncytial VirusMK-1654 (clesrovimab) (November 2021) | New Molecular Entities/VaccinesAntiviral COVID-19MK-4482Lagevrio(EU)(1)CoughMK-7264 (gefapixant) (U.S.)(6)(EU)Pneumococcal Vaccine AdultV114 (JPN) | Certain Supplemental FilingsCancerMK-3475Keytruda\u2022    High-Risk Early-Stage Triple-Negative Breast Cancer(KEYNOTE-522) (EU) (JPN)\u2022    Adjuvent Treatment of Stage IIB and IIC Melanoma(KEYNOTE-716) (EU)\u2022    Cervical Cancer (KEYNOTE-826) (JPN)\u2022    Adjuvent Renal Cell Cancer(KEYNOTE-564) (JPN)\u2022    Second-Line Hepatocellular Cancer(KEYNOTE-394) (U.S.)MK-7339 Lynparza(1)\u2022BRCA-Mutated HER2-Negative Adjuvant BreastCancer (OlympiA) (EU) (JPN)\u2022    First-Line Metastatic Prostate Cancer (PROpel) EU)MK-7902 Lenvima(1)(2)\u2022    First-Line Metastatic Hepatocellular Carcinoma(KEYNOTE-524) (U.S.)(7)\nFootnotes:(1)Being developed in a collaboration.(2)Being developed in combination withKeytruda.(3)Being developed as monotherapy and/or in combination withKeytruda.(4)On FDA clinical hold.(5)Available in the U.S. under Emergency Use Authorization.(6)In January 2022, the FDA issued a CRL for this application. Merck is reviewing the CRL and considering next steps.(7)In July 2020, the FDA issued a CRL for Merck\u2019s and Eisai\u2019s applications. Merck and Eisai intend to submit additional data when available to the FDA.  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021\nCash and investments | $ | 9,244 |  |  | $ | 8,466 | \nWorking capital | 8,868 |  |  | 6,394 | \nTotal debt to total liabilities and equity | 29.8 | % |  | 31.3 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | ($\u00a0in\u00a0millions)\nPeriod | Total\u00a0Numberof SharesPurchased(1) |  | Average\u00a0PricePaid PerShare |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0SharesThat May Yet Be PurchasedUnder the Plans or Programs(1)\nJanuary 1 - January 31 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nFebruary 1 - February 28 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nMarch 1 - March 31 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nTotal | \u2014 |  |  | $0.00 |  | \u2014 |  |  |   |  |  |  |  |  |  |  | \nNumber |  | Description\n | \n3.1 | \u2014 | Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) \u2013 Incorporated by reference to Current Report on Form 8-K filed on November\u00a04, 2009 (No. 1-6571)\n | \n3.2 | \u2014 | By-Laws of Merck & Co., Inc. (effective March 22, 2022) \u2013 Incorporated by reference to Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)\n |  | \n31.1 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Executive Officer\n | \n31.2 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Financial Officer\n | \n32.1 |  | \u2014 | Section 1350 Certification of Chief Executive Officer\n | \n32.2 |  | \u2014 | Section 1350 Certification of Chief Financial Officer\n | \n101.INS | \u2014 | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.\n |  | \n101.SCH | \u2014 | XBRL Taxonomy Extension Schema Document.\n |  | \n101.CAL | \u2014 | XBRL Taxonomy Extension Calculation Linkbase Document.\n |  | \n101.DEF | \u2014 | XBRL Taxonomy Extension Definition Linkbase Document.\n |  | \n101.LAB | \u2014 | XBRL Taxonomy Extension Label Linkbase Document.\n |  | \n101.PRE | \u2014 | XBRL Taxonomy Extension Presentation Linkbase Document.\n |  | \n104 |  | \u2014 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).  |  |  |  |  |  |  |  | \n |  | MERCK & CO., INC.\n |  | \nDate:  May 5, 2022 |  | /s/ Jennifer Zachary\n |  | JENNIFER ZACHARY\n |  | Executive Vice President and General Counsel\n |  | \nDate:  May 5, 2022 |  | /s/ Rita A. Karachun\n |  | RITA A. KARACHUN\n |  | Senior Vice President Finance - Global Controller"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Merck, in 2022 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  | \n  |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n |   |  |  |  |  |  |  |  | \nNew Jersey | 22-1918501\n(State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.)\n | \n126 East Lincoln Avenue\nRahway | New Jersey | 07065\n(Address of principal executive offices) (zip code)  |  |  |  |  |  |  |  | \n | 2000 Galloping Hill Road,Kenilworth,New Jersey07033 | \n(Former name, former address and former fiscal year, if changed since last report.)  |  |  |  |  |  |  |  | \nSecurities Registered pursuant to Section\u00a012(b) of the Act:\nTitle of each class | Trading Symbol(s) | Name of each exchange on which registered\nCommon Stock ($0.50\u00a0par value) | MRK | New York Stock Exchange\n0.500% Notes due 2024 | MRK 24 | New York Stock Exchange\n1.875% Notes due 2026 | MRK/26 | New York Stock Exchange\n2.500% Notes due 2034 | MRK/34 | New York Stock Exchange\n1.375% Notes due 2036 | MRK 36A | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 | Accelerated filer | \u2610\n |  |  | \nNon-accelerated filer | \u2610 | Smaller reporting company | \u2610\n |  |  | \n |  | Emerging growth company | \u2610  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page No.\nPART I | FINANCIAL INFORMATION | 3\n |  | \nItem 1. | Financial Statements | 3\n | Condensed Consolidated Statement of Income | 3\n | Condensed Consolidated Statement of Comprehensive Income | 3\n | Condensed Consolidated Balance Sheet | 4\n | Condensed Consolidated Statement of Cash Flows | 5\n | Notes to Condensed Consolidated Financial Statements | 6\n |  | \nItem 2. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 30\n |  | \nItem 3. | Quantitative and Qualitative Disclosures about Market Risk | 42\n |  | \nItem 4. | Controls and Procedures | 42\n |  | \n | Cautionary Factors That May Affect Future Results | 43\n |  | \nPART II | OTHER INFORMATION | 43\n |  | \nItem 1. | Legal Proceedings | 43\n |  | \nItem 1A. | Risk Factors | 43\n |  |  |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 44\n |  |  |  | \nItem 6. | Exhibits | 44\n |  | \n | Signatures |  |  | 45  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2022 |  | 2021 |  |  |  | \nSales | $ | 15,901 |  |  | $ | 10,627 |  |  |  |  | \nCosts, Expenses and Other |  |  |  |  |  |  | \nCost of sales | 5,380 |  |  | 3,199 |  |  |  |  | \nSelling, general and administrative | 2,323 |  |  | 2,187 |  |  |  |  | \nResearch and development | 2,576 |  |  | 2,412 |  |  |  |  | \nRestructuring costs | 53 |  |  | 297 |  |  |  |  | \nOther (income) expense, net | 708 |  |  | (455) |  |  |  |  | \n | 11,040 |  |  | 7,640 |  |  |  |  | \nIncome from Continuing Operations Before Taxes | 4,861 |  |  | 2,987 |  |  |  |  | \nTaxes on Income from Continuing Operations | 554 |  |  | 238 |  |  |  |  | \nNet Income from Continuing Operations | 4,307 |  |  | 2,749 |  |  |  |  | \nLess: Net (Loss) Income Attributable to Noncontrolling Interests | (3) |  |  | 4 |  |  |  |  | \nNet Income from Continuing Operations Attributable to Merck\u00a0& Co., Inc. | 4,310 |  |  | 2,745 |  |  |  |  | \nIncome from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | \u2014 |  |  | 434 |  |  |  |  | \nNet Income Attributable to Merck & Co., Inc. | $ | 4,310 |  |  | $ | 3,179 |  |  |  |  | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nIncome from Discontinued Operations | \u2014 |  |  | 0.17 |  |  |  |  | \nNet Income | $ | 1.70 |  |  | $ | 1.26 |  |  |  |  | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nIncome from Discontinued Operations | \u2014 |  |  | 0.17 |  |  |  |  | \nNet Income | $ | 1.70 |  |  | $ | 1.25 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2022 |  | 2021 |  |  |  | \nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,310 |  |  | $ | 3,179 |  |  |  |  | \nOther Comprehensive Income Net of Taxes: |  |  |  |  |  |  | \nNet unrealized gain on derivatives, net of reclassifications | 63 |  |  | 230 |  |  |  |  | \nBenefit plan net gain and prior service credit, net of amortization | 32 |  |  | 81 |  |  |  |  | \nCumulative translation adjustment | (35) |  |  | (299) |  |  |  |  | \n | 60 |  |  | 12 |  |  |  |  | \nComprehensive Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,370 |  |  | $ | 3,191 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\nAssets |  |  | \nCurrent Assets |  |  | \nCash and cash equivalents | $ | 8,556 |  |  | $ | 8,096 | \nShort-term investments | 372 |  |  | \u2014 | \nAccounts receivable (net of allowance for doubtful accounts of $95in 2022and $62in 2021) | 9,828 |  |  | 9,230 | \nInventories (excludes inventories of $2,495in 2022 and $2,194in 2021classified in Other assets - see Note\u00a07) | 5,774 |  |  | 5,953 | \nOther current assets | 6,654 |  |  | 6,987 | \nTotal current assets | 31,184 |  |  | 30,266 | \nInvestments | 316 |  |  | 370 | \nProperty, Plant and Equipment, at cost, net of accumulated depreciation of $18,498in 2022 and $18,192in 2021 | 19,747 |  |  | 19,279 | \nGoodwill | 21,258 |  |  | 21,264 | \nOther Intangibles, Net | 23,022 |  |  | 22,933 | \nOther Assets | 11,141 |  |  | 11,582 | \n | $ | 106,668 |  |  | $ | 105,694 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nLoans payable and current portion of long-term debt | $ | 1,208 |  |  | $ | 2,412 | \nTrade accounts payable | 3,715 |  |  | 4,609 | \nAccrued and other current liabilities | 14,051 |  |  | 13,859 | \nIncome taxes payable | 1,571 |  |  | 1,224 | \nDividends payable | 1,771 |  |  | 1,768 | \nTotal current liabilities | 22,316 |  |  | 23,872 | \nLong-Term Debt | 30,586 |  |  | 30,690 | \nDeferred Income Taxes | 3,071 |  |  | 3,441 | \nOther Noncurrent Liabilities | 9,742 |  |  | 9,434 | \nMerck\u00a0& Co., Inc. Stockholders\u2019 Equity |  |  | \nCommon stock, $0.50par valueAuthorized -6,500,000,000sharesIssued -3,577,103,522shares in 2022 and 2021 | 1,788 |  |  | 1,788 | \nOther paid-in capital | 44,275 |  |  | 44,238 | \nRetained earnings | 56,252 |  |  | 53,696 | \nAccumulated other comprehensive loss | (4,369) |  |  | (4,429) | \n | 97,946 |  |  | 95,293 | \nLess treasury stock, at cost:1,048,727,225shares in 2022 and1,049,499,023shares in 2021 | 57,063 |  |  | 57,109 | \nTotal Merck\u00a0& Co., Inc. stockholders\u2019 equity | 40,883 |  |  | 38,184 | \nNoncontrolling Interests | 70 |  |  | 73 | \nTotal equity | 40,953 |  |  | 38,257 | \n | $ | 106,668 |  |  | $ | 105,694 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31,\n | 2022 |  | 2021\nCash Flows from Operating Activities of Continuing Operations |  |  | \nNet income from continuing operations | $ | 4,307 |  |  | $ | 2,749 | \nAdjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations: |  |  | \nAmortization | 699 |  |  | 514 | \nDepreciation | 421 |  |  | 378 | \nLoss (income) from investments in equity securities, net | 708 |  |  | (574) | \nDeferred income taxes | (338) |  |  | 18 | \nShare-based compensation | 120 |  |  | 111 | \nOther | 143 |  |  | 236 | \nNet changes in assets and liabilities | (1,299) |  |  | (2,192) | \nNet Cash Provided by Operating Activities of Continuing Operations | 4,761 |  |  | 1,240 | \nCash Flows from Investing Activities of Continuing Operations |  |  | \nCapital expenditures | (984) |  |  | (1,082) | \nPurchases of securities and other investments | (372) |  |  | (1) | \nProceeds from sales of securities and other investments | 1 |  |  | 386 | \nOther | 182 |  |  | 11 | \nNet Cash Used in Investing Activities of Continuing Operations | (1,173) |  |  | (686) | \nCash Flows from Financing Activities of Continuing Operations |  |  | \nNet change in short-term borrowings | \u2014 |  |  | 788 | \nPayments on debt | (1,250) |  |  | (1,153) | \nDividends paid to stockholders | (1,745) |  |  | (1,645) | \nProceeds from exercise of stock options | 12 |  |  | 9 | \nOther | (103) |  |  | (97) | \nNet Cash Used in Financing Activities of Continuing Operations | (3,086) |  |  | (2,098) | \nCash Flows from Discontinued Operations |  |  | \nNet cash provided by operating activities | \u2014 |  |  | 551 | \nNet cash used in investing activities | \u2014 |  |  | (52) | \nNet Cash Flows Provided by Discontinued Operations | \u2014 |  |  | 499 | \nEffect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | (55) |  |  | (97) | \nNet Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash | 447 |  |  | (1,142) | \nCash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of$71and $103at January 1, 2022 and 2021, respectively, included in Other current assets) | 8,167 |  |  | 8,165 | \nLess: Cash and cash equivalents related to discontinued operations | \u2014 |  |  | 141 | \nCash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $58and $42at March\u00a031, 2022 and 2021, respectively, included in Other current assets) | $ | 8,614 |  |  | $ | 6,882 |   |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, |  | \n($ in millions) |  | 2021\nSales |  | $ | 1,453 |  |  | \nCosts, Expenses and Other |  |  |  | \nCost of sales |  | 471 |  |  | \nSelling, general and administrative |  | 446 |  |  | \nResearch and development |  | 53 |  |  | \nRestructuring costs |  | 1 |  |  | \nOther (income) expense, net |  | 7 |  |  | \n |  | 978 |  |  | \nIncome from discontinued operations before taxes |  | 475 |  |  | \nTax provision |  | 38 |  |  | \nIncome from discontinued operations, net of taxes |  | 437 |  |  | \nLess: Income of discontinued operations attributable to noncontrolling interests |  | 3 |  |  | \n |  | $ | 434 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nAlliance revenue - Lynparza | $ | 266 |  |  | $ | 228 |  |  |  |  | \nAlliance revenue - Koselugo | 9 |  |  | 5 |  |  |  |  | \nTotal alliance revenue | $ | 275 |  |  | $ | 233 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 299 |  |  | 42 |  |  |  |  | \nSelling, general and administrative | 44 |  |  | 40 |  |  |  |  | \nResearch and development | 26 |  |  | 29 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021 |  |  |  | \nReceivables from AstraZeneca included inOther current assets | $ | 275 |  |  | $ | 271 |  |  |  |  | \nPayables to AstraZeneca included inTrade accounts payableandAccrued and other current liabilities(2) | 190 |  |  | 415 |  |  |  |  | \nPayables to AstraZeneca included inOther Noncurrent Liabilities(2) | 600 |  |  | \u2014 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nAlliance revenue - Lenvima | $ | 227 |  |  | $ | 130 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 53 |  |  | 47 |  |  |  |  | \nSelling, general and administrative | 31 |  |  | 23 |  |  |  |  | \nResearch and development | 57 |  |  | 64 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021 |  |  |  | \nReceivables from Eisai included inOther current assets | $ | 241 |  |  | $ | 200 |  |  |  |  | \nPayables to Eisai included inAccrued and other current liabilities(2) | 325 |  |  | 625 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nAlliance revenue - Adempas/Verquvo | $ | 72 |  |  | $ | 74 |  |  |  |  | \nNet sales of Adempas recorded by Merck | 61 |  |  | 55 |  |  |  |  | \nNet sales of Verquvo recorded by Merck | 3 |  |  | \u2014 |  |  |  |  | \nTotal sales | $ | 136 |  |  | $ | 129 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 50 |  |  | 208 |  |  |  |  | \nSelling, general and administrative | 23 |  |  | 17 |  |  |  |  | \nResearch and development | 17 |  |  | 7 |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021 |  |  |  | \nReceivables from Bayer included inOther current assets | $ | 129 |  |  | $ | 114 |  |  |  |  | \nPayables to Bayer included inAccrued and other current liabilities(2) | 74 |  |  | 472 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nLagevriosales | $ | 3,247 |  |  | $ | \u2014 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 1,724 |  |  | 46 |  |  |  |  | \nSelling, general and administrative | 34 |  |  | 3 |  |  |  |  | \nResearch and development | 6 |  |  | 42 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021 |  |  |  | \nPayables to Ridgeback included inAccrued and other current liabilities(2) | $ | 1,568 |  |  | $ | 283 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, 2022 |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  |  |  |  |  |  |  | \nCost of sales | $ | \u2014 |  |  | $ | 18 |  |  | $ | 28 |  |  | $ | 46 |  |  |  |  |  |  |  |  | \nSelling, general and administrative | \u2014 |  |  | 4 |  |  | 17 |  |  | 21 |  |  |  |  |  |  |  |  | \nResearch and development | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 |  |  |  |  |  |  |  |  | \nRestructuring costs | 26 |  |  | \u2014 |  |  | 27 |  |  | 53 |  |  |  |  |  |  |  |  | \n | $ | 26 |  |  | $ | 29 |  |  | $ | 72 |  |  | $ | 127 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, 2021 |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  |  |  |  |  |  |  | \nCost of sales | $ | \u2014 |  |  | $ | 10 |  |  | $ | 17 |  |  | $ | 27 |  |  |  |  |  |  |  |  | \nSelling, general and administrative | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 3 |  |  |  |  |  |  |  |  | \nResearch and development | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 |  |  |  |  |  |  |  |  | \nRestructuring costs | 229 |  |  | \u2014 |  |  | 68 |  |  | 297 |  |  |  |  |  |  |  |  | \n | $ | 229 |  |  | $ | 20 |  |  | $ | 85 |  |  | $ | 334 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nRestructuring reserves January\u00a01, 2022 | $ | 596 |  |  | $ | \u2014 |  |  | $ | 41 |  |  | $ | 637 | \nExpense | 26 |  |  | 29 |  |  | 72 |  |  | 127 | \n(Payments) receipts, net | (68) |  |  | \u2014 |  |  | (45) |  |  | (113) | \nNon-cash activity | \u2014 |  |  | (29) |  |  | (39) |  |  | (68) | \nRestructuring reserves March\u00a031, 2022(1) | $ | 554 |  |  | $ | \u2014 |  |  | $ | 29 |  |  | $ | 583 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income(1) |  | Amount of Pretax (Gain) Loss Recognized inOther (income) expense, netfor Amounts Excluded from Effectiveness Testing\n | Three Months Ended March 31, |  |  |  | Three Months Ended March 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  |  |  | 2022 |  | 2021 |  |  |  | \nNet Investment Hedging Relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | $ | (16) |  |  | $ | (25) |  |  |  |  |  |  | $ | (1) |  |  | $ | (4) |  |  |  |  | \nEuro-denominated notes | (53) |  |  | (166) |  |  |  |  |  |  | \u2014 |  |  | \u2014 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022\n($ in millions) | Par Value of Debt |  | Number of Interest Rate Swaps Held |  | Total Swap Notional Amount\n2.40% notes due 2022 | $ | 1,000 |  |  | 4 |  |  | $ | 1,000 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Carrying Amount of Hedged Liabilities |  | Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount\n($ in millions) | March 31, 2022 |  | December 31, 2021 |  | March 31, 2022 |  | December 31, 2021\nBalance Sheet Line Item in which Hedged Item is Included |  |  |  |  |  |  | \nLoans payable and current portion of long-term debt | $ | 1,003 |  |  | $ | 2,263 |  |  | $ | 4 |  |  | $ | 13 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31, 2022 |  | December 31, 2021\n |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional\n($ in millions) |  | Asset |  | Liability |  | Asset |  | Liability | \nDerivatives Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts | Other current assets | $ | 4 |  |  | $ | \u2014 |  |  | $ | 1,000 |  |  | $ | 14 |  |  | $ | \u2014 |  |  | $ | 2,250 | \nForeign exchange contracts | Other current assets | 341 |  |  | \u2014 |  |  | 7,429 |  |  | 271 |  |  | \u2014 |  |  | 6,778 | \nForeign exchange contracts | Other Assets | 46 |  |  | \u2014 |  |  | 1,595 |  |  | 43 |  |  | \u2014 |  |  | 1,551 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 21 |  |  | 1,060 |  |  | \u2014 |  |  | 24 |  |  | 1,623 | \nForeign exchange contracts | Other Noncurrent Liabilities | \u2014 |  |  | 1 |  |  | 9 |  |  | \u2014 |  |  | 1 |  |  | 43 | \n |  | $ | 391 |  |  | $ | 22 |  |  | $ | 11,093 |  |  | $ | 328 |  |  | $ | 25 |  |  | $ | 12,245 | \nDerivatives Not Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Other current assets | $ | 288 |  |  | $ | \u2014 |  |  | $ | 12,466 |  |  | $ | 221 |  |  | $ | \u2014 |  |  | $ | 10,073 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 219 |  |  | 7,700 |  |  | \u2014 |  |  | 96 |  |  | 10,640 | \n |  | $ | 288 |  |  | $ | 219 |  |  | $ | 20,166 |  |  | $ | 221 |  |  | $ | 96 |  |  | $ | 20,713 | \n |  | $ | 679 |  |  | $ | 241 |  |  | $ | 31,259 |  |  | $ | 549 |  |  | $ | 121 |  |  | $ | 32,958 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\n($ in millions) | Asset |  | Liability |  | Asset |  | Liability\nGross amounts recognized in the condensed consolidated balance sheet | $ | 679 |  |  | $ | 241 |  |  | $ | 549 |  |  | $ | 121 | \nGross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet | (191) |  |  | (191) |  |  | (110) |  |  | (110) | \nCash collateral received | (220) |  |  | \u2014 |  |  | (164) |  |  | \u2014 | \nNet amounts | $ | 268 |  |  | $ | 50 |  |  | $ | 275 |  |  | $ | 11 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |  |  |  |  |  |  |  |  | \nFinancial Statement Line Items in which Effects of Fair Value or Cash FlowHedges are Recorded | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss) |  |  |  |  |  | \n | $ | 15,901 |  |  | $ | 10,627 |  |  | $ | 708 |  |  | $ | (455) |  |  | $ | 60 |  |  | $ | 12 |  |  |  |  |  |  |  |  |  |  |  |  | \n(Gain) loss on fair value hedging relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHedged items | \u2014 |  |  | \u2014 |  |  | (10) |  |  | (11) |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nDerivatives designated as hedging instruments | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nImpact of cash flow hedging relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 148 |  |  | 180 |  |  |  |  |  |  |  |  |  |  |  |  | \nIncrease (decrease) inSalesas a result ofAOCLreclassifications | 67 |  |  | (112) |  |  | \u2014 |  |  | \u2014 |  |  | (67) |  |  | 112 |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOther (income) expense, neton derivatives | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of loss recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Amount of Derivative Pretax (Gain) Loss Recognized in Income\n |  |  | Three Months Ended March 31, |  |  |  | \n($ in millions) |  |  | 2022 |  | 2021 |  |  |  | \nDerivatives Not Designated as Hedging Instruments | Income Statement Caption |  |  |  |  |  |  |  | \nForeign exchange contracts(1) | Other (income) expense, net |  | $ | 28 |  |  | $ | 50 |  |  |  |  | \nForeign exchange contracts(2) | Sales |  | (2) |  |  | (4) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\n | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue |  | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue\n($ in millions) | Gains |  | Losses |  | Gains |  | Losses | \nCommercial paper | $ | 372 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 372 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nU.S. government and agency securities | 75 |  |  | \u2014 |  |  | \u2014 |  |  | 75 |  |  | 80 |  |  | \u2014 |  |  | \u2014 |  |  | 80 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 | \nForeign government bonds | 3 |  |  | \u2014 |  |  | \u2014 |  |  | 3 |  |  | 2 |  |  | \u2014 |  |  | \u2014 |  |  | 2 | \nTotal debt securities | $ | 454 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 454 |  |  | $ | 86 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 86 | \nPublicly traded equity securities(1) |  |  |  |  |  |  | 1,397 |  |  |  |  |  |  |  |  | 1,647 | \nTotal debt and publicly traded equity securities |  |  |  |  |  |  | $ | 1,851 |  |  |  |  |  |  |  |  | $ | 1,733 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair Value Measurements Using |  | Fair Value Measurements Using\n | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |  | Total\n($ in millions) | March 31, 2022 |  | December 31, 2021\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCommercial paper | $ | \u2014 |  |  | $ | 372 |  |  | $ | \u2014 |  |  | $ | 372 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nForeign government bonds | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 2 | \nPublicly traded equity securities | 313 |  |  | \u2014 |  |  | \u2014 |  |  | 313 |  |  | 368 |  |  | \u2014 |  |  | \u2014 |  |  | 368 | \n | 313 |  |  | 375 |  |  | \u2014 |  |  | 688 |  |  | 368 |  |  | 2 |  |  | \u2014 |  |  | 370 | \nOther assets(1) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | 75 |  |  | \u2014 |  |  | \u2014 |  |  | 75 |  |  | 80 |  |  | \u2014 |  |  | \u2014 |  |  | 80 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 | \nPublicly traded equity securities | 1,084 |  |  | \u2014 |  |  | \u2014 |  |  | 1,084 |  |  | 1,279 |  |  | \u2014 |  |  | \u2014 |  |  | 1,279 | \n | 1,163 |  |  | \u2014 |  |  | \u2014 |  |  | 1,163 |  |  | 1,363 |  |  | \u2014 |  |  | \u2014 |  |  | 1,363 | \nDerivative assets(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 433 |  |  | \u2014 |  |  | 433 |  |  | \u2014 |  |  | 351 |  |  | \u2014 |  |  | 351 | \nPurchased currency options | \u2014 |  |  | 242 |  |  | \u2014 |  |  | 242 |  |  | \u2014 |  |  | 184 |  |  | \u2014 |  |  | 184 | \nInterest rate swaps | \u2014 |  |  | 4 |  |  | \u2014 |  |  | 4 |  |  | \u2014 |  |  | 14 |  |  | \u2014 |  |  | 14 | \n | \u2014 |  |  | 679 |  |  | \u2014 |  |  | 679 |  |  | \u2014 |  |  | 549 |  |  | \u2014 |  |  | 549 | \nTotal assets | $ | 1,476 |  |  | $ | 1,054 |  |  | $ | \u2014 |  |  | $ | 2,530 |  |  | $ | 1,731 |  |  | $ | 551 |  |  | $ | \u2014 |  |  | $ | 2,282 | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nContingent consideration | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 572 |  |  | $ | 572 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 777 |  |  | $ | 777 | \nDerivative liabilities(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 240 |  |  | \u2014 |  |  | 240 |  |  | \u2014 |  |  | 120 |  |  | \u2014 |  |  | 120 | \nWritten currency options | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 | \n | \u2014 |  |  | 241 |  |  | \u2014 |  |  | 241 |  |  | \u2014 |  |  | 121 |  |  | \u2014 |  |  | 121 | \nTotal liabilities | $ | \u2014 |  |  | $ | 241 |  |  | $ | 572 |  |  | $ | 813 |  |  | $ | \u2014 |  |  | $ | 121 |  |  | $ | 777 |  |  | $ | 898 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021\nFair value January 1 | $ | 777 |  |  | $ | 841 | \nChanges in estimated fair value(1) | (84) |  |  | (13) | \nPayments | (119) |  |  | \u2014 | \nOther | (2) |  |  | (12) | \nFair value March 31(2)(3) | $ | 572 |  |  | $ | 816 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021\nFinished goods | $ | 1,772 |  |  | $ | 1,747 | \nRaw materials and work in process | 6,365 |  |  | 6,220 | \nSupplies | 209 |  |  | 196 | \nTotal (approximates current cost) | 8,346 |  |  | 8,163 | \nDecrease to LIFO cost | (77) |  |  | (16) | \n | $ | 8,269 |  |  | $ | 8,147 | \nRecognized as: |  |  | \nInventories | $ | 5,774 |  |  | $ | 5,953 | \nOther assets | 2,495 |  |  | 2,194 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at January 1, 2021 | 3,577 |  | $ | 1,788 |  | $ | 39,588 |  | $ | 47,362 |  | $ | (6,634) |  | 1,047 |  | $ | (56,787) |  | $ | 87 |  | $ | 25,404 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 3,179 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3,179 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 12 |  | \u2014 |  | \u2014 |  | \u2014 |  | 12 | \nCash dividends declared on common stock ($0.65per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,653) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,653) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 25 |  | \u2014 |  | \u2014 |  | (1) |  | 65 |  | \u2014 |  | 90 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 7 |  | 7 | \nBalance at March 31, 2021 | 3,577 |  | $ | 1,788 |  | $ | 39,613 |  | $ | 48,888 |  | $ | (6,622) |  | 1,046 |  | $ | (56,722) |  | $ | 94 |  | $ | 27,039 | \nBalance at January 1, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,238 |  | $ | 53,696 |  | $ | (4,429) |  | 1,049 |  | $ | (57,109) |  | $ | 73 |  | $ | 38,257 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 4,310 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 4,310 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 60 |  | \u2014 |  | \u2014 |  | \u2014 |  | 60 | \nCash dividends declared on common stock ($0.69per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,754) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,754) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 37 |  | \u2014 |  | \u2014 |  | \u2014 |  | 46 |  | \u2014 |  | 83 | \nNet loss attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (3) |  | (3) | \nBalance at March 31, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,275 |  | $ | 56,252 |  | $ | (4,369) |  | 1,049 |  | $ | (57,063) |  | $ | 70 |  | $ | 40,953 |   |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  |  |  |  | \n |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2022 |  | 2021 |  |  |  | \n($ in millions) | U.S. |  | International |  | U.S. |  | International |  |  |  |  |  |  |  | \nService cost | $ | 99 |  |  | $ | 75 |  |  | $ | 100 |  |  | $ | 92 |  |  |  |  |  |  |  |  | \nInterest cost | 103 |  |  | 38 |  |  | 96 |  |  | 29 |  |  |  |  |  |  |  |  | \nExpected return on plan assets | (196) |  |  | (101) |  |  | (188) |  |  | (104) |  |  |  |  |  |  |  |  | \nAmortization of unrecognized prior service credit | (8) |  |  | (4) |  |  | (10) |  |  | (4) |  |  |  |  |  |  |  |  | \nNet loss amortization | 56 |  |  | 25 |  |  | 85 |  |  | 41 |  |  |  |  |  |  |  |  | \nTermination benefits | \u2014 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nCurtailments | 3 |  |  | \u2014 |  |  | 7 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nSettlements | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  | \n | $ | 58 |  |  | $ | 33 |  |  | $ | 91 |  |  | $ | 54 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nService cost | $ | 12 |  |  | $ | 13 |  |  |  |  | \nInterest cost | 11 |  |  | 11 |  |  |  |  | \nExpected return on plan assets | (21) |  |  | (20) |  |  |  |  | \nAmortization of unrecognized prior service credit | (25) |  |  | (25) |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n | $ | (23) |  |  | $ | (21) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nInterest income | $ | (7) |  |  | $ | (11) |  |  |  |  | \nInterest expense | 243 |  |  | 200 |  |  |  |  | \nExchange losses | 39 |  |  | 41 |  |  |  |  | \nLoss (income) from investments in equity securities, net(1) | 708 |  |  | (574) |  |  |  |  | \nNet periodic defined benefit plan (credit) cost other than service cost | (121) |  |  | (89) |  |  |  |  | \nOther, net | (154) |  |  | (22) |  |  |  |  | \n | $ | 708 |  |  | $ | (455) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ and shares in millions except per share amounts) | 2022 |  | 2021 |  |  |  | \nNet Income from Continuing Operations Attributable to Merck\u00a0& Co., Inc. | $ | 4,310 |  |  | $ | 2,745 |  |  |  |  | \nIncome from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | \u2014 |  |  | 434 |  |  |  |  | \nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,310 |  |  | $ | 3,179 |  |  |  |  | \nAverage common shares outstanding | 2,528 |  |  | 2,531 |  |  |  |  | \nCommon shares issuable(1) | 9 |  |  | 10 |  |  |  |  | \nAverage common shares outstanding assuming dilution | 2,537 |  |  | 2,541 |  |  |  |  | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nIncome from Discontinued Operations | \u2014 |  |  | 0.17 |  |  |  |  | \nNet Income | $ | 1.70 |  |  | $ | 1.26 |  |  |  |  | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nIncome from Discontinued Operations | \u2014 |  |  | 0.17 |  |  |  |  | \nNet Income | $ | 1.70 |  |  | $ | 1.25 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance January 1, 2021, net of taxes | $ | (266) |  |  | $ | (4,540) |  |  | $ | (1,828) |  |  | $ | (6,634) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 180 |  |  | (4) |  |  | (211) |  |  | (35) | \nTax | (38) |  |  | (1) |  |  | (88) |  |  | (127) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 142 |  |  | (5) |  |  | (299) |  |  | (162) | \nReclassification adjustments, pretax | 111 |  | (1) | 87 |  | (2) | \u2014 |  |  | 198 | \nTax | (23) |  |  | (1) |  |  | \u2014 |  |  | (24) | \nReclassification adjustments, net of taxes | 88 |  |  | 86 |  |  | \u2014 |  |  | 174 | \nOther comprehensive income (loss), net of taxes | 230 |  |  | 81 |  |  | (299) |  |  | 12 | \nBalance March 31, 2021, net of taxes | $ | (36) |  |  | $ | (4,459) |  |  | $ | (2,127) |  |  | $ | (6,622) | \nBalance January 1, 2022, net of taxes | $ | 144 |  |  | $ | (2,743) |  |  | $ | (1,830) |  |  | $ | (4,429) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 148 |  |  | 1 |  |  | (18) |  |  | 131 | \nTax | (31) |  |  | (2) |  |  | (17) |  |  | (50) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 117 |  |  | (1) |  |  | (35) |  |  | 81 | \nReclassification adjustments, pretax | (68) |  | (1) | 45 |  | (2) | \u2014 |  |  | (23) | \nTax | 14 |  |  | (12) |  |  | \u2014 |  |  | 2 | \nReclassification adjustments, net of taxes | (54) |  |  | 33 |  |  | \u2014 |  |  | (21) | \nOther comprehensive income (loss), net of taxes | 63 |  |  | 32 |  |  | (35) |  |  | 60 | \nBalance March 31, 2022, net of taxes | $ | 207 |  |  | $ | (2,711) |  |  | $ | (1,865) |  |  | $ | (4,369) |   |  |  |  |  |  |  |  |  | \n | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \n($ in millions) | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  |  |  |  |  |  |  |  |  |  |  | \nPharmaceutical: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nKeytruda | $ | 2,779 |  |  | $ | 2,030 |  |  | $ | 4,809 |  |  | $ | 2,181 |  |  | $ | 1,718 |  |  | $ | 3,899 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue - Lynparza(1) | 141 |  |  | 125 |  |  | 266 |  |  | 118 |  |  | 110 |  |  | 228 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue - Lenvima(1) | 156 |  |  | 71 |  |  | 227 |  |  | 85 |  |  | 44 |  |  | 130 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue - Reblozyl(2) | 27 |  |  | 25 |  |  | 52 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nVaccines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | 418 |  |  | 1,042 |  |  | 1,460 |  |  | 313 |  |  | 604 |  |  | 917 |  |  |  |  |  |  |  |  |  |  |  |  | \nProQuad/M-M-RII/Varivax | 371 |  |  | 99 |  |  | 470 |  |  | 333 |  |  | 117 |  |  | 449 |  |  |  |  |  |  |  |  |  |  |  |  | \nRotaTeq | 175 |  |  | 41 |  |  | 216 |  |  | 118 |  |  | 41 |  |  | 158 |  |  |  |  |  |  |  |  |  |  |  |  | \nPneumovax23 | 118 |  |  | 55 |  |  | 173 |  |  | 73 |  |  | 99 |  |  | 171 |  |  |  |  |  |  |  |  |  |  |  |  | \nVaqta | 29 |  |  | 7 |  |  | 36 |  |  | 25 |  |  | 9 |  |  | 34 |  |  |  |  |  |  |  |  |  |  |  |  | \nHospital Acute Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBridion | 195 |  |  | 199 |  |  | 395 |  |  | 167 |  |  | 173 |  |  | 340 |  |  |  |  |  |  |  |  |  |  |  |  | \nPrevymis | 40 |  |  | 54 |  |  | 94 |  |  | 35 |  |  | 47 |  |  | 82 |  |  |  |  |  |  |  |  |  |  |  |  | \nPrimaxin | 1 |  |  | 58 |  |  | 58 |  |  | \u2014 |  |  | 65 |  |  | 65 |  |  |  |  |  |  |  |  |  |  |  |  | \nNoxafil | 10 |  |  | 48 |  |  | 57 |  |  | 15 |  |  | 52 |  |  | 67 |  |  |  |  |  |  |  |  |  |  |  |  | \nCancidas | 1 |  |  | 52 |  |  | 53 |  |  | 3 |  |  | 55 |  |  | 57 |  |  |  |  |  |  |  |  |  |  |  |  | \nDificid | 49 |  |  | 3 |  |  | 52 |  |  | 25 |  |  | 2 |  |  | 27 |  |  |  |  |  |  |  |  |  |  |  |  | \nInvanz | 1 |  |  | 52 |  |  | 52 |  |  | 4 |  |  | 52 |  |  | 57 |  |  |  |  |  |  |  |  |  |  |  |  | \nZerbaxa | 18 |  |  | 12 |  |  | 30 |  |  | (2) |  |  | (6) |  |  | (8) |  |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue - Adempas/Verquvo(3) | 71 |  |  | 1 |  |  | 72 |  |  | 68 |  |  | 6 |  |  | 74 |  |  |  |  |  |  |  |  |  |  |  |  | \nAdempas | \u2014 |  |  | 61 |  |  | 61 |  |  | \u2014 |  |  | 55 |  |  | 55 |  |  |  |  |  |  |  |  |  |  |  |  | \nVirology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLagevrio | 1,523 |  |  | 1,723 |  |  | 3,247 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nIsentress/IsentressHD | 61 |  |  | 97 |  |  | 158 |  |  | 71 |  |  | 138 |  |  | 209 |  |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBelsomra | 20 |  |  | 48 |  |  | 69 |  |  | 18 |  |  | 61 |  |  | 79 |  |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSimponi | \u2014 |  |  | 186 |  |  | 186 |  |  | \u2014 |  |  | 214 |  |  | 214 |  |  |  |  |  |  |  |  |  |  |  |  | \nRemicade | \u2014 |  |  | 61 |  |  | 61 |  |  | \u2014 |  |  | 85 |  |  | 85 |  |  |  |  |  |  |  |  |  |  |  |  | \nDiabetes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nJanuvia | 325 |  |  | 454 |  |  | 779 |  |  | 348 |  |  | 461 |  |  | 809 |  |  |  |  |  |  |  |  |  |  |  |  | \nJanumet | 63 |  |  | 391 |  |  | 454 |  |  | 84 |  |  | 401 |  |  | 486 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther pharmaceutical(4) | 181 |  |  | 339 |  |  | 520 |  |  | 212 |  |  | 341 |  |  | 554 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal Pharmaceutical segment sales | 6,773 |  |  | 7,334 |  |  | 14,107 |  |  | 4,294 |  |  | 4,944 |  |  | 9,238 |  |  |  |  |  |  |  |  |  |  |  |  | \nAnimal Health: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLivestock | 171 |  |  | 661 |  |  | 832 |  |  | 157 |  |  | 662 |  |  | 819 |  |  |  |  |  |  |  |  |  |  |  |  | \nCompanion Animals | 302 |  |  | 348 |  |  | 650 |  |  | 280 |  |  | 319 |  |  | 599 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal Animal Health segment sales | 473 |  |  | 1,009 |  |  | 1,482 |  |  | 437 |  |  | 981 |  |  | 1,418 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal segment sales | 7,246 |  |  | 8,343 |  |  | 15,589 |  |  | 4,731 |  |  | 5,925 |  |  | 10,656 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther(5) | 93 |  |  | 220 |  |  | 312 |  |  | 59 |  |  | (88) |  |  | (29) |  |  |  |  |  |  |  |  |  |  |  |  | \n | $ | 7,339 |  |  | $ | 8,563 |  |  | $ | 15,901 |  |  | $ | 4,790 |  |  | $ | 5,837 |  |  | $ | 10,627 |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nUnited States | $ | 7,339 |  |  | $ | 4,790 |  |  |  |  | \nEurope, Middle East and Africa | 4,359 |  |  | 3,237 |  |  |  |  | \nChina | 1,143 |  |  | 721 |  |  |  |  | \nJapan | 989 |  |  | 629 |  |  |  |  | \nAsia Pacific (other than China and Japan) | 930 |  |  | 575 |  |  |  |  | \nLatin America | 607 |  |  | 500 |  |  |  |  | \nOther | 534 |  |  | 175 |  |  |  |  | \n | $ | 15,901 |  |  | $ | 10,627 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nSegment profits: |  |  |  |  |  |  | \nPharmaceutical segment | $ | 9,501 |  |  | $ | 6,589 |  |  |  |  | \nAnimal Health segment | 585 |  |  | 572 |  |  |  |  | \nTotal segment profits | 10,086 |  |  | 7,161 |  |  |  |  | \nOther profits | 194 |  |  | (50) |  |  |  |  | \nUnallocated: |  |  |  |  |  |  | \nInterest income | 7 |  |  | 11 |  |  |  |  | \nInterest expense | (243) |  |  | (200) |  |  |  |  | \nAmortization | (699) |  |  | (514) |  |  |  |  | \nDepreciation | (378) |  |  | (340) |  |  |  |  | \nResearch and development | (2,446) |  |  | (2,305) |  |  |  |  | \nRestructuring costs | (53) |  |  | (297) |  |  |  |  | \nOther unallocated, net | (1,607) |  |  | (479) |  |  |  |  | \n | $ | 4,861 |  |  | $ | 2,987 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nUnited States | $ | 7,339 |  |  | $ | 4,790 |  |  | 53 | % |  | 53 | % |  |  |  |  |  |  |  | \nInternational | 8,563 |  |  | 5,837 |  |  | 47 | % |  | 52 | % |  |  |  |  |  |  |  | \nTotal | $ | 15,901 |  |  | $ | 10,627 |  |  | 50 | % |  | 52 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nKeytruda | $ | 4,809 |  |  | $ | 3,899 |  |  | 23 | % |  | 27 | % |  |  |  |  |  |  |  | \nAlliance Revenue - Lynparza(1) | 266 |  |  | 228 |  |  | 17 | % |  | 20 | % |  |  |  |  |  |  |  | \nAlliance Revenue-Lenvima(1) | 227 |  |  | 130 |  |  | 75 | % |  | 77 | % |  |  |  |  |  |  |  |   |  |  |  |  | \nDate | Approval\nJanuary 2022 | European Commission (EC) approval as monotherapy for the adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions based on the KEYNOTE-564 trial.\nFebruary 2022 | Japan Ministry of Health, Labour and Welfare approval of the combination ofKeytrudaplus Lenvima for radically unresectable or metastatic RCC based on the CLEAR (Study 307)/KEYNOTE-581 trial.\nFebruary 2022 | Japan Pharmaceuticals and Medical Devices Agency approval for the treatment of adult patients with advanced or recurrent TMB-H solid tumors that have progressed after chemotherapy (limited to use when difficult to treat with standard of care) based on the KEYNOTE-158 trial.\nMarch 2022 | U.S. Food and Drug Administration (FDA) approval as a single agent for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation based on the KEYNOTE-158 trial (Cohorts D & K).\nApril 2022 | EC approval in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in certain adults whose tumors express PD-L1 based on the KEYNOTE-826 trial.\nApril 2022 | EC approval as monotherapy for the treatment of certain patients with unresectable or metastatic MSI-H/dMMR colorectal, gastric, small intestine or biliary cancer, as well as advanced or recurrent MSI-H/dMMR endometrial cancer based on data from KEYNOTE-164 and KEYNOTE-158.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | $ | 1,460 |  |  | $ | 917 |  |  | 59 | % |  | 60 | % |  |  |  |  |  |  |  | \nProQuad | 162 |  |  | 165 |  |  | (2) | % |  | (1) | % |  |  |  |  |  |  |  | \nM-M-RII | 103 |  |  | 80 |  |  | 29 | % |  | 31 | % |  |  |  |  |  |  |  | \nVarivax | 204 |  |  | 204 |  |  | \u2014 | % |  | 1 | % |  |  |  |  |  |  |  | \nRotaTeq | 216 |  |  | 158 |  |  | 36 | % |  | 38 | % |  |  |  |  |  |  |  | \nPneumovax 23 | 173 |  |  | 171 |  |  | 1 | % |  | 3 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nBridion | $ | 395 |  |  | $ | 340 |  |  | 16 | % |  | 20 | % |  |  |  |  |  |  |  | \nZerbaxa | 30 |  |  | (8) |  |  | * |  | * |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nAlliance Revenue - Adempas/Verquvo(1) | $ | 72 |  |  | $ | 74 |  |  | (3) | % |  | (3) | % |  |  |  |  |  |  |  | \nAdempas | 61 |  |  | 55 |  |  | 11 | % |  | 20 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nLagevrio | $ | 3,247 |  |  | $ | \u2014 |  |  | \u2014 |  | \u2014 |  |  |  |  |  |  |  | \nIsentress/Isentress HD | 158 |  |  | 209 |  |  | (24) | % |  | (21) | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nJanuvia/Janumet | $ | 1,233 |  |  | $ | 1,295 |  |  | (5) | % |  | (1) | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nLivestock | $ | 832 |  |  | $ | 819 |  |  | 2 | % |  | 7 | % |  |  |  |  |  |  |  | \nCompanion Animal | 650 |  |  | 599 |  |  | 9 | % |  | 13 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  | \nCost of sales | $ | 5,380 |  |  | $ | 3,199 |  |  | 68 | % |  |  |  |  |  | \nSelling, general and administrative | 2,323 |  |  | 2,187 |  |  | 6 | % |  |  |  |  |  | \nResearch and development | 2,576 |  |  | 2,412 |  |  | 7 | % |  |  |  |  |  | \nRestructuring costs | 53 |  |  | 297 |  |  | (82) | % |  |  |  |  |  | \nOther (income) expense, net | 708 |  |  | (455) |  |  | * |  |  |  |  |  | \n | $ | 11,040 |  |  | $ | 7,640 |  |  | 45 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSegment Profits |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nPharmaceutical segment profits | $ | 9,501 |  |  | $ | 6,589 |  |  |  |  | \nAnimal Health segment profits | 585 |  |  | 572 |  |  |  |  | \nOther | (5,225) |  |  | (4,174) |  |  |  |  | \nIncome from Continuing Operations Before Taxes | $ | 4,861 |  |  | $ | 2,987 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions except per share amounts) | 2022 |  | 2021 |  |  |  | \nIncome from continuing operations before taxes as reported under GAAP | $ | 4,861 |  |  | $ | 2,987 |  |  |  |  | \nIncrease (decrease) for excluded items: |  |  |  |  |  |  | \nAcquisition and divestiture-related costs | 637 |  |  | 497 |  |  |  |  | \nRestructuring costs | 127 |  |  | 334 |  |  |  |  | \nLoss (income) from investments in equity securities, net | 684 |  |  | (561) |  |  |  |  | \nOther items: |  |  |  |  |  |  | \nCharge for the discontinuation of COVID-19 development programs | \u2014 |  |  | 188 |  |  |  |  | \nNon-GAAP income from continuing operations before taxes | 6,309 |  |  | 3,445 |  |  |  |  | \nTaxes on income from continuing operations as reported under GAAP | 554 |  |  | 238 |  |  |  |  | \nEstimated tax benefit on excluded items(1) | 329 |  |  | 48 |  |  |  |  | \nNet tax benefit from the settlement of certain federal income tax matters | \u2014 |  |  | 208 |  |  |  |  | \nNon-GAAP taxes on income from continuing operations | 883 |  |  | 494 |  |  |  |  | \nNon-GAAP net income from continuing operations | 5,426 |  |  | 2,951 |  |  |  |  | \nLess: Net (loss) income attributable to noncontrolling interests as reported under GAAP | (3) |  |  | 4 |  |  |  |  | \nNon-GAAP net income from continuing operations attributable to Merck\u00a0& Co., Inc. | $ | 5,429 |  |  | $ | 2,947 |  |  |  |  | \nEPS assuming dilution from continuing operations as reported under GAAP | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nEPS difference | 0.44 |  |  | 0.08 |  |  |  |  | \nNon-GAAP EPS assuming dilution from continuing operations | $ | 2.14 |  |  | $ | 1.16 |  |  |  |  |   |  |  |  |  |  |  |  | \nPhase 2\nCancerMK-0482(3)Non-Small-Cell LungMK-1026 (nemtabrutinib)Hematological MalignanciesMK-1308 (quavonlimab)(2)Non-Small-Cell LungMK-1308A (quavonlimab+pembrolizumab)Advanced Solid TumorsColorectalHepatocellularMelanomaSmall-Cell LungMK-2140 (zilovertamab vedotin)BreastHematological MalignanciesNon-Small-Cell LungSolid TumorsMK-3475KeytrudaAdvanced Solid TumorsMK-4280 (favezelimab)(2)Hematological MalignanciesNon-Small-Cell LungMK-4280A (favezelimab+pembrolizumab)Renal CellSmall-Cell LungMK-4830(2)ColorectalNon-Small-Cell LungRenal CellSmall-Cell LungMK-5890(3)Non-Small-Cell LungSmall-Cell Lung | CancerMK-6440 (ladiratuzumab vedotin)(1)(3)BreastEsophagealGastricHead and NeckMelanomaNon-Small-Cell LungProstateSmall-Cell LungMK-6482Welireg(3)BiliaryColorectalHepatocellularPancreaticRare cancersVon Hippel-Lindau Disease-Associated Tumors (EU)MK-7119 Tukysa(1)Advanced Solid TumorsBiliaryBladderCervicalColorectalEndometrialGastricNon-Small-Cell LungMK-7339 Lynparza(1)(3)Advanced Solid TumorsMK-7684 (vibostolimab)(2)MelanomaMK-7684A (vibostolimab+pembrolizumab)BiliaryBreastCervicalEndometrialEsophagealHead and NeckHematological MalignanciesHepatocellularProstate | CancerMK-7902 Lenvima(1)(2)BiliaryGlioblastomaPancreaticProstateSmall-Cell LungV937BreastCutaneous Squamous CellHead and NeckMelanomaSolid TumorsCardiovascularMK-2060Chikungunya Virus VaccineV184HIV-1 InfectionMK-8591B (islatravir+MK-8507)(4)MK-8591D (islatravir+lenacapavir)(1)(4)HypercholesterolemiaMK-0616Nonalcoholic Steatohepatitis (NASH)MK-3655MK-6024Overgrowth SyndromeMK-7075 (miransertib)Pneumococcal Vaccine AdultV116Pulmonary Arterial HypertensionMK-5475SchizophreniaMK-8189Treatment Resistant DepressionMK-1942  |  |  |  |  |  |  |  | \nPhase 3 (Phase 3 entry date) | Under Review\nAntiviral COVID-19MK-4482Lagevrio(U.S.) (May 2021)(1)(5)CancerMK-1308A (quavonlimab+pembrolizumab)Renal Cell (April 2021)MK-3475KeytrudaBiliary (September 2019)Cutaneous Squamous Cell (August 2019) (EU)Gastric (May 2015) (EU)Hepatocellular (May 2016) (EU)Mesothelioma (May 2018)Ovarian (December 2018)Prostate (May 2019)Small-Cell Lung (May 2017)MK-3475 (pembrolizumab subcutaneous)Non-Small-Cell Lung (August 2021)MK-4280A (favezelimab+pembrolizumab)Colorectal (November 2021)MK-6482Welireg(3)Renal Cell (February 2020)MK-7119 Tukysa(1)Breast (October 2019)MK-7339 Lynparza(1)(3)Colorectal (August 2020)Non-Small-Cell Lung (June 2019)Small-Cell Lung (December 2020)MK-7684A (vibostolimab+pembrolizumab)Non-Small-Cell Lung (April 2021)Small-Cell Lung (March 2022)MK-7902 Lenvima(1)(2)Colorectal (April 2021)Esophageal (July 2021)Gastric (December 2020)Head and Neck (February 2020)Melanoma (March 2019)Non-Small-Cell Lung (March 2019)HIV-1 InfectionMK-8591A (doravirine+islatravir) (February 2020)(4)HIV-1 PreventionMK-8591 (islatravir) (February 2021)(4)Pulmonary Arterial HypertensionMK-7962 (sotatercept) (January 2021)Respiratory Syncytial VirusMK-1654 (clesrovimab) (November 2021) | New Molecular Entities/VaccinesAntiviral COVID-19MK-4482Lagevrio(EU)(1)CoughMK-7264 (gefapixant) (U.S.)(6)(EU)Pneumococcal Vaccine AdultV114 (JPN) | Certain Supplemental FilingsCancerMK-3475Keytruda\u2022    High-Risk Early-Stage Triple-Negative Breast Cancer(KEYNOTE-522) (EU) (JPN)\u2022    Adjuvent Treatment of Stage IIB and IIC Melanoma(KEYNOTE-716) (EU)\u2022    Cervical Cancer (KEYNOTE-826) (JPN)\u2022    Adjuvent Renal Cell Cancer(KEYNOTE-564) (JPN)\u2022    Second-Line Hepatocellular Cancer(KEYNOTE-394) (U.S.)MK-7339 Lynparza(1)\u2022BRCA-Mutated HER2-Negative Adjuvant BreastCancer (OlympiA) (EU) (JPN)\u2022    First-Line Metastatic Prostate Cancer (PROpel) EU)MK-7902 Lenvima(1)(2)\u2022    First-Line Metastatic Hepatocellular Carcinoma(KEYNOTE-524) (U.S.)(7)\nFootnotes:(1)Being developed in a collaboration.(2)Being developed in combination withKeytruda.(3)Being developed as monotherapy and/or in combination withKeytruda.(4)On FDA clinical hold.(5)Available in the U.S. under Emergency Use Authorization.(6)In January 2022, the FDA issued a CRL for this application. Merck is reviewing the CRL and considering next steps.(7)In July 2020, the FDA issued a CRL for Merck\u2019s and Eisai\u2019s applications. Merck and Eisai intend to submit additional data when available to the FDA.  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021\nCash and investments | $ | 9,244 |  |  | $ | 8,466 | \nWorking capital | 8,868 |  |  | 6,394 | \nTotal debt to total liabilities and equity | 29.8 | % |  | 31.3 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | ($\u00a0in\u00a0millions)\nPeriod | Total\u00a0Numberof SharesPurchased(1) |  | Average\u00a0PricePaid PerShare |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0SharesThat May Yet Be PurchasedUnder the Plans or Programs(1)\nJanuary 1 - January 31 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nFebruary 1 - February 28 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nMarch 1 - March 31 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nTotal | \u2014 |  |  | $0.00 |  | \u2014 |  |  |   |  |  |  |  |  |  |  | \nNumber |  | Description\n | \n3.1 | \u2014 | Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) \u2013 Incorporated by reference to Current Report on Form 8-K filed on November\u00a04, 2009 (No. 1-6571)\n | \n3.2 | \u2014 | By-Laws of Merck & Co., Inc. (effective March 22, 2022) \u2013 Incorporated by reference to Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)\n |  | \n31.1 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Executive Officer\n | \n31.2 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Financial Officer\n | \n32.1 |  | \u2014 | Section 1350 Certification of Chief Executive Officer\n | \n32.2 |  | \u2014 | Section 1350 Certification of Chief Financial Officer\n | \n101.INS | \u2014 | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.\n |  | \n101.SCH | \u2014 | XBRL Taxonomy Extension Schema Document.\n |  | \n101.CAL | \u2014 | XBRL Taxonomy Extension Calculation Linkbase Document.\n |  | \n101.DEF | \u2014 | XBRL Taxonomy Extension Definition Linkbase Document.\n |  | \n101.LAB | \u2014 | XBRL Taxonomy Extension Label Linkbase Document.\n |  | \n101.PRE | \u2014 | XBRL Taxonomy Extension Presentation Linkbase Document.\n |  | \n104 |  | \u2014 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).  |  |  |  |  |  |  |  | \n |  | MERCK & CO., INC.\n |  | \nDate:  May 5, 2022 |  | /s/ Jennifer Zachary\n |  | JENNIFER ZACHARY\n |  | Executive Vice President and General Counsel\n |  | \nDate:  May 5, 2022 |  | /s/ Rita A. Karachun\n |  | RITA A. KARACHUN\n |  | Senior Vice President Finance - Global Controller"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Merck, in 2022 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  | \n  |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n |   |  |  |  |  |  |  |  | \nNew Jersey | 22-1918501\n(State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.)\n | \n126 East Lincoln Avenue\nRahway | New Jersey | 07065\n(Address of principal executive offices) (zip code)  |  |  |  |  |  |  |  | \n | Not Applicable | \n(Former name, former address and former fiscal year, if changed since last report.)  |  |  |  |  |  |  |  | \nSecurities Registered pursuant to Section\u00a012(b) of the Act:\nTitle of each class | Trading Symbol(s) | Name of each exchange on which registered\nCommon Stock ($0.50\u00a0par value) | MRK | New York Stock Exchange\n0.500% Notes due 2024 | MRK 24 | New York Stock Exchange\n1.875% Notes due 2026 | MRK/26 | New York Stock Exchange\n2.500% Notes due 2034 | MRK/34 | New York Stock Exchange\n1.375% Notes due 2036 | MRK 36A | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 | Accelerated filer | \u2610\n |  |  | \nNon-accelerated filer | \u2610 | Smaller reporting company | \u2610\n |  |  | \n |  | Emerging growth company | \u2610  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page No.\nPART I | FINANCIAL INFORMATION | 3\n |  | \nItem 1. | Financial Statements | 3\n | Condensed Consolidated Statement of Income | 3\n | Condensed Consolidated Statement of Comprehensive Income | 3\n | Condensed Consolidated Balance Sheet | 4\n | Condensed Consolidated Statement of Cash Flows | 5\n | Notes to Condensed Consolidated Financial Statements | 6\n |  | \nItem 2. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 34\n |  | \nItem 3. | Quantitative and Qualitative Disclosures about Market Risk | 48\n |  | \nItem 4. | Controls and Procedures | 49\n |  | \n | Cautionary Factors That May Affect Future Results | 49\n |  | \nPART II | OTHER INFORMATION | 49\n |  | \nItem 1. | Legal Proceedings | 49\n |  | \nItem 1A. | Risk Factors | 49\n |  |  |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 50\n |  |  |  | \nItem 6. | Exhibits | 50\n |  | \n | Signatures |  |  | 51  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nSales | $ | 14,593 |  |  | $ | 11,402 |  |  | $ | 30,494 |  |  | $ | 22,029 | \nCosts, Expenses and Other |  |  |  |  |  |  | \nCost of sales | 4,216 |  |  | 3,104 |  |  | 9,596 |  |  | 6,303 | \nSelling, general and administrative | 2,512 |  |  | 2,281 |  |  | 4,834 |  |  | 4,468 | \nResearch and development | 2,798 |  |  | 4,321 |  |  | 5,374 |  |  | 6,732 | \nRestructuring costs | 142 |  |  | 82 |  |  | 194 |  |  | 380 | \nOther (income) expense, net | 438 |  |  | (103) |  |  | 1,148 |  |  | (558) | \n | 10,106 |  |  | 9,685 |  |  | 21,146 |  |  | 17,325 | \nIncome from Continuing Operations Before Taxes | 4,487 |  |  | 1,717 |  |  | 9,348 |  |  | 4,704 | \nTaxes on Income from Continuing Operations | 538 |  |  | 503 |  |  | 1,092 |  |  | 741 | \nNet Income from Continuing Operations | 3,949 |  |  | 1,214 |  |  | 8,256 |  |  | 3,963 | \nLess: Net Income Attributable to Noncontrolling Interests | 5 |  |  | 1 |  |  | 2 |  |  | 5 | \nNet Income from Continuing Operations Attributable to Merck\u00a0& Co., Inc. | 3,944 |  |  | 1,213 |  |  | 8,254 |  |  | 3,958 | \nIncome from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | \u2014 |  |  | 332 |  |  | \u2014 |  |  | 766 | \nNet Income Attributable to Merck & Co., Inc. | $ | 3,944 |  |  | $ | 1,545 |  |  | $ | 8,254 |  |  | $ | 4,724 | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.56 |  |  | $ | 0.48 |  |  | $ | 3.26 |  |  | $ | 1.56 | \nIncome from Discontinued Operations | \u2014 |  |  | 0.13 |  |  | \u2014 |  |  | 0.30 | \nNet Income | $ | 1.56 |  |  | $ | 0.61 |  |  | $ | 3.26 |  |  | $ | 1.87 | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.55 |  |  | $ | 0.48 |  |  | $ | 3.25 |  |  | $ | 1.56 | \nIncome from Discontinued Operations | \u2014 |  |  | 0.13 |  |  | \u2014 |  |  | 0.30 | \nNet Income | $ | 1.55 |  |  | $ | 0.61 |  |  | $ | 3.25 |  |  | $ | 1.86 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 3,944 |  |  | $ | 1,545 |  |  | $ | 8,254 |  |  | $ | 4,724 | \nOther Comprehensive Income Net of Taxes: |  |  |  |  |  |  | \nNet unrealized gain on derivatives, net of reclassifications | 183 |  |  | 10 |  |  | 246 |  |  | 240 | \nBenefit plan net gain and prior service credit, net of amortization | 246 |  |  | 1,403 |  |  | 278 |  |  | 1,484 | \nCumulative translation adjustment | (387) |  |  | 132 |  |  | (422) |  |  | (167) | \n | 42 |  |  | 1,545 |  |  | 102 |  |  | 1,557 | \nComprehensive Income Attributable to Merck\u00a0& Co., Inc. | $ | 3,986 |  |  | $ | 3,090 |  |  | $ | 8,356 |  |  | $ | 6,281 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022 |  | December 31, 2021\nAssets |  |  | \nCurrent Assets |  |  | \nCash and cash equivalents | $ | 9,675 |  |  | $ | 8,096 | \nShort-term investments | 453 |  |  | \u2014 | \nAccounts receivable (net of allowance for doubtful accounts of $82in 2022and $62in 2021) | 9,643 |  |  | 9,230 | \nInventories (excludes inventories of $2,764in 2022 and $2,194in 2021classified in Other assets - see Note\u00a07) | 5,535 |  |  | 5,953 | \nOther current assets | 6,810 |  |  | 6,987 | \nTotal current assets | 32,116 |  |  | 30,266 | \nInvestments | 238 |  |  | 370 | \nProperty, Plant and Equipment, at cost, net of accumulated depreciation of $17,798in 2022 and $18,192in 2021 | 20,059 |  |  | 19,279 | \nGoodwill | 21,213 |  |  | 21,264 | \nOther Intangibles, Net | 22,497 |  |  | 22,933 | \nOther Assets | 10,972 |  |  | 11,582 | \n | $ | 107,095 |  |  | $ | 105,694 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nLoans payable and current portion of long-term debt | $ | 2,979 |  |  | $ | 2,412 | \nTrade accounts payable | 3,482 |  |  | 4,609 | \nAccrued and other current liabilities | 13,501 |  |  | 13,859 | \nIncome taxes payable | 1,438 |  |  | 1,224 | \nDividends payable | 1,768 |  |  | 1,768 | \nTotal current liabilities | 23,168 |  |  | 23,872 | \nLong-Term Debt | 28,684 |  |  | 30,690 | \nDeferred Income Taxes | 2,974 |  |  | 3,441 | \nOther Noncurrent Liabilities | 8,951 |  |  | 9,434 | \nMerck\u00a0& Co., Inc. Stockholders\u2019 Equity |  |  | \nCommon stock, $0.50par valueAuthorized -6,500,000,000sharesIssued -3,577,103,522shares in 2022 and 2021 | 1,788 |  |  | 1,788 | \nOther paid-in capital | 44,115 |  |  | 44,238 | \nRetained earnings | 58,437 |  |  | 53,696 | \nAccumulated other comprehensive loss | (4,327) |  |  | (4,429) | \n | 100,013 |  |  | 95,293 | \nLess treasury stock, at cost:1,043,894,068shares in 2022 and1,049,499,023shares in 2021 | 56,770 |  |  | 57,109 | \nTotal Merck\u00a0& Co., Inc. stockholders\u2019 equity | 43,243 |  |  | 38,184 | \nNoncontrolling Interests | 75 |  |  | 73 | \nTotal equity | 43,318 |  |  | 38,257 | \n | $ | 107,095 |  |  | $ | 105,694 |   |  |  |  |  |  |  |  |  |  |  | \n | Six Months EndedJune 30,\n | 2022 |  | 2021\nCash Flows from Operating Activities of Continuing Operations |  |  | \nNet income from continuing operations | $ | 8,256 |  |  | $ | 3,963 | \nAdjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations: |  |  | \nAmortization | 1,163 |  |  | 871 | \nDepreciation | 895 |  |  | 749 | \nIntangible asset impairment charges | 23 |  |  | \u2014 | \nLoss (income) from investments in equity securities, net | 991 |  |  | (854) | \nCharge for the acquisition of Pandion Therapeutics, Inc. | \u2014 |  |  | 1,556 | \nDeferred income taxes | (600) |  |  | 29 | \nShare-based compensation | 257 |  |  | 243 | \nOther | 776 |  |  | 328 | \nNet changes in assets and liabilities | (2,698) |  |  | (3,655) | \nNet Cash Provided by Operating Activities of Continuing Operations | 9,063 |  |  | 3,230 | \nCash Flows from Investing Activities of Continuing Operations |  |  | \nCapital expenditures | (2,113) |  |  | (2,068) | \nPurchases of securities and other investments | (705) |  |  | (1) | \nProceeds from sales of securities and other investments | 374 |  |  | 386 | \nAcquisition of Pandion Therapeutics, Inc., net of cash acquired | \u2014 |  |  | (1,554) | \nOther acquisitions, net of cash acquired | \u2014 |  |  | (90) | \nOther | 194 |  |  | 16 | \nNet Cash Used in Investing Activities of Continuing Operations | (2,250) |  |  | (3,311) | \nCash Flows from Financing Activities of Continuing Operations |  |  | \nNet change in short-term borrowings | \u2014 |  |  | (3,983) | \nPayments on debt | (1,250) |  |  | (1,153) | \nDistribution from Organon & Co. | \u2014 |  |  | 9,000 | \nPurchases of treasury stock | \u2014 |  |  | (239) | \nDividends paid to stockholders | (3,515) |  |  | (3,318) | \nProceeds from exercise of stock options | 109 |  |  | 51 | \nOther | (207) |  |  | (194) | \nNet Cash (Used in) Provided by Financing Activities of Continuing Operations | (4,863) |  |  | 164 | \nCash Flows from Discontinued Operations |  |  | \nNet cash provided by operating activities | \u2014 |  |  | 1,051 | \nNet cash used in investing activities | \u2014 |  |  | (134) | \nNet cash used in financing activities | \u2014 |  |  | (504) | \nNet Cash Flows Provided by Discontinued Operations | \u2014 |  |  | 413 | \nEffect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | (364) |  |  | (19) | \nNet Increase in Cash, Cash Equivalents and Restricted Cash | 1,586 |  |  | 477 | \nCash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of$71and $103at January 1, 2022 and 2021, respectively, included in Other current assets) | 8,167 |  |  | 8,153 | \nCash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $78and $55at June\u00a030, 2022 and 2021, respectively, included in Other current assets) | $ | 9,753 |  |  | $ | 8,630 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n($ in millions) | 2021(1)\nSales | $ | 1,059 |  |  | $ | 2,512 | \nCosts, Expenses and Other |  |  | \nCost of sales | 318 |  |  | 789 | \nSelling, general and administrative | 431 |  |  | 877 | \nResearch and development | 50 |  |  | 103 | \nRestructuring costs | \u2014 |  |  | 1 | \nOther (income) expense, net | (23) |  |  | (15) | \n | 776 |  |  | 1,755 | \nIncome from discontinued operations before taxes | 283 |  |  | 757 | \nIncome tax benefit | (49) |  |  | (12) | \nIncome from discontinued operations, net of taxes | 332 |  |  | 769 | \nLess: Income of discontinued operations attributable to noncontrolling interests | \u2014 |  |  | 3 | \n | $ | 332 |  |  | $ | 766 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nAlliance revenue - Lynparza | $ | 275 |  |  | $ | 248 |  |  | $ | 541 |  |  | $ | 475 | \nAlliance revenue - Koselugo | 24 |  |  | 8 |  |  | 33 |  |  | 14 | \nTotal alliance revenue | $ | 299 |  |  | $ | 256 |  |  | $ | 574 |  |  | $ | 489 | \n |  |  |  |  |  |  | \nCost of sales(1) | 62 |  |  | 42 |  |  | 361 |  |  | 84 | \nSelling, general and administrative | 46 |  |  | 43 |  |  | 90 |  |  | 83 | \nResearch and development | 25 |  |  | 31 |  |  | 51 |  |  | 60 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | June 30, 2022 |  | December 31, 2021\nReceivables from AstraZeneca included inOther current assets |  |  |  |  | $ | 300 |  |  | $ | 271 | \nPayables to AstraZeneca included inTrade accounts payableandAccrued and other current liabilities(2) |  |  |  |  | 12 |  |  | 415 | \nPayables to AstraZeneca included inOther Noncurrent Liabilities(2) |  |  |  |  | 600 |  |  | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nAlliance revenue - Lenvima | $ | 231 |  |  | $ | 181 |  |  | $ | 459 |  |  | $ | 310 | \n |  |  |  |  |  |  | \nCost of sales(1) | 53 |  |  | 47 |  |  | 106 |  |  | 94 | \nSelling, general and administrative | 42 |  |  | 31 |  |  | 73 |  |  | 54 | \nResearch and development | 47 |  |  | 57 |  |  | 104 |  |  | 121 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | June 30, 2022 |  | December 31, 2021\nReceivables from Eisai included inOther current assets |  |  |  |  | $ | 247 |  |  | $ | 200 | \nPayables to Eisai included inAccrued and other current liabilities(2) |  |  |  |  | 25 |  |  | 625 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nAlliance revenue - Adempas/Verquvo | $ | 98 |  |  | $ | 74 |  |  | $ | 170 |  |  | $ | 149 | \nNet sales of Adempas recorded by Merck | 63 |  |  | 74 |  |  | 124 |  |  | 129 | \nNet sales of Verquvo recorded by Merck | 6 |  |  | 1 |  |  | 9 |  |  | 1 | \nTotal sales | $ | 167 |  |  | $ | 149 |  |  | $ | 303 |  |  | $ | 279 | \n |  |  |  |  |  |  | \nCost of sales(1) | 54 |  |  | 67 |  |  | 103 |  |  | 275 | \nSelling, general and administrative | 42 |  |  | 34 |  |  | 65 |  |  | 51 | \nResearch and development | 17 |  |  | 13 |  |  | 34 |  |  | 20 | \n($ in millions) |  |  |  |  | June 30, 2022 |  | December 31, 2021\nReceivables from Bayer included inOther current assets |  |  |  |  | $ | 144 |  |  | $ | 114 | \nPayables to Bayer included inAccrued and other current liabilities(2) |  |  |  |  | 74 |  |  | 472 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nLagevriosales | $ | 1,177 |  |  | $ | \u2014 |  |  | $ | 4,424 |  |  | $ | \u2014 | \n |  |  |  |  |  |  | \nCost of sales(1) | 622 |  |  | 6 |  |  | 2,338 |  |  | 52 | \nSelling, general and administrative | 30 |  |  | 4 |  |  | 65 |  |  | 7 | \nResearch and development | 15 |  |  | 68 |  |  | 21 |  |  | 110 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | June 30, 2022 |  | December 31, 2021\nPayables to Ridgeback included inAccrued and other current liabilities(2) |  |  |  |  | $ | 683 |  |  | $ | 283 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, 2022 |  | Six Months Ended June 30, 2022\n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nCost of sales | $ | \u2014 |  |  | $ | 17 |  |  | $ | 50 |  |  | $ | 67 |  |  | $ | \u2014 |  |  | $ | 35 |  |  | $ | 78 |  |  | $ | 113 | \nSelling, general and administrative | \u2014 |  |  | 8 |  |  | 19 |  |  | 27 |  |  | \u2014 |  |  | 12 |  |  | 36 |  |  | 48 | \nResearch and development | \u2014 |  |  | 22 |  |  | \u2014 |  |  | 22 |  |  | \u2014 |  |  | 29 |  |  | \u2014 |  |  | 29 | \nRestructuring costs | 106 |  |  | \u2014 |  |  | 36 |  |  | 142 |  |  | 132 |  |  | \u2014 |  |  | 62 |  |  | 194 | \n | $ | 106 |  |  | $ | 47 |  |  | $ | 105 |  |  | $ | 258 |  |  | $ | 132 |  |  | $ | 76 |  |  | $ | 176 |  |  | $ | 384 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, 2021 |  | Six Months Ended June 30, 2021\n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nCost of sales | $ | \u2014 |  |  | $ | 11 |  |  | $ | 27 |  |  | $ | 38 |  |  | $ | \u2014 |  |  | $ | 21 |  |  | $ | 44 |  |  | $ | 65 | \nSelling, general and administrative | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 4 |  |  | \u2014 |  |  | 4 | \nResearch and development | \u2014 |  |  | 6 |  |  | \u2014 |  |  | 6 |  |  | \u2014 |  |  | 13 |  |  | \u2014 |  |  | 13 | \nRestructuring costs | 64 |  |  | \u2014 |  |  | 18 |  |  | 82 |  |  | 293 |  |  | \u2014 |  |  | 87 |  |  | 380 | \n | $ | 64 |  |  | $ | 19 |  |  | $ | 45 |  |  | $ | 128 |  |  | $ | 293 |  |  | $ | 38 |  |  | $ | 131 |  |  | $ | 462 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nRestructuring reserves January\u00a01, 2022 | $ | 596 |  |  | $ | \u2014 |  |  | $ | 41 |  |  | $ | 637 | \nExpense | 132 |  |  | 76 |  |  | 176 |  |  | 384 | \n(Payments) receipts, net | (167) |  |  | \u2014 |  |  | (280) |  |  | (447) | \nNon-cash activity | \u2014 |  |  | (76) |  |  | 90 |  |  | 14 | \nRestructuring reserves June\u00a030, 2022(1) | $ | 561 |  |  | $ | \u2014 |  |  | $ | 27 |  |  | $ | 588 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income(1) |  | Amount of Pretax (Gain) Loss Recognized inOther (income) expense, netfor Amounts Excluded from Effectiveness Testing\n | Three Months Ended June 30, |  | Six Months Ended June 30, |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021\nNet Investment Hedging Relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | $ | (31) |  |  | $ | (3) |  |  | $ | (46) |  |  | $ | (28) |  |  | $ | (1) |  |  | $ | (4) |  |  | $ | (2) |  |  | $ | (8) | \nEuro-denominated notes | (128) |  |  | 45 |  |  | (181) |  |  | (122) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022\n($ in millions) | Par Value of Debt |  | Number of Interest Rate Swaps Held |  | Total Swap Notional Amount\n2.40% notes due 2022 | $ | 1,000 |  |  | 4 |  |  | $ | 1,000 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Carrying Amount of Hedged Liabilities |  | Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount\n($ in millions) | June 30, 2022 |  | December 31, 2021 |  | June 30, 2022 |  | December 31, 2021\nBalance Sheet Line Item in which Hedged Item is Included |  |  |  |  |  |  | \nLoans payable and current portion of long-term debt | $ | 999 |  |  | $ | 2,263 |  |  | $ | (1) |  |  | $ | 13 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30, 2022 |  | December 31, 2021\n |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional\n($ in millions) |  | Asset |  | Liability |  | Asset |  | Liability | \nDerivatives Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts | Other current assets | $ | 1 |  |  | $ | \u2014 |  |  | $ | 1,000 |  |  | $ | 14 |  |  | $ | \u2014 |  |  | $ | 2,250 | \nForeign exchange contracts | Other current assets | 467 |  |  | \u2014 |  |  | 6,751 |  |  | 271 |  |  | \u2014 |  |  | 6,778 | \nForeign exchange contracts | Other Assets | 57 |  |  | \u2014 |  |  | 1,334 |  |  | 43 |  |  | \u2014 |  |  | 1,551 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 2 |  |  | 510 |  |  | \u2014 |  |  | 24 |  |  | 1,623 | \nForeign exchange contracts | Other Noncurrent Liabilities | \u2014 |  |  | 1 |  |  | 126 |  |  | \u2014 |  |  | 1 |  |  | 43 | \n |  | $ | 525 |  |  | $ | 3 |  |  | $ | 9,721 |  |  | $ | 328 |  |  | $ | 25 |  |  | $ | 12,245 | \nDerivatives Not Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Other current assets | $ | 407 |  |  | $ | \u2014 |  |  | $ | 10,931 |  |  | $ | 221 |  |  | $ | \u2014 |  |  | $ | 10,073 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 131 |  |  | 7,074 |  |  | \u2014 |  |  | 96 |  |  | 10,640 | \n |  | $ | 407 |  |  | $ | 131 |  |  | $ | 18,005 |  |  | $ | 221 |  |  | $ | 96 |  |  | $ | 20,713 | \n |  | $ | 932 |  |  | $ | 134 |  |  | $ | 27,726 |  |  | $ | 549 |  |  | $ | 121 |  |  | $ | 32,958 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022 |  | December 31, 2021\n($ in millions) | Asset |  | Liability |  | Asset |  | Liability\nGross amounts recognized in the condensed consolidated balance sheet | $ | 932 |  |  | $ | 134 |  |  | $ | 549 |  |  | $ | 121 | \nGross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet | (123) |  |  | (123) |  |  | (110) |  |  | (110) | \nCash collateral received | (527) |  |  | \u2014 |  |  | (164) |  |  | \u2014 | \nNet amounts | $ | 282 |  |  | $ | 11 |  |  | $ | 275 |  |  | $ | 11 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021\nFinancial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss) |  | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss)\n | $ | 14,593 |  |  | $ | 11,402 |  |  | $ | 438 |  |  | $ | (103) |  |  | $ | 42 |  |  | $ | 1,545 |  |  | $ | 30,494 |  |  | $ | 22,029 |  |  | $ | 1,148 |  |  | $ | (558) |  |  | $ | 102 |  |  | $ | 1,557 | \n(Gain) loss on fair value hedging relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHedged items | \u2014 |  |  | \u2014 |  |  | (4) |  |  | (9) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (14) |  |  | (19) |  |  | \u2014 |  |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  |  | \u2014 |  |  | 1 |  |  | (1) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nImpact of cash flow hedging relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain (loss) recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 403 |  |  | (58) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 551 |  |  | 121 | \nIncrease (decrease) inSalesas a result ofAOCLreclassifications | 172 |  |  | (71) |  |  | \u2014 |  |  | \u2014 |  |  | (172) |  |  | 71 |  |  | 239 |  |  | (183) |  |  | \u2014 |  |  | \u2014 |  |  | (239) |  |  | 183 | \nInterest rate contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOther (income) expense, neton derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |  |  | \u2014 |  |  | \u2014 | \nAmount of loss recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Amount of Derivative Pretax (Gain) Loss Recognized in Income\n |  |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n($ in millions) |  |  | 2022 |  | 2021 |  | 2022 |  | 2021\nDerivatives Not Designated as Hedging Instruments | Income Statement Caption |  |  |  |  |  |  |  | \nForeign exchange contracts(1) | Other (income) expense, net |  | $ | (64) |  |  | $ | 167 |  |  | $ | (36) |  |  | $ | 217 | \nForeign exchange contracts(2) | Sales |  | (36) |  |  | 14 |  |  | (38) |  |  | 10 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022 |  | December 31, 2021\n | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue |  | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue\n($ in millions) | Gains |  | Losses |  | Gains |  | Losses | \nCommercial paper | $ | 334 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 334 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nU.S. government and agency securities | 72 |  |  | \u2014 |  |  | \u2014 |  |  | 72 |  |  | 80 |  |  | \u2014 |  |  | \u2014 |  |  | 80 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 | \nForeign government bonds | 2 |  |  | \u2014 |  |  | \u2014 |  |  | 2 |  |  | 2 |  |  | \u2014 |  |  | \u2014 |  |  | 2 | \nTotal debt securities | $ | 412 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 412 |  |  | $ | 86 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 86 | \nPublicly traded equity securities(1) |  |  |  |  |  |  | 1,530 |  |  |  |  |  |  |  |  | 1,647 | \nTotal debt and publicly traded equity securities |  |  |  |  |  |  | $ | 1,942 |  |  |  |  |  |  |  |  | $ | 1,733 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair Value Measurements Using |  | Fair Value Measurements Using\n | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |  | Total\n($ in millions) | June 30, 2022 |  | December 31, 2021\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCommercial paper | $ | \u2014 |  |  | $ | 334 |  |  | $ | \u2014 |  |  | $ | 334 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nForeign government bonds | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 2 | \nPublicly traded equity securities | 355 |  |  | \u2014 |  |  | \u2014 |  |  | 355 |  |  | 368 |  |  | \u2014 |  |  | \u2014 |  |  | 368 | \n | 355 |  |  | 336 |  |  | \u2014 |  |  | 691 |  |  | 368 |  |  | 2 |  |  | \u2014 |  |  | 370 | \nOther assets(1) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | 72 |  |  | \u2014 |  |  | \u2014 |  |  | 72 |  |  | 80 |  |  | \u2014 |  |  | \u2014 |  |  | 80 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 | \nPublicly traded equity securities | 1,175 |  |  | \u2014 |  |  | \u2014 |  |  | 1,175 |  |  | 1,279 |  |  | \u2014 |  |  | \u2014 |  |  | 1,279 | \n | 1,251 |  |  | \u2014 |  |  | \u2014 |  |  | 1,251 |  |  | 1,363 |  |  | \u2014 |  |  | \u2014 |  |  | 1,363 | \nDerivative assets(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 576 |  |  | \u2014 |  |  | 576 |  |  | \u2014 |  |  | 351 |  |  | \u2014 |  |  | 351 | \nPurchased currency options | \u2014 |  |  | 355 |  |  | \u2014 |  |  | 355 |  |  | \u2014 |  |  | 184 |  |  | \u2014 |  |  | 184 | \nInterest rate swaps | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 14 |  |  | \u2014 |  |  | 14 | \n | \u2014 |  |  | 932 |  |  | \u2014 |  |  | 932 |  |  | \u2014 |  |  | 549 |  |  | \u2014 |  |  | 549 | \nTotal assets | $ | 1,606 |  |  | $ | 1,268 |  |  | $ | \u2014 |  |  | $ | 2,874 |  |  | $ | 1,731 |  |  | $ | 551 |  |  | $ | \u2014 |  |  | $ | 2,282 | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nContingent consideration | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 542 |  |  | $ | 542 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 777 |  |  | $ | 777 | \nDerivative liabilities(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 133 |  |  | \u2014 |  |  | 133 |  |  | \u2014 |  |  | 120 |  |  | \u2014 |  |  | 120 | \nWritten currency options | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 | \n | \u2014 |  |  | 134 |  |  | \u2014 |  |  | 134 |  |  | \u2014 |  |  | 121 |  |  | \u2014 |  |  | 121 | \nTotal liabilities | $ | \u2014 |  |  | $ | 134 |  |  | $ | 542 |  |  | $ | 676 |  |  | $ | \u2014 |  |  | $ | 121 |  |  | $ | 777 |  |  | $ | 898 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021\nFair value January 1 | $ | 777 |  |  | $ | 841 | \nChanges in estimated fair value(1) | (114) |  |  | 50 | \nPayments | (119) |  |  | \u2014 | \nOther | (2) |  |  | (12) | \nFair value June 30(2) | $ | 542 |  |  | $ | 879 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | June 30, 2022 |  | December 31, 2021\nFinished goods | $ | 1,680 |  |  | $ | 1,747 | \nRaw materials and work in process | 6,542 |  |  | 6,220 | \nSupplies | 217 |  |  | 196 | \nTotal (approximates current cost) | 8,439 |  |  | 8,163 | \nDecrease to LIFO cost | (140) |  |  | (16) | \n | $ | 8,299 |  |  | $ | 8,147 | \nRecognized as: |  |  | \nInventories | $ | 5,535 |  |  | $ | 5,953 | \nOther assets | 2,764 |  |  | 2,194 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at April 1, 2021 | 3,577 |  | $ | 1,788 |  | $ | 39,613 |  | $ | 48,888 |  | $ | (6,622) |  | 1,046 |  | $ | (56,722) |  | $ | 94 |  | $ | 27,039 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 1,545 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1,545 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1,545 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1,545 | \nCash dividends declared on common stock ($0.65per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,656) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,656) | \nTreasury stock shares purchased | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3 |  | (239) |  | \u2014 |  | (239) | \nSpin-off of Organon & Co. | \u2014 |  | \u2014 |  | 4,643 |  | \u2014 |  | 449 |  | \u2014 |  | \u2014 |  | (1) |  | 5,091 | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (217) |  | \u2014 |  | \u2014 |  | (5) |  | 279 |  | \u2014 |  | 62 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1 |  | 1 | \nBalance at June 30, 2021 | 3,577 |  | $ | 1,788 |  | $ | 44,039 |  | $ | 48,777 |  | $ | (4,628) |  | 1,044 |  | $ | (56,682) |  | $ | 94 |  | $ | 33,388 | \nBalance at April 1, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,275 |  | $ | 56,252 |  | $ | (4,369) |  | 1,049 |  | $ | (57,063) |  | $ | 70 |  | $ | 40,953 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 3,944 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3,944 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 42 |  | \u2014 |  | \u2014 |  | \u2014 |  | 42 | \nCash dividends declared on common stock ($0.69per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,759) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,759) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (160) |  | \u2014 |  | \u2014 |  | (5) |  | 293 |  | \u2014 |  | 133 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 5 |  | 5 | \nBalance at June 30, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,115 |  | $ | 58,437 |  | $ | (4,327) |  | 1,044 |  | $ | (56,770) |  | $ | 75 |  | $ | 43,318 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at January\u00a01, 2021 | 3,577 |  | $ | 1,788 |  | $ | 39,588 |  | $ | 47,362 |  | $ | (6,634) |  | 1,047 |  | $ | (56,787) |  | $ | 87 |  | $ | 25,404 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 4,724 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 4,724 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1,557 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1,557 | \nCash dividends declared on common stock ($1.30per share) | \u2014 |  | \u2014 |  | \u2014 |  | (3,309) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (3,309) | \nTreasury stock shares purchased | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3 |  | (239) |  | \u2014 |  | (239) | \nSpin-off of Organon & Co. | \u2014 |  | \u2014 |  | 4,643 |  | \u2014 |  | 449 |  | \u2014 |  | \u2014 |  | (1) |  | 5,091 | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (192) |  | \u2014 |  | \u2014 |  | (6) |  | 344 |  | \u2014 |  | 152 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 8 |  | 8 | \nBalance at June 30, 2021 | 3,577 |  | $ | 1,788 |  | $ | 44,039 |  | $ | 48,777 |  | $ | (4,628) |  | 1,044 |  | $ | (56,682) |  | $ | 94 |  | $ | 33,388 | \nBalance at January\u00a01, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,238 |  | $ | 53,696 |  | $ | (4,429) |  | 1,049 |  | $ | (57,109) |  | $ | 73 |  | $ | 38,257 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 8,254 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 8,254 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 102 |  | \u2014 |  | \u2014 |  | \u2014 |  | 102 | \nCash dividends declared on common stock ($1.38per share) | \u2014 |  | \u2014 |  | \u2014 |  | (3,513) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (3,513) | \n |  |  |  |  |  |  |  |  | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (123) |  | \u2014 |  | \u2014 |  | (5) |  | 339 |  | \u2014 |  | 216 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 2 |  | 2 | \n |  |  |  |  |  |  |  |  | \nBalance at June 30, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,115 |  | $ | 58,437 |  | $ | (4,327) |  | 1,044 |  | $ | (56,770) |  | $ | 75 |  | $ | 43,318 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\n($ in millions) | U.S. |  | International |  | U.S. |  | International |  | U.S. |  | International |  | U.S. |  | International\nService cost | $ | 99 |  |  | $ | 72 |  |  | $ | 98 |  |  | $ | 87 |  |  | $ | 198 |  |  | $ | 147 |  |  | $ | 198 |  |  | $ | 179 | \nInterest cost | 103 |  |  | 37 |  |  | 106 |  |  | 30 |  |  | 206 |  |  | 75 |  |  | 202 |  |  | 59 | \nExpected return on plan assets | (197) |  |  | (98) |  |  | (191) |  |  | (104) |  |  | (393) |  |  | (199) |  |  | (379) |  |  | (209) | \nAmortization of unrecognized prior service credit | (8) |  |  | (3) |  |  | (11) |  |  | (4) |  |  | (16) |  |  | (7) |  |  | (20) |  |  | (9) | \nNet loss amortization | 56 |  |  | 25 |  |  | 58 |  |  | 38 |  |  | 112 |  |  | 50 |  |  | 142 |  |  | 78 | \nTermination benefits | 1 |  |  | \u2014 |  |  | 52 |  |  | 2 |  |  | 1 |  |  | \u2014 |  |  | 53 |  |  | 3 | \nCurtailments | 4 |  |  | \u2014 |  |  | 9 |  |  | (27) |  |  | 8 |  |  | \u2014 |  |  | 16 |  |  | (27) | \nSettlements | 101 |  |  | \u2014 |  |  | \u2014 |  |  | 2 |  |  | 101 |  |  | \u2014 |  |  | \u2014 |  |  | 2 | \n | $ | 159 |  |  | $ | 33 |  |  | $ | 121 |  |  | $ | 24 |  |  | $ | 217 |  |  | $ | 66 |  |  | $ | 212 |  |  | $ | 76 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nService cost | $ | 12 |  |  | $ | 13 |  |  | $ | 25 |  |  | $ | 26 | \nInterest cost | 11 |  |  | 11 |  |  | 23 |  |  | 22 | \nExpected return on plan assets | (21) |  |  | (20) |  |  | (43) |  |  | (39) | \nAmortization of unrecognized prior service credit | (25) |  |  | (25) |  |  | (50) |  |  | (50) | \n |  |  |  |  |  |  | \nTermination benefits | \u2014 |  |  | 37 |  |  | \u2014 |  |  | 37 | \nCurtailments | \u2014 |  |  | (27) |  |  | \u2014 |  |  | (28) | \n | $ | (23) |  |  | $ | (11) |  |  | $ | (45) |  |  | $ | (32) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nInterest income | $ | (15) |  |  | $ | (9) |  |  | $ | (22) |  |  | $ | (20) | \nInterest expense | 240 |  |  | 202 |  |  | 483 |  |  | 401 | \nExchange losses | 86 |  |  | 114 |  |  | 124 |  |  | 155 | \nLoss (income) from investments in equity securities, net(1) | 284 |  |  | (280) |  |  | 991 |  |  | (854) | \nNet periodic defined benefit plan (credit) cost other than service cost | (27) |  |  | (110) |  |  | (148) |  |  | (199) | \nOther, net | (130) |  |  | (20) |  |  | (280) |  |  | (41) | \n | $ | 438 |  |  | $ | (103) |  |  | $ | 1,148 |  |  | $ | (558) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ and shares in millions except per share amounts) | 2022 |  | 2021 |  | 2022 |  | 2021\nNet Income from Continuing Operations Attributable to Merck\u00a0& Co., Inc. | $ | 3,944 |  |  | $ | 1,213 |  |  | $ | 8,254 |  |  | $ | 3,958 | \nIncome from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | \u2014 |  |  | 332 |  |  | \u2014 |  |  | 766 | \nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 3,944 |  |  | $ | 1,545 |  |  | $ | 8,254 |  |  | $ | 4,724 | \nAverage common shares outstanding | 2,531 |  |  | 2,533 |  |  | 2,529 |  |  | 2,532 | \nCommon shares issuable(1) | 9 |  |  | 7 |  |  | 9 |  |  | 8 | \nAverage common shares outstanding assuming dilution | 2,540 |  |  | 2,540 |  |  | 2,538 |  |  | 2,540 | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.56 |  |  | $ | 0.48 |  |  | $ | 3.26 |  |  | $ | 1.56 | \nIncome from Discontinued Operations | \u2014 |  |  | 0.13 |  |  | \u2014 |  |  | 0.30 | \nNet Income | $ | 1.56 |  |  | $ | 0.61 |  |  | $ | 3.26 |  |  | $ | 1.87 | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.55 |  |  | $ | 0.48 |  |  | $ | 3.25 |  |  | $ | 1.56 | \nIncome from Discontinued Operations | \u2014 |  |  | 0.13 |  |  | \u2014 |  |  | 0.30 | \nNet Income | $ | 1.55 |  |  | $ | 0.61 |  |  | $ | 3.25 |  |  | $ | 1.86 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance April 1, 2021, net of taxes | $ | (36) |  |  | $ | (4,459) |  |  | $ | (2,127) |  |  | $ | (6,622) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | (59) |  |  | 1,767 |  |  | 140 |  |  | 1,848 | \nTax | 13 |  |  | (400) |  |  | (8) |  |  | (395) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | (46) |  |  | 1,367 |  |  | 132 |  |  | 1,453 | \nReclassification adjustments, pretax | 71 |  | (1) | 55 |  | (2) | \u2014 |  |  | 126 | \nTax | (15) |  |  | (19) |  |  | \u2014 |  |  | (34) | \nReclassification adjustments, net of taxes | 56 |  |  | 36 |  |  | \u2014 |  |  | 92 | \nOther comprehensive income (loss), net of taxes | 10 |  |  | 1,403 |  |  | 132 |  |  | 1,545 | \nSpin-off of Organon (see Note\u00a02) | \u2014 |  |  | 28 |  |  | 421 |  |  | 449 | \nBalance June 30, 2021, net of taxes | $ | (26) |  |  | $ | (3,028) |  |  | $ | (1,574) |  |  | $ | (4,628) | \nBalance April 1, 2022, net of taxes | $ | 207 |  |  | $ | (2,711) |  |  | $ | (1,865) |  |  | $ | (4,369) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 403 |  |  | 168 |  |  | (365) |  |  | 206 | \nTax | (85) |  |  | (35) |  |  | (22) |  |  | (142) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 318 |  |  | 133 |  |  | (387) |  |  | 64 | \nReclassification adjustments, pretax | (171) |  | (1) | 144 |  | (2) | \u2014 |  |  | (27) | \nTax | 36 |  |  | (31) |  |  | \u2014 |  |  | 5 | \nReclassification adjustments, net of taxes | (135) |  |  | 113 |  |  | \u2014 |  |  | (22) | \nOther comprehensive income (loss), net of taxes | 183 |  |  | 246 |  |  | (387) |  |  | 42 | \nBalance June 30, 2022, net of taxes | $ | 390 |  |  | $ | (2,465) |  |  | $ | (2,252) |  |  | $ | (4,327) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance January 1, 2021, net of taxes | $ | (266) |  |  | $ | (4,540) |  |  | $ | (1,828) |  |  | $ | (6,634) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 121 |  |  | 1,763 |  |  | (71) |  |  | 1,813 | \nTax | (25) |  |  | (401) |  |  | (96) |  |  | (522) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 96 |  |  | 1,362 |  |  | (167) |  |  | 1,291 | \nReclassification adjustments, pretax | 182 |  | (1) | 142 |  | (3) | \u2014 |  |  | 324 | \nTax | (38) |  |  | (20) |  |  | \u2014 |  |  | (58) | \nReclassification adjustments, net of taxes | 144 |  |  | 122 |  |  | \u2014 |  |  | 266 | \nOther comprehensive income (loss), net of taxes | 240 |  |  | 1,484 |  |  | (167) |  |  | 1,557 | \nSpin-off of Organon (see Note\u00a02) | \u2014 |  |  | 28 |  |  | 421 |  |  | 449 | \nBalance June 30, 2021, net of taxes | $ | (26) |  |  | $ | (3,028) |  |  | $ | (1,574) |  |  | $ | (4,628) | \nBalance January 1, 2022, net of taxes | $ | 144 |  |  | $ | (2,743) |  |  | $ | (1,830) |  |  | $ | (4,429) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 551 |  |  | 169 |  |  | (383) |  |  | 337 | \nTax | (116) |  |  | (37) |  |  | (39) |  |  | (192) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 435 |  |  | 132 |  |  | (422) |  |  | 145 | \nReclassification adjustments, pretax | (239) |  | (1) | 189 |  | (3) | \u2014 |  |  | (50) | \nTax | 50 |  |  | (43) |  |  | \u2014 |  |  | 7 | \nReclassification adjustments, net of taxes | (189) |  |  | 146 |  |  | \u2014 |  |  | (43) | \nOther comprehensive income (loss), net of taxes | 246 |  |  | 278 |  |  | (422) |  |  | 102 | \nBalance June 30, 2022, net of taxes | $ | 390 |  |  | $ | (2,465) |  |  | $ | (2,252) |  |  | $ | (4,327) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\n($ in millions) | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total\nPharmaceutical: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nKeytruda | $ | 3,197 |  |  | $ | 2,055 |  |  | $ | 5,252 |  |  | $ | 2,347 |  |  | $ | 1,829 |  |  | $ | 4,176 |  |  | $ | 5,976 |  |  | $ | 4,085 |  |  | $ | 10,061 |  |  | $ | 4,528 |  |  | $ | 3,548 |  |  | $ | 8,076 | \nAlliance revenue-Lynparza(1) | 143 |  |  | 132 |  |  | 275 |  |  | 124 |  |  | 124 |  |  | 248 |  |  | 283 |  |  | 257 |  |  | 541 |  |  | 242 |  |  | 233 |  |  | 475 | \nAlliance revenue-Lenvima(1) | 128 |  |  | 103 |  |  | 231 |  |  | 88 |  |  | 93 |  |  | 181 |  |  | 284 |  |  | 175 |  |  | 459 |  |  | 173 |  |  | 137 |  |  | 310 | \nAlliance revenue-Reblozyl(2) | 28 |  |  | 5 |  |  | 33 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 55 |  |  | 30 |  |  | 86 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nVaccines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | 428 |  |  | 1,245 |  |  | 1,674 |  |  | 454 |  |  | 781 |  |  | 1,234 |  |  | 846 |  |  | 2,287 |  |  | 3,133 |  |  | 766 |  |  | 1,385 |  |  | 2,151 | \nProQuad/M-M-RII/Varivax | 434 |  |  | 143 |  |  | 578 |  |  | 386 |  |  | 130 |  |  | 516 |  |  | 805 |  |  | 243 |  |  | 1,047 |  |  | 718 |  |  | 246 |  |  | 965 | \nRotaTeq | 98 |  |  | 75 |  |  | 173 |  |  | 111 |  |  | 97 |  |  | 208 |  |  | 273 |  |  | 116 |  |  | 389 |  |  | 229 |  |  | 137 |  |  | 366 | \nPneumovax23 | 94 |  |  | 59 |  |  | 153 |  |  | 100 |  |  | 52 |  |  | 152 |  |  | 212 |  |  | 114 |  |  | 325 |  |  | 173 |  |  | 150 |  |  | 323 | \nVaqta | 16 |  |  | 19 |  |  | 35 |  |  | 22 |  |  | 34 |  |  | 56 |  |  | 45 |  |  | 25 |  |  | 71 |  |  | 47 |  |  | 43 |  |  | 90 | \nHospital Acute Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBridion | 237 |  |  | 190 |  |  | 426 |  |  | 197 |  |  | 190 |  |  | 387 |  |  | 432 |  |  | 389 |  |  | 821 |  |  | 364 |  |  | 363 |  |  | 727 | \nPrevymis | 47 |  |  | 56 |  |  | 103 |  |  | 37 |  |  | 56 |  |  | 93 |  |  | 87 |  |  | 110 |  |  | 197 |  |  | 72 |  |  | 103 |  |  | 174 | \nPrimaxin | \u2014 |  |  | 64 |  |  | 64 |  |  | \u2014 |  |  | 60 |  |  | 60 |  |  | 1 |  |  | 122 |  |  | 122 |  |  | \u2014 |  |  | 125 |  |  | 125 | \nDificid | 63 |  |  | 3 |  |  | 66 |  |  | 32 |  |  | 2 |  |  | 34 |  |  | 113 |  |  | 6 |  |  | 119 |  |  | 56 |  |  | 4 |  |  | 61 | \nNoxafil | 16 |  |  | 45 |  |  | 60 |  |  | 14 |  |  | 52 |  |  | 66 |  |  | 25 |  |  | 92 |  |  | 118 |  |  | 29 |  |  | 104 |  |  | 133 | \nInvanz | 2 |  |  | 45 |  |  | 46 |  |  | (4) |  |  | 52 |  |  | 48 |  |  | 2 |  |  | 96 |  |  | 99 |  |  | \u2014 |  |  | 104 |  |  | 104 | \nCancidas | 2 |  |  | 39 |  |  | 42 |  |  | 1 |  |  | 53 |  |  | 54 |  |  | 4 |  |  | 91 |  |  | 95 |  |  | 3 |  |  | 108 |  |  | 111 | \nZerbaxa | 22 |  |  | 24 |  |  | 46 |  |  | (2) |  |  | 1 |  |  | (1) |  |  | 40 |  |  | 36 |  |  | 76 |  |  | (4) |  |  | (5) |  |  | (9) | \nCardiovascular |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue-Adempas/Verquvo(3) | 88 |  |  | 10 |  |  | 98 |  |  | 81 |  |  | (7) |  |  | 74 |  |  | 159 |  |  | 11 |  |  | 170 |  |  | 149 |  |  | \u2014 |  |  | 149 | \nAdempas | \u2014 |  |  | 63 |  |  | 63 |  |  | \u2014 |  |  | 74 |  |  | 74 |  |  | \u2014 |  |  | 124 |  |  | 124 |  |  | \u2014 |  |  | 129 |  |  | 129 | \nVirology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLagevrio | \u2014 |  |  | 1,177 |  |  | 1,177 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1,523 |  |  | 2,901 |  |  | 4,424 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nIsentress/IsentressHD | 67 |  |  | 80 |  |  | 147 |  |  | 74 |  |  | 118 |  |  | 192 |  |  | 128 |  |  | 177 |  |  | 305 |  |  | 145 |  |  | 256 |  |  | 401 | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBelsomra | 19 |  |  | 50 |  |  | 69 |  |  | 14 |  |  | 63 |  |  | 78 |  |  | 39 |  |  | 98 |  |  | 137 |  |  | 32 |  |  | 125 |  |  | 157 | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSimponi | \u2014 |  |  | 181 |  |  | 181 |  |  | \u2014 |  |  | 202 |  |  | 202 |  |  | \u2014 |  |  | 366 |  |  | 366 |  |  | \u2014 |  |  | 416 |  |  | 416 | \nRemicade | \u2014 |  |  | 53 |  |  | 53 |  |  | \u2014 |  |  | 75 |  |  | 75 |  |  | \u2014 |  |  | 114 |  |  | 114 |  |  | \u2014 |  |  | 160 |  |  | 160 | \nDiabetes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nJanuvia | 301 |  |  | 455 |  |  | 756 |  |  | 284 |  |  | 500 |  |  | 784 |  |  | 626 |  |  | 909 |  |  | 1,535 |  |  | 632 |  |  | 961 |  |  | 1,593 | \nJanumet | 105 |  |  | 371 |  |  | 476 |  |  | 74 |  |  | 403 |  |  | 477 |  |  | 168 |  |  | 762 |  |  | 931 |  |  | 158 |  |  | 805 |  |  | 962 | \nOther pharmaceutical(4) | 191 |  |  | 288 |  |  | 479 |  |  | 213 |  |  | 299 |  |  | 512 |  |  | 372 |  |  | 628 |  |  | 998 |  |  | 429 |  |  | 640 |  |  | 1,069 | \nTotal Pharmaceutical segment sales | 5,726 |  |  | 7,030 |  |  | 12,756 |  |  | 4,647 |  |  | 5,333 |  |  | 9,980 |  |  | 12,498 |  |  | 14,364 |  |  | 26,863 |  |  | 8,941 |  |  | 10,277 |  |  | 19,218 | \nAnimal Health: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLivestock | 164 |  |  | 662 |  |  | 826 |  |  | 161 |  |  | 659 |  |  | 821 |  |  | 335 |  |  | 1,322 |  |  | 1,658 |  |  | 318 |  |  | 1,322 |  |  | 1,640 | \nCompanion Animals | 313 |  |  | 328 |  |  | 641 |  |  | 298 |  |  | 353 |  |  | 651 |  |  | 616 |  |  | 676 |  |  | 1,291 |  |  | 578 |  |  | 672 |  |  | 1,250 | \nTotal Animal Health segment sales | 477 |  |  | 990 |  |  | 1,467 |  |  | 459 |  |  | 1,012 |  |  | 1,472 |  |  | 951 |  |  | 1,998 |  |  | 2,949 |  |  | 896 |  |  | 1,994 |  |  | 2,890 | \nTotal segment sales | 6,203 |  |  | 8,020 |  |  | 14,223 |  |  | 5,106 |  |  | 6,345 |  |  | 11,452 |  |  | 13,449 |  |  | 16,362 |  |  | 29,812 |  |  | 9,837 |  |  | 12,271 |  |  | 22,108 | \nOther(5) | 35 |  |  | 335 |  |  | 370 |  |  | (6) |  |  | (44) |  |  | (50) |  |  | 128 |  |  | 555 |  |  | 682 |  |  | 53 |  |  | (132) |  |  | (79) | \n | $ | 6,238 |  |  | $ | 8,355 |  |  | $ | 14,593 |  |  | $ | 5,100 |  |  | $ | 6,301 |  |  | $ | 11,402 |  |  | $ | 13,577 |  |  | $ | 16,917 |  |  | $ | 30,494 |  |  | $ | 9,890 |  |  | $ | 12,139 |  |  | $ | 22,029 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nUnited States | $ | 6,238 |  |  | $ | 5,100 |  |  | $ | 13,577 |  |  | $ | 9,890 | \nEurope, Middle East and Africa | 3,582 |  |  | 3,333 |  |  | 7,942 |  |  | 6,569 | \nChina | 1,372 |  |  | 975 |  |  | 2,515 |  |  | 1,697 | \nJapan | 1,114 |  |  | 661 |  |  | 2,103 |  |  | 1,291 | \nAsia Pacific (other than China and Japan) | 1,008 |  |  | 594 |  |  | 1,938 |  |  | 1,168 | \nLatin America | 642 |  |  | 532 |  |  | 1,249 |  |  | 1,032 | \nOther | 637 |  |  | 207 |  |  | 1,170 |  |  | 382 | \n | $ | 14,593 |  |  | $ | 11,402 |  |  | $ | 30,494 |  |  | $ | 22,029 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nSegment profits: |  |  |  |  |  |  | \nPharmaceutical segment | $ | 9,173 |  |  | $ | 7,257 |  |  | $ | 18,673 |  |  | $ | 13,845 | \nAnimal Health segment | 571 |  |  | 552 |  |  | 1,156 |  |  | 1,124 | \nTotal segment profits | 9,744 |  |  | 7,809 |  |  | 19,829 |  |  | 14,969 | \nOther profits | 260 |  |  | (79) |  |  | 454 |  |  | (113) | \nUnallocated: |  |  |  |  |  |  | \nInterest income | 15 |  |  | 9 |  |  | 22 |  |  | 20 | \nInterest expense | (240) |  |  | (202) |  |  | (483) |  |  | (401) | \nAmortization | (463) |  |  | (357) |  |  | (1,163) |  |  | (871) | \nDepreciation | (431) |  |  | (332) |  |  | (809) |  |  | (673) | \nResearch and development | (2,652) |  |  | (4,175) |  |  | (5,097) |  |  | (6,480) | \nRestructuring costs | (142) |  |  | (82) |  |  | (194) |  |  | (380) | \nOther unallocated, net | (1,604) |  |  | (874) |  |  | (3,211) |  |  | (1,367) | \n | $ | 4,487 |  |  | $ | 1,717 |  |  | $ | 9,348 |  |  | $ | 4,704 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2022 |  | 2021 |  | % Change |  |  | 2022 |  | 2021 |  | % Change | \nUnited States | $ | 6,238 |  |  | $ | 5,100 |  |  | 22 | % |  | 22 | % |  | $ | 13,577 |  |  | $ | 9,890 |  |  | 37 | % |  | 37 | %\nInternational | 8,355 |  |  | 6,301 |  |  | 33 | % |  | 38 | % |  | 16,917 |  |  | 12,139 |  |  | 39 | % |  | 45 | %\nTotal | $ | 14,593 |  |  | $ | 11,402 |  |  | 28 | % |  | 31 | % |  | $ | 30,494 |  |  | $ | 22,029 |  |  | 38 | % |  | 41 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2022 |  | 2021 |  | % Change |  |  | 2022 |  | 2021 |  | % Change | \nKeytruda | $ | 5,252 |  |  | $ | 4,176 |  |  | 26 | % |  | 30 | % |  | $ | 10,061 |  |  | $ | 8,076 |  |  | 25 | % |  | 29 | %\nAlliance Revenue - Lynparza(1) | 275 |  |  | 248 |  |  | 11 | % |  | 17 | % |  | 541 |  |  | 475 |  |  | 14 | % |  | 18 | %\nAlliance Revenue-Lenvima(1) | 231 |  |  | 181 |  |  | 28 | % |  | 33 | % |  | 459 |  |  | 310 |  |  | 48 | % |  | 51 | %  |  |  |  |  | \nDate | Approval\nJanuary 2022 | European Commission (EC) approval as monotherapy for the adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions based on the KEYNOTE-564 trial.\nFebruary 2022 | Japan Ministry of Health, Labour and Welfare approval of the combination ofKeytrudaplus Lenvima for radically unresectable or metastatic RCC based on the CLEAR (Study 307)/KEYNOTE-581 trial.\nFebruary 2022 | Japan Pharmaceuticals and Medical Devices Agency approval for the treatment of adult patients with advanced or recurrent TMB-H solid tumors that have progressed after chemotherapy (limited to use when difficult to treat with standard of care) based on the KEYNOTE-158 trial.\nMarch 2022 | U.S. Food and Drug Administration (FDA) approval as a single agent for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation based on the KEYNOTE-158 trial (Cohorts D & K).\nApril 2022 | EC approval in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in certain adults whose tumors express PD-L1 based on the KEYNOTE-826 trial.\nApril 2022 | EC approval as monotherapy for the treatment of certain adult patients with unresectable or metastatic MSI-H/dMMR colorectal, gastric, small intestine or biliary cancer, as well as advanced or recurrent MSI-H/dMMR endometrial cancer based on data from the KEYNOTE-164 and KEYNOTE-158 trials.\nMay 2022 | EC approval in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage TNBC at high risk of recurrence based on the KEYNOTE-522 trial.\nJune 2022 | EC approval as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma and who have undergone complete resection based on the KEYNOTE-716 trial. Additionally, EC approval expanding the indications in advanced (unresectable or metastatic) melanoma and stage III melanoma with lymph node involvement (as adjuvant treatment following complete resection) to include adolescent patients aged 12 years and older.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2022 |  | 2021 |  | % Change |  |  | 2022 |  | 2021 |  | % Change | \nGardasil/Gardasil9 | $ | 1,674 |  |  | $ | 1,234 |  |  | 36 | % |  | 40 | % |  | $ | 3,133 |  |  | $ | 2,151 |  |  | 46 | % |  | 48 | %\nProQuad | 214 |  |  | 189 |  |  | 13 | % |  | 15 | % |  | 376 |  |  | 354 |  |  | 6 | % |  | 8 | %\nM-M-RII | 103 |  |  | 87 |  |  | 17 | % |  | 19 | % |  | 206 |  |  | 167 |  |  | 23 | % |  | 25 | %\nVarivax | 261 |  |  | 240 |  |  | 9 | % |  | 10 | % |  | 465 |  |  | 444 |  |  | 5 | % |  | 6 | %\nRotaTeq | 173 |  |  | 208 |  |  | (17) | % |  | (14) | % |  | 389 |  |  | 366 |  |  | 6 | % |  | 8 | %\nPneumovax 23 | 153 |  |  | 152 |  |  | 1 | % |  | 4 | % |  | 325 |  |  | 323 |  |  | 1 | % |  | 3 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2022 |  | 2021 |  | % Change |  |  | 2022 |  | 2021 |  | % Change | \nBridion | $ | 426 |  |  | $ | 387 |  |  | 10 | % |  | 15 | % |  | $ | 821 |  |  | $ | 727 |  |  | 13 | % |  | 17 | %\nZerbaxa | 46 |  |  | (1) |  |  | * |  | * |  | 76 |  |  | (9) |  |  | * |  | *  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2022 |  | 2021 |  | % Change |  |  | 2022 |  | 2021 |  | % Change | \nAlliance Revenue - Adempas/Verquvo(1) | $ | 98 |  |  | $ | 74 |  |  | 33 | % |  | 33 | % |  | $ | 170 |  |  | $ | 149 |  |  | 14 | % |  | 15 | %\nAdempas | 63 |  |  | 74 |  |  | (14) | % |  | (5) | % |  | 124 |  |  | 129 |  |  | (4) | % |  | 6 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2022 |  | 2021 |  | % Change |  |  | 2022 |  | 2021 |  | % Change | \nLagevrio | $ | 1,177 |  |  | $ | \u2014 |  |  | \u2014 |  | \u2014 |  | $ | 4,424 |  |  | $ | \u2014 |  |  | \u2014 |  | \u2014\nIsentress/Isentress HD | 147 |  |  | 192 |  |  | (24) | % |  | (19) | % |  | 305 |  |  | 401 |  |  | (24) | % |  | (20) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2022 |  | 2021 |  | % Change |  |  | 2022 |  | 2021 |  | % Change | \nJanuvia/Janumet | $ | 1,233 |  |  | $ | 1,261 |  |  | (2) | % |  | 3 | % |  | $ | 2,466 |  |  | $ | 2,556 |  |  | (4) | % |  | 1 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2022 |  | 2021 |  | % Change |  |  | 2022 |  | 2021 |  | % Change | \nLivestock | $ | 826 |  |  | $ | 821 |  |  | 1 | % |  | 6 | % |  | $ | 1,658 |  |  | $ | 1,640 |  |  | 1 | % |  | 7 | %\nCompanion Animal | 641 |  |  | 651 |  |  | (2) | % |  | 3 | % |  | 1,291 |  |  | 1,250 |  |  | 3 | % |  | 7 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | Six Months EndedJune 30, |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  | 2022 |  | 2021 |  | % Change\nCost of sales | $ | 4,216 |  |  | $ | 3,104 |  |  | 36 | % |  | $ | 9,596 |  |  | $ | 6,303 |  |  | 52 | %\nSelling, general and administrative | 2,512 |  |  | 2,281 |  |  | 10 | % |  | 4,834 |  |  | 4,468 |  |  | 8 | %\nResearch and development | 2,798 |  |  | 4,321 |  |  | (35) | % |  | 5,374 |  |  | 6,732 |  |  | (20) | %\nRestructuring costs | 142 |  |  | 82 |  |  | 73 | % |  | 194 |  |  | 380 |  |  | (49) | %\nOther (income) expense, net | 438 |  |  | (103) |  |  | * |  | 1,148 |  |  | (558) |  |  | *\n | $ | 10,106 |  |  | $ | 9,685 |  |  | 4 | % |  | $ | 21,146 |  |  | $ | 17,325 |  |  | 22 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSegment Profits |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nPharmaceutical segment profits | $ | 9,173 |  |  | $ | 7,257 |  |  | $ | 18,673 |  |  | $ | 13,845 | \nAnimal Health segment profits | 571 |  |  | 552 |  |  | 1,156 |  |  | 1,124 | \nOther | (5,257) |  |  | (6,092) |  |  | (10,481) |  |  | (10,265) | \nIncome from Continuing Operations Before Taxes | $ | 4,487 |  |  | $ | 1,717 |  |  | $ | 9,348 |  |  | $ | 4,704 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions except per share amounts) | 2022 |  | 2021 |  | 2022 |  | 2021\nIncome from continuing operations before taxes as reported under GAAP | $ | 4,487 |  |  | $ | 1,717 |  |  | $ | 9,348 |  |  | $ | 4,704 | \nIncrease (decrease) for excluded items: |  |  |  |  |  |  | \nAcquisition and divestiture-related costs | 530 |  |  | 503 |  |  | 1,168 |  |  | 1,000 | \nRestructuring costs | 258 |  |  | 128 |  |  | 384 |  |  | 462 | \nLoss (income) from investments in equity securities, net | 234 |  |  | (258) |  |  | 918 |  |  | (819) | \nOther items: |  |  |  |  |  |  | \nCharges for the discontinuation of COVID-19 development programs | \u2014 |  |  | 37 |  |  | \u2014 |  |  | 225 | \nNon-GAAP income from continuing operations before taxes | 5,509 |  |  | 2,127 |  |  | 11,818 |  |  | 5,572 | \nTaxes on income from continuing operations as reported under GAAP | 538 |  |  | 503 |  |  | 1,092 |  |  | 741 | \nEstimated tax benefit on excluded items(1) | 223 |  |  | 65 |  |  | 552 |  |  | 113 | \nNet tax (expense) benefit from the settlement of certain federal income tax matters | \u2014 |  |  | (1) |  |  | \u2014 |  |  | 207 | \nNon-GAAP taxes on income from continuing operations | 761 |  |  | 567 |  |  | 1,644 |  |  | 1,061 | \nNon-GAAP net income from continuing operations | 4,748 |  |  | 1,560 |  |  | 10,174 |  |  | 4,511 | \nLess: Net income attributable to noncontrolling interests as reported under GAAP | 5 |  |  | 1 |  |  | 2 |  |  | 5 | \nNon-GAAP net income from continuing operations attributable to Merck\u00a0& Co., Inc. | $ | 4,743 |  |  | $ | 1,559 |  |  | $ | 10,172 |  |  | $ | 4,506 | \nEPS assuming dilution from continuing operations as reported under GAAP | $ | 1.55 |  |  | $ | 0.48 |  |  | $ | 3.25 |  |  | $ | 1.56 | \nEPS difference | 0.32 |  |  | 0.13 |  |  | 0.76 |  |  | 0.21 | \nNon-GAAP EPS assuming dilution from continuing operations | $ | 1.87 |  |  | $ | 0.61 |  |  | $ | 4.01 |  |  | $ | 1.77 |   |  |  |  |  |  |  |  | \nPhase 2\nCancerMK-0482(3)Non-Small-Cell LungMK-1026 (nemtabrutinib)Hematological MalignanciesMK-1200Neoplasm MalignantMK-1308 (quavonlimab)(2)Non-Small-Cell LungMK-1308A (quavonlimab+pembrolizumab)Advanced Solid TumorsColorectalHepatocellularMelanomaSmall-Cell LungMK-2140 (zilovertamab vedotin)BreastGastricHematological MalignanciesNon-Small-Cell LungOvarianPancreaticSolid TumorsMK-2870(1)(3)Neoplasm MalignantMK-3475KeytrudaAdvanced Solid TumorsMK-4280 (favezelimab)(2)Hematological MalignanciesNon-Small-Cell LungMK-4280A (favezelimab+pembrolizumab)Renal CellSmall-Cell LungMK-4830(2)ColorectalMelanomaNon-Small-Cell LungRenal CellSmall-Cell LungMK-5684(1)Neoplasm MalignantMK-5890(3)Non-Small-Cell LungSmall-Cell Lung | CancerMK-6440 (ladiratuzumab vedotin)(1)(3)BreastEsophagealGastricHead and NeckMelanomaNon-Small-Cell LungProstateSmall-Cell LungMK-6482Welireg(3)BiliaryColorectalHepatocellularPancreaticRare cancersVon Hippel-Lindau Disease-Associated Tumors (EU)MK-7119 Tukysa(1)Advanced Solid TumorsBiliaryBladderCervicalColorectalEndometrialGastricNon-Small-Cell LungMK-7339 Lynparza(1)(3)Advanced Solid TumorsMK-7684 (vibostolimab)(2)MelanomaMK-7684A (vibostolimab+pembrolizumab)BiliaryBreastCervicalColorectalEndometrialEsophagealHead and NeckHematological MalignanciesHepatocellularProstate | CancerMK-7902 Lenvima(1)(2)BiliaryGlioblastomaPancreaticProstateSmall-Cell LungV937BreastCutaneous Squamous CellHead and NeckMelanomaSolid TumorsCardiovascularMK-2060Chikungunya Virus VaccineV184HIV-1 InfectionMK-8591B (islatravir+MK-8507)(4)MK-8591D (islatravir+lenacapavir)(1)(4)HypercholesterolemiaMK-0616Nonalcoholic Steatohepatitis (NASH)MK-3655MK-6024Overgrowth SyndromeMK-7075 (miransertib)Pulmonary Arterial HypertensionMK-5475SchizophreniaMK-8189Treatment Resistant DepressionMK-1942  |  |  |  |  |  |  |  | \nPhase 3 (Phase 3 entry date) | Under Review\nAntiviral COVID-19MK-4482Lagevrio(U.S.) (May 2021)(1)(5)CancerMK-1308A (quavonlimab+pembrolizumab)Renal Cell (April 2021)MK-3475KeytrudaBiliary (September 2019)Cutaneous Squamous Cell (August 2019) (EU)Gastric (May 2015) (EU)Hepatocellular (May 2016) (EU)Mesothelioma (May 2018)Ovarian (December 2018)Prostate (May 2019)Small-Cell Lung (May 2017)MK-3475 (pembrolizumab subcutaneous)Non-Small-Cell Lung (August 2021)MK-4280A (favezelimab+pembrolizumab)Colorectal (November 2021)MK-6482Welireg(3)Renal Cell (February 2020)MK-7119 Tukysa(1)Breast (October 2019)MK-7339 Lynparza(1)(3)Non-Small-Cell Lung (June 2019)Small-Cell Lung (December 2020)MK-7684A (vibostolimab+pembrolizumab)Non-Small-Cell Lung (April 2021)Small-Cell Lung (March 2022)MK-7902 Lenvima(1)(2)Colorectal (April 2021)Esophageal (July 2021)Gastric (December 2020)Head and Neck (February 2020)Melanoma (March 2019)Non-Small-Cell Lung (March 2019)HIV-1 InfectionMK-8591A (doravirine+islatravir) (February 2020)(4)HIV-1 PreventionMK-8591 (islatravir) (February 2021)(4)Pneumococcal Vaccine AdultV116 (July 2022)Pulmonary Arterial HypertensionMK-7962 (sotatercept) (January 2021)Respiratory Syncytial VirusMK-1654 (clesrovimab) (November 2021) | New Molecular Entities/VaccinesAntiviral COVID-19MK-4482Lagevrio(EU)(1)CoughMK-7264 (gefapixant) (U.S.)(6)(EU)Pneumococcal Vaccine Adult/PediatricV114 (JPN) | Certain Supplemental FilingsCancerMK-3475Keytruda\u2022    Second-Line Hepatocellular Cancer(KEYNOTE-394) (U.S.)\u2022    Adjuvent Non-Small-Cell Lung Cancer(KEYNOTE-091) (U.S.) (EU)\u2022    High-Risk Early-Stage Triple-Negative Breast Cancer(KEYNOTE-522) (JPN)\u2022    Cervical Cancer (KEYNOTE-826) (JPN)\u2022    Adjuvent Renal Cell Cancer(KEYNOTE-564) (JPN)MK-7339 Lynparza(1)\u2022BRCA-Mutated HER2-Negative Adjuvant BreastCancer (OlympiA) (JPN)\u2022    First-Line Metastatic Prostate Cancer(PROpel) (EU) (JPN)MK-7902 Lenvima(1)(2)\u2022    First-Line Metastatic Hepatocellular Carcinoma(KEYNOTE-524) (U.S.)(7)\nFootnotes:(1)Being developed in a collaboration.(2)Being developed in combination withKeytruda.(3)Being developed as monotherapy and/or in combination withKeytruda.(4)On FDA clinical hold.(5)Available in the U.S. under Emergency Use Authorization.(6)In response to the CRL received from the FDA for this application in January 2022, Merck is performing additional analyses and anticipates submitting this information to the FDA in the first half of 2023.(7)In July 2020, the FDA issued a CRL for Merck\u2019s and Eisai\u2019s applications. Merck and Eisai intend to submit additional data when available to the FDA.  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | June 30, 2022 |  | December 31, 2021\nCash and investments | $ | 10,366 |  |  | $ | 8,466 | \nWorking capital | 8,948 |  |  | 6,394 | \nTotal debt to total liabilities and equity | 29.6 | % |  | 31.3 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | ($\u00a0in\u00a0millions)\nPeriod | Total\u00a0Numberof SharesPurchased(1) |  | Average\u00a0PricePaid PerShare |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0SharesThat May Yet Be PurchasedUnder the Plans or Programs(1)\nApril 1 - April 30 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nMay 1 - May 31 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nJune 1 - June 30 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nTotal | \u2014 |  |  | $0.00 |  | \u2014 |  |  |   |  |  |  |  |  |  |  | \nNumber |  | Description\n | \n3.1 | \u2014 | Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) \u2013 Incorporated by reference to Current Report on Form 8-K filed on November\u00a04, 2009 (No. 1-6571)\n | \n3.2 | \u2014 | By-Laws of Merck & Co., Inc. (effective March 22, 2022) \u2013 Incorporated by reference to Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)\n |  | \n31.1 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Executive Officer\n | \n31.2 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Financial Officer\n | \n32.1 |  | \u2014 | Section 1350 Certification of Chief Executive Officer\n | \n32.2 |  | \u2014 | Section 1350 Certification of Chief Financial Officer\n | \n101.INS | \u2014 | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.\n |  | \n101.SCH | \u2014 | XBRL Taxonomy Extension Schema Document.\n |  | \n101.CAL | \u2014 | XBRL Taxonomy Extension Calculation Linkbase Document.\n |  | \n101.DEF | \u2014 | XBRL Taxonomy Extension Definition Linkbase Document.\n |  | \n101.LAB | \u2014 | XBRL Taxonomy Extension Label Linkbase Document.\n |  | \n101.PRE | \u2014 | XBRL Taxonomy Extension Presentation Linkbase Document.\n |  | \n104 |  | \u2014 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).  |  |  |  |  |  |  |  | \n |  | MERCK & CO., INC.\n |  | \nDate:  August 4, 2022 |  | /s/ Jennifer Zachary\n |  | JENNIFER ZACHARY\n |  | Executive Vice President and General Counsel\n |  | \nDate:  August 4, 2022 |  | /s/ Rita A. Karachun\n |  | RITA A. KARACHUN\n |  | Senior Vice President Finance - Global Controller"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Merck, in 2023 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  | \n  |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n |   |  |  |  |  |  |  |  | \nNew Jersey | 22-1918501\n(State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.)\n | \n126 East Lincoln Avenue\nRahway | New Jersey | 07065\n(Address of principal executive offices) (zip code)  |  |  |  |  |  |  |  | \n | Not Applicable | \n(Former name, former address and former fiscal year, if changed since last report.)  |  |  |  |  |  |  |  | \nSecurities Registered pursuant to Section\u00a012(b) of the Act:\nTitle of each class | Trading Symbol(s) | Name of each exchange on which registered\nCommon Stock ($0.50\u00a0par value) | MRK | New York Stock Exchange\n0.500% Notes due 2024 | MRK 24 | New York Stock Exchange\n1.875% Notes due 2026 | MRK/26 | New York Stock Exchange\n2.500% Notes due 2034 | MRK/34 | New York Stock Exchange\n1.375% Notes due 2036 | MRK 36A | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 | Accelerated filer | \u2610\n |  |  | \nNon-accelerated filer | \u2610 | Smaller reporting company | \u2610\n |  |  | \n |  | Emerging growth company | \u2610  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page No.\nPART I | FINANCIAL INFORMATION | 3\n |  | \nItem 1. | Financial Statements | 3\n | Condensed Consolidated Statement of Income | 3\n | Condensed Consolidated Statement of Comprehensive Income | 3\n | Condensed Consolidated Balance Sheet | 4\n | Condensed Consolidated Statement of Cash Flows | 5\n | Notes to Condensed Consolidated Financial Statements | 6\n |  | \nItem 2. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 27\n |  | \nItem 3. | Quantitative and Qualitative Disclosures about Market Risk | 39\n |  | \nItem 4. | Controls and Procedures | 39\n |  | \n | Cautionary Factors That May Affect Future Results | 39\n |  | \nPART II | OTHER INFORMATION | 40\n |  | \nItem 1. | Legal Proceedings | 40\n |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 40\n |  |  |  | \nItem 6. | Exhibits | 41\n |  | \n | Signatures |  |  | 42  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2023 |  | 2022 |  |  |  | \nSales | $ | 14,487 |  |  | $ | 15,901 |  |  |  |  | \nCosts, Expenses and Other |  |  |  |  |  |  | \nCost of sales | 3,926 |  |  | 5,380 |  |  |  |  | \nSelling, general and administrative | 2,479 |  |  | 2,323 |  |  |  |  | \nResearch and development | 4,276 |  |  | 2,576 |  |  |  |  | \nRestructuring costs | 67 |  |  | 53 |  |  |  |  | \nOther (income) expense, net | 89 |  |  | 708 |  |  |  |  | \n | 10,837 |  |  | 11,040 |  |  |  |  | \nIncome Before Taxes | 3,650 |  |  | 4,861 |  |  |  |  | \nTaxes on Income | 825 |  |  | 554 |  |  |  |  | \nNet Income | 2,825 |  |  | 4,307 |  |  |  |  | \nLess: Net Income (Loss) Attributable to Noncontrolling Interests | 4 |  |  | (3) |  |  |  |  | \nNet Income Attributable to Merck & Co., Inc. | $ | 2,821 |  |  | $ | 4,310 |  |  |  |  | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | $ | 1.11 |  |  | $ | 1.70 |  |  |  |  | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | $ | 1.11 |  |  | $ | 1.70 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2023 |  | 2022 |  |  |  | \nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 2,821 |  |  | $ | 4,310 |  |  |  |  | \nOther Comprehensive (Loss) Income Net of Taxes: |  |  |  |  |  |  | \nNet unrealized (loss) gain on derivatives, net of reclassifications | (133) |  |  | 63 |  |  |  |  | \nBenefit plan net (loss) gain and prior service (cost) credit, net of amortization | (50) |  |  | 32 |  |  |  |  | \nCumulative translation adjustment | 68 |  |  | (35) |  |  |  |  | \n | (115) |  |  | 60 |  |  |  |  | \nComprehensive Income Attributable to Merck\u00a0& Co., Inc. | $ | 2,706 |  |  | $ | 4,370 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\nAssets |  |  | \nCurrent Assets |  |  | \nCash and cash equivalents | $ | 9,707 |  |  | $ | 12,694 | \nShort-term investments | 680 |  |  | 498 | \nAccounts receivable (net of allowance for doubtful accounts of $76in 2023and $72in 2022) | 10,415 |  |  | 9,450 | \nInventories (excludes inventories of $3,284in 2023 and $2,938in 2022classified in Other assets - see Note\u00a07) | 5,863 |  |  | 5,911 | \nOther current assets | 6,737 |  |  | 7,169 | \nTotal current assets | 33,402 |  |  | 35,722 | \nInvestments | 1,290 |  |  | 1,015 | \nProperty, Plant and Equipment, at cost, net of accumulated depreciation of $18,256in 2023 and $17,985in 2022 | 21,758 |  |  | 21,422 | \nGoodwill | 21,209 |  |  | 21,204 | \nOther Intangibles, Net | 19,857 |  |  | 20,269 | \nOther Assets | 10,280 |  |  | 9,528 | \n | $ | 107,796 |  |  | $ | 109,160 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nLoans payable and current portion of long-term debt | $ | 2,672 |  |  | $ | 1,946 | \nTrade accounts payable | 3,680 |  |  | 4,264 | \nAccrued and other current liabilities | 13,000 |  |  | 14,159 | \nIncome taxes payable | 1,872 |  |  | 1,986 | \nDividends payable | 1,907 |  |  | 1,884 | \nTotal current liabilities | 23,131 |  |  | 24,239 | \nLong-Term Debt | 28,074 |  |  | 28,745 | \nDeferred Income Taxes | 1,442 |  |  | 1,795 | \nOther Noncurrent Liabilities | 8,244 |  |  | 8,323 | \nMerck\u00a0& Co., Inc. Stockholders\u2019 Equity |  |  | \nCommon stock, $0.50par valueAuthorized -6,500,000,000sharesIssued -3,577,103,522shares in 2023 and 2022 | 1,788 |  |  | 1,788 | \nOther paid-in capital | 44,467 |  |  | 44,379 | \nRetained earnings | 62,039 |  |  | 61,081 | \nAccumulated other comprehensive loss | (4,883) |  |  | (4,768) | \n | 103,411 |  |  | 102,480 | \nLess treasury stock, at cost:1,039,651,210shares in 2023 and1,039,269,638shares in 2022 | 56,577 |  |  | 56,489 | \nTotal Merck\u00a0& Co., Inc. stockholders\u2019 equity | 46,834 |  |  | 45,991 | \nNoncontrolling Interests | 71 |  |  | 67 | \nTotal equity | 46,905 |  |  | 46,058 | \n | $ | 107,796 |  |  | $ | 109,160 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31,\n | 2023 |  | 2022\nCash Flows from Operating Activities |  |  | \nNet income | $ | 2,825 |  |  | $ | 4,307 | \nAdjustments to reconcile net income to net cash provided by operating activities: |  |  | \nAmortization | 543 |  |  | 699 | \nDepreciation | 448 |  |  | 421 | \n(Income) loss from investments in equity securities, net | (450) |  |  | 708 | \nCharge for the acquisition of Imago BioSciences, Inc. | 1,192 |  |  | \u2014 | \nDeferred income taxes | (277) |  |  | (338) | \nShare-based compensation | 145 |  |  | 120 | \nOther | (197) |  |  | 143 | \nNet changes in assets and liabilities | (2,890) |  |  | (1,299) | \nNet Cash Provided by Operating Activities | 1,339 |  |  | 4,761 | \nCash Flows from Investing Activities |  |  | \nCapital expenditures | (1,007) |  |  | (984) | \nPurchases of securities and other investments | (562) |  |  | (372) | \nProceeds from sales of securities and other investments | 500 |  |  | 1 | \nAcquisition of Imago BioSciences, Inc., net of cash acquired | (1,327) |  |  | \u2014 | \nOther | 37 |  |  | 182 | \nNet Cash Used in Investing Activities | (2,359) |  |  | (1,173) | \nCash Flows from Financing Activities |  |  | \nPayments on debt | (1) |  |  | (1,250) | \nPurchases of treasury stock | (149) |  |  | \u2014 | \nDividends paid to stockholders | (1,853) |  |  | (1,745) | \nProceeds from exercise of stock options | 30 |  |  | 12 | \nOther | (81) |  |  | (103) | \nNet Cash Used in Financing Activities | (2,054) |  |  | (3,086) | \nEffect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | 87 |  |  | (55) | \nNet (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash | (2,987) |  |  | 447 | \nCash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of$79and $71at January 1, 2023 and 2022, respectively, included inOther current assets) | 12,773 |  |  | 8,167 | \nCash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $79and $58at March\u00a031, 2023 and 2022, respectively, included inOther current assets) | $ | 9,786 |  |  | $ | 8,614 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nAlliance revenue - Lynparza | $ | 275 |  |  | $ | 266 |  |  |  |  | \nAlliance revenue - Koselugo | 23 |  |  | 9 |  |  |  |  | \nTotal alliance revenue | $ | 298 |  |  | $ | 275 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 70 |  |  | 299 |  |  |  |  | \nSelling, general and administrative | 47 |  |  | 44 |  |  |  |  | \nResearch and development | 21 |  |  | 26 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2023 |  | December 31, 2022 |  |  |  | \nReceivables from AstraZeneca included inOther current assets | $ | 303 |  |  | $ | 303 |  |  |  |  | \nPayables to AstraZeneca included inAccrued and other current liabilities(2) | 21 |  |  | 123 |  |  |  |  | \nPayables to AstraZeneca included inOther Noncurrent Liabilities(2) | 600 |  |  | 600 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nAlliance revenue - Lenvima | $ | 232 |  |  | $ | 227 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 126 |  |  | 53 |  |  |  |  | \nSelling, general and administrative | 51 |  |  | 31 |  |  |  |  | \nResearch and development | 39 |  |  | 57 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2023 |  | December 31, 2022 |  |  |  | \nReceivables from Eisai included inOther current assets | $ | 244 |  |  | $ | 214 |  |  |  |  | \nPayables to Eisai included inAccrued and other current liabilities(2) | 125 |  |  | \u2014 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nAlliance revenue - Adempas/Verquvo | $ | 99 |  |  | $ | 72 |  |  |  |  | \nNet sales of Adempas recorded by Merck | 59 |  |  | 61 |  |  |  |  | \nNet sales of Verquvo recorded by Merck | 7 |  |  | 3 |  |  |  |  | \nTotal sales | $ | 165 |  |  | $ | 136 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 57 |  |  | 50 |  |  |  |  | \nSelling, general and administrative | 33 |  |  | 23 |  |  |  |  | \nResearch and development | 25 |  |  | 17 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2023 |  | December 31, 2022 |  |  |  | \nReceivables from Bayer included inOther current assets | $ | 142 |  |  | $ | 143 |  |  |  |  | \nPayables to Bayer included inAccrued and other current liabilities | 68 |  |  | 80 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nNet sales ofLagevriorecorded by Merck | $ | 392 |  |  | $ | 3,247 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1)(2) | 221 |  |  | 1,726 |  |  |  |  | \nSelling, general and administrative(2) | 27 |  |  | 35 |  |  |  |  | \nResearch and development(2) | 16 |  |  | 25 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2023 |  | December 31, 2022 |  |  |  | \nPayables to Ridgeback included inAccrued and other current liabilities(3) | $ | 191 |  |  | $ | 348 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, 2023 |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  |  |  |  |  |  |  | \nCost of sales | $ | \u2014 |  |  | $ | 21 |  |  | $ | 8 |  |  | $ | 29 |  |  |  |  |  |  |  |  | \nSelling, general and administrative | \u2014 |  |  | \u2014 |  |  | 1 |  |  | 1 |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRestructuring costs | 41 |  |  | \u2014 |  |  | 26 |  |  | 67 |  |  |  |  |  |  |  |  | \n | $ | 41 |  |  | $ | 21 |  |  | $ | 35 |  |  | $ | 97 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, 2022 |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  |  |  |  |  |  |  | \nCost of sales | $ | \u2014 |  |  | $ | 18 |  |  | $ | 28 |  |  | $ | 46 |  |  |  |  |  |  |  |  | \nSelling, general and administrative | \u2014 |  |  | 4 |  |  | 17 |  |  | 21 |  |  |  |  |  |  |  |  | \nResearch and development | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 |  |  |  |  |  |  |  |  | \nRestructuring costs | 26 |  |  | \u2014 |  |  | 27 |  |  | 53 |  |  |  |  |  |  |  |  | \n | $ | 26 |  |  | $ | 29 |  |  | $ | 72 |  |  | $ | 127 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nRestructuring reserves January\u00a01, 2023 | $ | 479 |  |  | $ | \u2014 |  |  | $ | 34 |  |  | $ | 513 | \nExpenses | 41 |  |  | 21 |  |  | 35 |  |  | 97 | \n(Payments) receipts, net | (47) |  |  | \u2014 |  |  | (27) |  |  | (74) | \nNon-cash activity | \u2014 |  |  | (21) |  |  | (9) |  |  | (30) | \nRestructuring reserves March\u00a031, 2023(1) | $ | 473 |  |  | $ | \u2014 |  |  | $ | 33 |  |  | $ | 506 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income(1) |  | Amount of Pretax (Gain) Loss Recognized inOther (income) expense, netfor Amounts Excluded from Effectiveness Testing\n | Three Months Ended March 31, |  |  |  | Three Months Ended March 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  |  |  | 2023 |  | 2022 |  |  |  | \nNet Investment Hedging Relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | $ | 1 |  |  | $ | (16) |  |  |  |  |  |  | $ | 1 |  |  | $ | (1) |  |  |  |  | \nEuro-denominated notes | 52 |  |  | (53) |  |  |  |  |  |  | \u2014 |  |  | \u2014 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31, 2023 |  | December 31, 2022\n |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional\n($ in millions) |  | Asset |  | Liability |  | Asset |  | Liability | \nDerivatives Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts | Other Assets | $ | 1 |  |  | $ | \u2014 |  |  | $ | 300 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nInterest rate swap contracts | Other Noncurrent Liabilities | \u2014 |  |  | 1 |  |  | 200 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nForeign exchange contracts | Other current assets | 104 |  |  | \u2014 |  |  | 4,253 |  |  | 220 |  |  | \u2014 |  |  | 4,824 | \nForeign exchange contracts | Other Assets | 32 |  |  | \u2014 |  |  | 1,756 |  |  | 27 |  |  | \u2014 |  |  | 1,609 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 116 |  |  | 3,444 |  |  | \u2014 |  |  | 101 |  |  | 2,691 | \nForeign exchange contracts | Other Noncurrent Liabilities | \u2014 |  |  | 2 |  |  | 120 |  |  | \u2014 |  |  | 1 |  |  | 91 | \n |  | $ | 137 |  |  | $ | 119 |  |  | $ | 10,073 |  |  | $ | 247 |  |  | $ | 102 |  |  | $ | 9,215 | \nDerivatives Not Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Other current assets | $ | 121 |  |  | $ | \u2014 |  |  | $ | 9,507 |  |  | $ | 186 |  |  | $ | \u2014 |  |  | $ | 8,540 | \nForeign exchange contracts | Other Assets | 1 |  |  | \u2014 |  |  | 65 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 164 |  |  | 10,592 |  |  | \u2014 |  |  | 307 |  |  | 10,926 | \nForeign exchange contracts | Other Noncurrent Liabilities | \u2014 |  |  | 1 |  |  | 124 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \n |  | $ | 122 |  |  | $ | 165 |  |  | $ | 20,288 |  |  | $ | 186 |  |  | $ | 307 |  |  | $ | 19,466 | \n |  | $ | 259 |  |  | $ | 284 |  |  | $ | 30,361 |  |  | $ | 433 |  |  | $ | 409 |  |  | $ | 28,681 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\n($ in millions) | Asset |  | Liability |  | Asset |  | Liability\nGross amounts recognized in the condensed consolidated balance sheet | $ | 259 |  |  | $ | 284 |  |  | $ | 433 |  |  | $ | 409 | \nGross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet | (148) |  |  | (148) |  |  | (220) |  |  | (220) | \nCash collateral received/posted | (13) |  |  | \u2014 |  |  | (66) |  |  | (19) | \nNet amounts | $ | 98 |  |  | $ | 136 |  |  | $ | 147 |  |  | $ | 170 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  |  |  |  |  |  |  |  |  |  |  | \nFinancial Statement Caption in which Effects of Fair Value or Cash FlowHedges are Recorded | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss) |  |  |  |  |  | \n | $ | 14,487 |  |  | $ | 15,901 |  |  | $ | 89 |  |  | $ | 708 |  |  | $ | (115) |  |  | $ | 60 |  |  |  |  |  |  |  |  |  |  |  |  | \n(Gain) loss on fair value hedging relationships: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHedged items | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (10) |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nDerivatives designated as hedging instruments | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nImpact of cash flow hedging relationships: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of (loss) gain recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (66) |  |  | 148 |  |  |  |  |  |  |  |  |  |  |  |  | \nIncrease inSalesas a result ofAOCLreclassifications | 101 |  |  | 67 |  |  | \u2014 |  |  | \u2014 |  |  | (101) |  |  | (67) |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOther (income) expense, neton derivatives | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of loss recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Amount of Derivative Pretax (Gain) Loss Recognized in Income\n |  |  | Three Months Ended March 31, |  | \n($ in millions) |  |  | 2023 |  | 2022 |  |  |  | \nDerivatives Not Designated as Hedging Instruments | Income Statement Caption |  |  |  |  |  |  |  | \nForeign exchange contracts(1) | Other (income) expense, net |  | $ | 13 |  |  | $ | 28 |  |  |  |  | \nForeign exchange contracts(2) | Sales |  | 2 |  |  | (2) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\n | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue |  | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue\n($ in millions) | Gains |  | Losses |  | Gains |  | Losses | \nCommercial paper | $ | 663 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 663 |  |  | $ | 498 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 498 | \nU.S. government and agency securities | 92 |  |  | \u2014 |  |  | \u2014 |  |  | 92 |  |  | 68 |  |  | \u2014 |  |  | \u2014 |  |  | 68 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 3 |  |  | \u2014 |  |  | \u2014 |  |  | 3 | \nForeign government bonds | 1 |  |  | \u2014 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nTotal debt securities | $ | 760 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 760 |  |  | $ | 569 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 569 | \nPublicly traded equity securities(1) |  |  |  |  |  |  | 1,585 |  |  |  |  |  |  |  |  | 1,284 | \nTotal debt and publicly traded equity securities |  |  |  |  |  |  | $ | 2,345 |  |  |  |  |  |  |  |  | $ | 1,853 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair Value Measurements Using |  | Fair Value Measurements Using\n | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |  | Total\n($ in millions) | March 31, 2023 |  | December 31, 2022\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCommercial paper | $ | \u2014 |  |  | $ | 663 |  |  | $ | \u2014 |  |  | $ | 663 |  |  | $ | \u2014 |  |  | $ | 498 |  |  | $ | \u2014 |  |  | $ | 498 | \nU.S. government and agency securities | \u2014 |  |  | 22 |  |  | \u2014 |  |  | 22 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nForeign government bonds | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nPublicly traded equity securities | 1,284 |  |  | \u2014 |  |  | \u2014 |  |  | 1,284 |  |  | 1,015 |  |  | \u2014 |  |  | \u2014 |  |  | 1,015 | \n | 1,284 |  |  | 686 |  |  | \u2014 |  |  | 1,970 |  |  | 1,015 |  |  | 498 |  |  | \u2014 |  |  | 1,513 | \nOther assets(1) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | 70 |  |  | \u2014 |  |  | \u2014 |  |  | 70 |  |  | 68 |  |  | \u2014 |  |  | \u2014 |  |  | 68 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 3 |  |  | \u2014 |  |  | \u2014 |  |  | 3 | \nPublicly traded equity securities | 301 |  |  | \u2014 |  |  | \u2014 |  |  | 301 |  |  | 269 |  |  | \u2014 |  |  | \u2014 |  |  | 269 | \n | 375 |  |  | \u2014 |  |  | \u2014 |  |  | 375 |  |  | 340 |  |  | \u2014 |  |  | \u2014 |  |  | 340 | \nDerivative assets(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPurchased currency options | \u2014 |  |  | 139 |  |  | \u2014 |  |  | 139 |  |  | \u2014 |  |  | 215 |  |  | \u2014 |  |  | 215 | \nForward exchange contracts | \u2014 |  |  | 119 |  |  | \u2014 |  |  | 119 |  |  | \u2014 |  |  | 218 |  |  | \u2014 |  |  | 218 | \nInterest rate swap contracts | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \n | \u2014 |  |  | 259 |  |  | \u2014 |  |  | 259 |  |  | \u2014 |  |  | 433 |  |  | \u2014 |  |  | 433 | \nTotal assets | $ | 1,659 |  |  | $ | 945 |  |  | $ | \u2014 |  |  | $ | 2,604 |  |  | $ | 1,355 |  |  | $ | 931 |  |  | $ | \u2014 |  |  | $ | 2,286 | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nContingent consideration | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 353 |  |  | $ | 353 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 456 |  |  | $ | 456 | \nDerivative liabilities(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 276 |  |  | \u2014 |  |  | 276 |  |  | \u2014 |  |  | 402 |  |  | \u2014 |  |  | 402 | \nWritten currency options | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 | \nInterest rate swap contracts | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \n | \u2014 |  |  | 284 |  |  | \u2014 |  |  | 284 |  |  | \u2014 |  |  | 409 |  |  | \u2014 |  |  | 409 | \nTotal liabilities | $ | \u2014 |  |  | $ | 284 |  |  | $ | 353 |  |  | $ | 637 |  |  | $ | \u2014 |  |  | $ | 409 |  |  | $ | 456 |  |  | $ | 865 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022\nFair value January 1 | $ | 456 |  |  | $ | 777 | \nChanges in estimated fair value(1) | 14 |  |  | (84) | \nPayments | (117) |  |  | (119) | \nOther | \u2014 |  |  | (2) | \nFair value March 31(2) | $ | 353 |  |  | $ | 572 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | March 31, 2023 |  | December 31, 2022\nFinished goods | $ | 1,883 |  |  | $ | 1,841 | \nRaw materials and work in process | 7,348 |  |  | 7,063 | \nSupplies | 266 |  |  | 238 | \nTotal (approximates current cost) | 9,497 |  |  | 9,142 | \nDecrease to LIFO cost | (350) |  |  | (293) | \n | $ | 9,147 |  |  | $ | 8,849 | \nRecognized as: |  |  | \nInventories | $ | 5,863 |  |  | $ | 5,911 | \nOther Assets | 3,284 |  |  | 2,938 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at January 1, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,238 |  | $ | 53,696 |  | $ | (4,429) |  | 1,049 |  | $ | (57,109) |  | $ | 73 |  | $ | 38,257 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 4,310 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 4,310 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 60 |  | \u2014 |  | \u2014 |  | \u2014 |  | 60 | \nCash dividends declared on common stock ($0.69per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,754) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,754) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 37 |  | \u2014 |  | \u2014 |  | \u2014 |  | 46 |  | \u2014 |  | 83 | \nNet loss attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (3) |  | (3) | \n |  |  |  |  |  |  |  |  | \nBalance at March 31, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,275 |  | $ | 56,252 |  | $ | (4,369) |  | 1,049 |  | $ | (57,063) |  | $ | 70 |  | $ | 40,953 | \nBalance at January 1, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,379 |  | $ | 61,081 |  | $ | (4,768) |  | 1,039 |  | $ | (56,489) |  | $ | 67 |  | $ | 46,058 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 2,821 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 2,821 | \nOther comprehensive loss, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (115) |  | \u2014 |  | \u2014 |  | \u2014 |  | (115) | \nCash dividends declared on common stock ($0.73per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,863) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,863) | \nTreasury stock shares purchased | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1 |  | (149) |  | \u2014 |  | (149) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 88 |  | \u2014 |  | \u2014 |  | \u2014 |  | 61 |  | \u2014 |  | 149 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 4 |  | 4 | \n |  |  |  |  |  |  |  |  | \nBalance at March 31, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,467 |  | $ | 62,039 |  | $ | (4,883) |  | 1,040 |  | $ | (56,577) |  | $ | 71 |  | $ | 46,905 |   |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  |  |  |  | \n |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2023 |  | 2022 |  |  |  | \n($ in millions) | U.S. |  | International |  | U.S. |  | International |  |  |  |  |  |  |  | \nService cost | $ | 76 |  |  | $ | 49 |  |  | $ | 99 |  |  | $ | 75 |  |  |  |  |  |  |  |  | \nInterest cost | 133 |  |  | 74 |  |  | 103 |  |  | 38 |  |  |  |  |  |  |  |  | \nExpected return on plan assets | (187) |  |  | (128) |  |  | (196) |  |  | (101) |  |  |  |  |  |  |  |  | \nAmortization of unrecognized prior service credit | \u2014 |  |  | (3) |  |  | (8) |  |  | (4) |  |  |  |  |  |  |  |  | \nNet (gain) loss amortization | \u2014 |  |  | (1) |  |  | 56 |  |  | 25 |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCurtailments | 2 |  |  | \u2014 |  |  | 3 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nSettlements | 21 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  |  |  |  |  |  |  | \n | $ | 45 |  |  | $ | (9) |  |  | $ | 58 |  |  | $ | 33 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nService cost | $ | 8 |  |  | $ | 12 |  |  |  |  | \nInterest cost | 16 |  |  | 11 |  |  |  |  | \nExpected return on plan assets | (16) |  |  | (21) |  |  |  |  | \nAmortization of unrecognized prior service credit | (12) |  |  | (14) |  |  |  |  | \nNet gain amortization | (11) |  |  | (11) |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n | $ | (15) |  |  | $ | (23) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nInterest income | $ | (112) |  |  | $ | (7) |  |  |  |  | \nInterest expense | 242 |  |  | 243 |  |  |  |  | \nExchange losses | 61 |  |  | 39 |  |  |  |  | \n(Income) loss from investments in equity securities, net(1) | (450) |  |  | 708 |  |  |  |  | \nNet periodic defined benefit plan (credit) cost other than service cost | (115) |  |  | (121) |  |  |  |  | \nOther, net | 463 |  |  | (154) |  |  |  |  | \n | $ | 89 |  |  | $ | 708 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ and shares in millions except per share amounts) | 2023 |  | 2022 |  |  |  | \nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 2,821 |  |  | $ | 4,310 |  |  |  |  | \nAverage common shares outstanding | 2,538 |  |  | 2,528 |  |  |  |  | \nCommon shares issuable(1) | 13 |  |  | 9 |  |  |  |  | \nAverage common shares outstanding assuming dilution | 2,551 |  |  | 2,537 |  |  |  |  | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | $ | 1.11 |  |  | $ | 1.70 |  |  |  |  | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | $ | 1.11 |  |  | $ | 1.70 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance January 1, 2022, net of taxes | $ | 144 |  |  | $ | (2,743) |  |  | $ | (1,830) |  |  | $ | (4,429) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 148 |  |  | 1 |  |  | (18) |  |  | 131 | \nTax | (31) |  |  | (2) |  |  | (17) |  |  | (50) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 117 |  |  | (1) |  |  | (35) |  |  | 81 | \nReclassification adjustments, pretax | (68) |  | (1) | 45 |  | (2) | \u2014 |  |  | (23) | \nTax | 14 |  |  | (12) |  |  | \u2014 |  |  | 2 | \nReclassification adjustments, net of taxes | (54) |  |  | 33 |  |  | \u2014 |  |  | (21) | \nOther comprehensive income (loss), net of taxes | 63 |  |  | 32 |  |  | (35) |  |  | 60 | \nBalance March 31, 2022, net of taxes | $ | 207 |  |  | $ | (2,711) |  |  | $ | (1,865) |  |  | $ | (4,369) | \nBalance January 1, 2023, net of taxes | $ | 73 |  |  | $ | (2,408) |  |  | $ | (2,433) |  |  | $ | (4,768) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | (66) |  |  | (47) |  |  | 79 |  |  | (34) | \nTax | 14 |  |  | 2 |  |  | (20) |  |  | (4) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | (52) |  |  | (45) |  |  | 59 |  |  | (38) | \nReclassification adjustments, pretax | (102) |  | (1) | (7) |  | (2) | 9 |  |  | (100) | \nTax | 21 |  |  | 2 |  |  | \u2014 |  |  | 23 | \nReclassification adjustments, net of taxes | (81) |  |  | (5) |  |  | 9 |  |  | (77) | \nOther comprehensive income (loss), net of taxes | (133) |  |  | (50) |  |  | 68 |  |  | (115) | \nBalance March 31, 2023, net of taxes | $ | (60) |  |  | $ | (2,458) |  |  | $ | (2,365) |  |  | $ | (4,883) |   |  |  |  |  |  |  |  |  | \n | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \n($ in millions) | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  |  |  |  |  |  |  |  |  |  |  | \nPharmaceutical: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nKeytruda | $ | 3,485 |  |  | $ | 2,310 |  |  | $ | 5,795 |  |  | $ | 2,779 |  |  | $ | 2,030 |  |  | $ | 4,809 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue-Lynparza(1) | 142 |  |  | 133 |  |  | 275 |  |  | 141 |  |  | 125 |  |  | 266 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue-Lenvima(1) | 153 |  |  | 79 |  |  | 232 |  |  | 156 |  |  | 71 |  |  | 227 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue-Reblozyl(2) | 30 |  |  | 12 |  |  | 43 |  |  | 27 |  |  | 25 |  |  | 52 |  |  |  |  |  |  |  |  |  |  |  |  | \nWelireg | 41 |  |  | 1 |  |  | 42 |  |  | 18 |  |  | \u2014 |  |  | 18 |  |  |  |  |  |  |  |  |  |  |  |  | \nVaccines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | 416 |  |  | 1,556 |  |  | 1,972 |  |  | 418 |  |  | 1,042 |  |  | 1,460 |  |  |  |  |  |  |  |  |  |  |  |  | \nProQuad/M-M-RII/Varivax | 421 |  |  | 107 |  |  | 528 |  |  | 371 |  |  | 99 |  |  | 470 |  |  |  |  |  |  |  |  |  |  |  |  | \nRotaTeq | 180 |  |  | 117 |  |  | 297 |  |  | 175 |  |  | 41 |  |  | 216 |  |  |  |  |  |  |  |  |  |  |  |  | \nVaxneuvance | 94 |  |  | 13 |  |  | 106 |  |  | 5 |  |  | \u2014 |  |  | 5 |  |  |  |  |  |  |  |  |  |  |  |  | \nPneumovax23 | 40 |  |  | 56 |  |  | 96 |  |  | 118 |  |  | 55 |  |  | 173 |  |  |  |  |  |  |  |  |  |  |  |  | \nVaqta | 30 |  |  | 10 |  |  | 40 |  |  | 29 |  |  | 7 |  |  | 36 |  |  |  |  |  |  |  |  |  |  |  |  | \nHospital Acute Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBridion | 276 |  |  | 210 |  |  | 487 |  |  | 195 |  |  | 199 |  |  | 395 |  |  |  |  |  |  |  |  |  |  |  |  | \nPrevymis | 54 |  |  | 75 |  |  | 129 |  |  | 40 |  |  | 54 |  |  | 94 |  |  |  |  |  |  |  |  |  |  |  |  | \nPrimaxin | 4 |  |  | 76 |  |  | 80 |  |  | 1 |  |  | 58 |  |  | 58 |  |  |  |  |  |  |  |  |  |  |  |  | \nDificid | 62 |  |  | 3 |  |  | 65 |  |  | 49 |  |  | 3 |  |  | 52 |  |  |  |  |  |  |  |  |  |  |  |  | \nNoxafil | 14 |  |  | 46 |  |  | 60 |  |  | 10 |  |  | 48 |  |  | 57 |  |  |  |  |  |  |  |  |  |  |  |  | \nZerbaxa | 27 |  |  | 23 |  |  | 50 |  |  | 18 |  |  | 12 |  |  | 30 |  |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue-Adempas/Verquvo(3) | 83 |  |  | 16 |  |  | 99 |  |  | 71 |  |  | 1 |  |  | 72 |  |  |  |  |  |  |  |  |  |  |  |  | \nAdempas | \u2014 |  |  | 59 |  |  | 59 |  |  | \u2014 |  |  | 61 |  |  | 61 |  |  |  |  |  |  |  |  |  |  |  |  | \nVirology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLagevrio | (2) |  |  | 394 |  |  | 392 |  |  | 1,523 |  |  | 1,723 |  |  | 3,247 |  |  |  |  |  |  |  |  |  |  |  |  | \nIsentress/IsentressHD | 52 |  |  | 71 |  |  | 123 |  |  | 61 |  |  | 97 |  |  | 158 |  |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBelsomra | 16 |  |  | 40 |  |  | 56 |  |  | 20 |  |  | 48 |  |  | 69 |  |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSimponi | \u2014 |  |  | 180 |  |  | 180 |  |  | \u2014 |  |  | 186 |  |  | 186 |  |  |  |  |  |  |  |  |  |  |  |  | \nRemicade | \u2014 |  |  | 51 |  |  | 51 |  |  | \u2014 |  |  | 61 |  |  | 61 |  |  |  |  |  |  |  |  |  |  |  |  | \nDiabetes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nJanuvia | 271 |  |  | 280 |  |  | 551 |  |  | 325 |  |  | 454 |  |  | 779 |  |  |  |  |  |  |  |  |  |  |  |  | \nJanumet | 56 |  |  | 272 |  |  | 329 |  |  | 63 |  |  | 391 |  |  | 454 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther pharmaceutical(4) | 172 |  |  | 414 |  |  | 584 |  |  | 160 |  |  | 443 |  |  | 602 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal Pharmaceutical segment sales | 6,117 |  |  | 6,604 |  |  | 12,721 |  |  | 6,773 |  |  | 7,334 |  |  | 14,107 |  |  |  |  |  |  |  |  |  |  |  |  | \nAnimal Health: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLivestock | 174 |  |  | 676 |  |  | 849 |  |  | 171 |  |  | 661 |  |  | 832 |  |  |  |  |  |  |  |  |  |  |  |  | \nCompanion Animals | 308 |  |  | 334 |  |  | 642 |  |  | 302 |  |  | 348 |  |  | 650 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal Animal Health segment sales | 482 |  |  | 1,010 |  |  | 1,491 |  |  | 473 |  |  | 1,009 |  |  | 1,482 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal segment sales | 6,599 |  |  | 7,614 |  |  | 14,212 |  |  | 7,246 |  |  | 8,343 |  |  | 15,589 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther(5) | 60 |  |  | 214 |  |  | 275 |  |  | 93 |  |  | 220 |  |  | 312 |  |  |  |  |  |  |  |  |  |  |  |  | \n | $ | 6,659 |  |  | $ | 7,828 |  |  | $ | 14,487 |  |  | $ | 7,339 |  |  | $ | 8,563 |  |  | $ | 15,901 |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nUnited States | $ | 6,659 |  |  | $ | 7,339 |  |  |  |  | \nEurope, Middle East and Africa | 3,303 |  |  | 4,359 |  |  |  |  | \nChina | 1,715 |  |  | 1,143 |  |  |  |  | \nAsia Pacific (other than China and Japan) | 846 |  |  | 930 |  |  |  |  | \nJapan | 758 |  |  | 989 |  |  |  |  | \nLatin America | 661 |  |  | 607 |  |  |  |  | \nOther | 545 |  |  | 534 |  |  |  |  | \n | $ | 14,487 |  |  | $ | 15,901 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nSegment profits: |  |  |  |  |  |  | \nPharmaceutical segment | $ | 9,140 |  |  | $ | 9,501 |  |  |  |  | \nAnimal Health segment | 566 |  |  | 585 |  |  |  |  | \nTotal segment profits | 9,706 |  |  | 10,086 |  |  |  |  | \nOther profits | 164 |  |  | 194 |  |  |  |  | \nUnallocated: |  |  |  |  |  |  | \nInterest income | 112 |  |  | 7 |  |  |  |  | \nInterest expense | (242) |  |  | (243) |  |  |  |  | \nAmortization | (543) |  |  | (699) |  |  |  |  | \nDepreciation | (398) |  |  | (378) |  |  |  |  | \nResearch and development | (4,147) |  |  | (2,446) |  |  |  |  | \nRestructuring costs | (67) |  |  | (53) |  |  |  |  | \nCharge for Zetia antitrust litigation settlements | (573) |  |  | \u2014 |  |  |  |  | \nOther unallocated, net | (362) |  |  | (1,607) |  |  |  |  | \n | $ | 3,650 |  |  | $ | 4,861 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  |  |  | \nUnited States | $ | 6,659 |  |  | $ | 7,339 |  |  | (9) | % |  | (9) | % |  |  |  |  |  |  |  | \nInternational | 7,828 |  |  | 8,563 |  |  | (9) | % |  | (2) | % |  |  |  |  |  |  |  | \nTotal | $ | 14,487 |  |  | $ | 15,901 |  |  | (9) | % |  | (5) | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  |  |  | \nKeytruda | $ | 5,795 |  |  | $ | 4,809 |  |  | 20 | % |  | 24 | % |  |  |  |  |  |  |  | \nAlliance Revenue - Lynparza(1) | 275 |  |  | 266 |  |  | 3 | % |  | 8 | % |  |  |  |  |  |  |  | \nAlliance Revenue-Lenvima(1) | 232 |  |  | 227 |  |  | 2 | % |  | 5 | % |  |  |  |  |  |  |  | \nAlliance Revenue-Reblozyl(2) | 43 |  |  | 52 |  |  | (19) | % |  | (19) | % |  |  |  |  |  |  |  | \nWelireg | 42 |  |  | 18 |  |  | * |  | * |  |  |  |  |  |  |  |   |  |  |  |  | \nDate | Approval\nJanuary 2023 | FDA approval as a single agent for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a \u22654 cm), II, or IIIA NSCLC, based on the KEYNOTE-091 trial.\nMarch 2023 | FDA full approval for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. The conversion from an accelerated to a full (regular) approval is based on results from the Phase 2 KEYNOTE-158, KEYNOTE-164 and KEYNOTE-051 trials.\nApril 2023 | FDA accelerated approval in combination with enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy, based on data from the KEYNOTE-869 trial dose escalation cohort, Cohort A and Cohort K, which was conducted in collaboration with Seagen and Astellas.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | $ | 1,972 |  |  | $ | 1,460 |  |  | 35 | % |  | 43 | % |  |  |  |  |  |  |  | \nProQuad | 190 |  |  | 162 |  |  | 17 | % |  | 18 | % |  |  |  |  |  |  |  | \nM-M-RII | 102 |  |  | 103 |  |  | (1) | % |  | \u2014 | % |  |  |  |  |  |  |  | \nVarivax | 236 |  |  | 204 |  |  | 15 | % |  | 17 | % |  |  |  |  |  |  |  | \nRotaTeq | 297 |  |  | 216 |  |  | 38 | % |  | 42 | % |  |  |  |  |  |  |  | \nVaxneuvance | 106 |  |  | 5 |  |  | * |  | * |  |  |  |  |  |  |  | \nPneumovax 23 | 96 |  |  | 173 |  |  | (44) | % |  | (40) | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  |  |  | \nBridion | $ | 487 |  |  | $ | 395 |  |  | 23 | % |  | 27 | % |  |  |  |  |  |  |  | \nPrevymis | 129 |  |  | 94 |  |  | 38 | % |  | 44 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  |  |  | \nAlliance Revenue - Adempas/Verquvo(1) | $ | 99 |  |  | $ | 72 |  |  | 38 | % |  | 38 | % |  |  |  |  |  |  |  | \nAdempas | 59 |  |  | 61 |  |  | (3) | % |  | 5 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  |  |  | \nLagevrio | $ | 392 |  |  | $ | 3,247 |  |  | (88) | % |  | (87) | % |  |  |  |  |  |  |  | \nIsentress/Isentress HD | 123 |  |  | 158 |  |  | (23) | % |  | (20) | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  |  |  | \nJanuvia/Janumet | $ | 880 |  |  | $ | 1,233 |  |  | (29) | % |  | (25) | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  |  |  | \nLivestock | $ | 849 |  |  | $ | 832 |  |  | 2 | % |  | 8 | % |  |  |  |  |  |  |  | \nCompanion Animal | 642 |  |  | 650 |  |  | (1) | % |  | 2 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  | \nCost of sales | $ | 3,926 |  |  | $ | 5,380 |  |  | (27) | % |  |  |  |  |  | \nSelling, general and administrative | 2,479 |  |  | 2,323 |  |  | 7 | % |  |  |  |  |  | \nResearch and development | 4,276 |  |  | 2,576 |  |  | 66 | % |  |  |  |  |  | \nRestructuring costs | 67 |  |  | 53 |  |  | 26 | % |  |  |  |  |  | \nOther (income) expense, net | 89 |  |  | 708 |  |  | (87) | % |  |  |  |  |  | \n | $ | 10,837 |  |  | $ | 11,040 |  |  | (2) | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSegment Profits |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nPharmaceutical segment profits | $ | 9,140 |  |  | $ | 9,501 |  |  |  |  | \nAnimal Health segment profits | 566 |  |  | 585 |  |  |  |  | \nOther | (6,056) |  |  | (5,225) |  |  |  |  | \nIncome Before Taxes | $ | 3,650 |  |  | $ | 4,861 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions except per share amounts) | 2023 |  | 2022 |  |  |  | \nIncome before taxes as reported under GAAP | $ | 3,650 |  |  | $ | 4,861 |  |  |  |  | \nIncrease (decrease) for excluded items: |  |  |  |  |  |  | \nAcquisition- and divestiture-related costs | 590 |  |  | 637 |  |  |  |  | \nRestructuring costs | 97 |  |  | 127 |  |  |  |  | \n(Income) loss from investments in equity securities, net | (429) |  |  | 684 |  |  |  |  | \nOther items: |  |  |  |  |  |  | \nCharge for Zetia antitrust litigation settlements | 573 |  |  | \u2014 |  |  |  |  | \nNon-GAAP income before taxes | 4,481 |  |  | 6,309 |  |  |  |  | \nTaxes on income as reported under GAAP | 825 |  |  | 554 |  |  |  |  | \nEstimated tax benefit on excluded items(1) | 88 |  |  | 329 |  |  |  |  | \nNon-GAAP taxes on income | 913 |  |  | 883 |  |  |  |  | \nNon-GAAP net income | 3,568 |  |  | 5,426 |  |  |  |  | \nLess: Net income (loss) attributable to noncontrolling interests as reported under GAAP | 4 |  |  | (3) |  |  |  |  | \nNon-GAAP net income attributable to Merck\u00a0& Co., Inc. | $ | 3,564 |  |  | $ | 5,429 |  |  |  |  | \nEPS assuming dilution as reported under GAAP | $ | 1.11 |  |  | $ | 1.70 |  |  |  |  | \nEPS difference | 0.29 |  |  | 0.44 |  |  |  |  | \nNon-GAAP EPS assuming dilution | $ | 1.40 |  |  | $ | 2.14 |  |  |  |  |   |  |  |  |  |  |  |  | \nPhase 2\nCancerMK-0482(2)Non-Small-Cell LungMK-1308 (quavonlimab)(2)Non-Small-Cell LungMK-1308A (quavonlimab+pembrolizumab)ColorectalHepatocellularMelanomaSmall-Cell LungMK-2140 (zilovertamab vedotin)BladderBreastGastricHematological MalignanciesNon-Small-Cell LungOvarianPancreaticMK-2870(1)(3)Neoplasm MalignantMK-3475KeytrudaAdvanced Solid TumorsProstateMK-3543 (bomedemstat)Myeloproliferative DisordersMK-4280 (favezelimab)(2)Non-Small-Cell LungMK-4280A (favezelimab+pembrolizumab)BaldderEsophagealMelanomaRenal CellSmall-Cell LungMK-4830(2)ColorectalEsophagealMelanomaNon-Small-Cell LungOvarianRenal CellSmall-Cell LungMK-5684(1)ProstateMK-5890 (boserolimab)(2)Non-Small-Cell LungSmall-Cell Lung | CancerMK-6440 (ladiratuzumab vedotin)(1)(3)BreastEsophagealGastricHead and NeckMelanomaNon-Small-Cell LungProstateSmall-Cell LungMK-6482Welireg(3)BiliaryColorectalEndometrialEsophagealHepatocellularPancreaticRare cancersVon Hippel-Lindau Disease-Associated Tumors (EU)MK-7119 Tukysa(1)Advanced Solid TumorsBiliaryBladderCervicalEndometrialGastricNon-Small-Cell LungMK-7339 Lynparza(1)(3)Advanced Solid TumorsMK-7684A (vibostolimab+pembrolizumab)BiliaryBladderBreastCervicalColorectalEndometrialEsophagealGastricHead and NeckHematological MalignanciesHepatocellularOvarianProstate | CancerMK-7902 Lenvima(1)(2)BiliaryMelanomaPancreaticProstateSmall-Cell LungV940(1)(2)MelanomaDengue Fever Virus VaccineV181HIV-1 InfectionMK-8591B (islatravir+MK-8507)(4)MK-8591D (islatravir+lenacapavir)(1)(5)HypercholesterolemiaMK-0616Nonalcoholic Steatohepatitis (NASH)MK-6024 (efinopegdutide)Pulmonary Arterial HypertensionMK-5475Pulmonary Hypertension Due To Left Heart DiseaseMK-7962 (sotatercept)SchizophreniaMK-8189(6)ThrombosisMK-2060Treatment Resistant DepressionMK-1942  |  |  |  |  |  |  |  | \nPhase 3 (Phase 3 entry date) | Under Review\nAntiviral COVID-19MK-4482Lagevrio(U.S.) (May 2021)(1)(7)CancerMK-1026 (nemtabrutinib)Hematological Malignancies (March 2023)MK-1308A (quavonlimab+pembrolizumab)Renal Cell (April 2021)MK-3475KeytrudaBiliary (September 2019)Cutaneous Squamous Cell (August 2019) (EU)Hepatocellular (May 2016) (EU)Mesothelioma (May 2018)Ovarian (December 2018)Small-Cell Lung (May 2017)MK-3475 (pembrolizumab subcutaneous)Non-Small-Cell Lung (August 2021)MK-3475A (pembrolizumab+hyaluronidase subcutaneous)Non-Small-Cell Lung (February 2023)MK-4280A (favezelimab+pembrolizumab)Colorectal (November 2021)Hematological Malignancies (October 2022)MK-6482Welireg(3)Renal Cell (February 2020)MK-7119 Tukysa(1)Breast (October 2019)Colorectal (August 2022)MK-7339 Lynparza(1)(2)Non-Small-Cell Lung (June 2019)Small-Cell Lung (December 2020)MK-7684A (vibostolimab+pembrolizumab)Melanoma (January 2023)Non-Small-Cell Lung (April 2021)Small-Cell Lung (March 2022)MK-7902 Lenvima(1)(2)Esophageal (July 2021)Gastric (December 2020)Head and Neck (February 2020)Non-Small-Cell Lung (March 2019)HIV-1 InfectionMK-8591A (doravirine+islatravir) (February 2020)(5)Pneumococcal Vaccine AdultV116 (July 2022)Pulmonary Arterial HypertensionMK-7962 (sotatercept) (January 2021)Respiratory Syncytial VirusMK-1654 (clesrovimab) (November 2021) | New Molecular EntitiesAntiviral COVID-19MK-4482Lagevrio(EU)(1)(8)CoughMK-7264 (gefapixant) (U.S.)(9)(EU) | Certain Supplemental FilingsCancerMK-3475Keytruda\u2022    Second-Line Hepatocellular Carcinoma(KEYNOTE-394) (U.S.)\u2022    Locally Advanced or Metastatic Merkel Cell Carcinoma(KEYNOTE-913) (U.S.)\u2022    First-Line HER2 Negative Locally Advanced Unresectable or Metastatic Gastric Cancer(KEYNOTE-859) (U.S.) (EU)\u2022    Resectable Stage II, IIIA or IIIB NSCLC(KEYNOTE-671) (U.S.) (EU)\u2022    Adjuvant Non-Small-Cell Lung Cancer(KEYNOTE-091) (EU)\u2022    Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma(KEYNOTE-170/KEYNOTE-A33) (JPN)MK-7339 Lynparza(1)\u2022    First-Line Metastatic Prostate Cancer(PROpel) (U.S.) (JPN)\nFootnotes:(1)Being developed in a collaboration.(2)Being developed in combination withKeytruda.(3)Being developed as monotherapy and/or in combination withKeytruda.(4)On FDA clinical hold.(5)On FDA partial clinical hold for higher doses than those used in current clinical trials.(6)Phase 2b development costs are being co-funded.(7)Available in the U.S. under Emergency Use Authorization.(8)Requested re-examination of EU MAA following CHMP recommendation for the refusal of the marketing authorization.(9)In response to the CRL received from the FDA for this application in January 2022, Merck is performing additional analyses and anticipates submitting this information to the FDA in the second quarter of 2023.  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | March 31, 2023 |  | December 31, 2022\nCash and investments | $ | 11,677 |  |  | $ | 14,207 | \nWorking capital | 10,271 |  |  | 11,483 | \nTotal debt to total liabilities and equity | 28.5 | % |  | 28.1 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | ($\u00a0in\u00a0millions)\nPeriod | Total\u00a0Numberof SharesPurchased(1) |  | Average\u00a0PricePaid PerShare |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0SharesThat May Yet Be PurchasedUnder the Plans or Programs(1)\nJanuary 1 - January 31 | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | $5,047\nFebruary 1 - February 28 | 328,800 |  |  | $108.43 |  | 328,800 |  |  | $5,012\nMarch 1 - March 31 | 1,066,937 |  |  | $106.55 |  | 1,066,937 |  |  | $4,898\nTotal | 1,395,737 |  |  | $107.00 |  | 1,395,737 |  |  |   |  |  |  |  |  |  |  | \nNumber |  | Description\n | \n3.1 | \u2014 | Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) \u2013 Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on November\u00a04, 2009 (No. 1-6571)\n | \n3.2 | \u2014 | By-Laws of Merck & Co., Inc. (effective March 22, 2022) \u2013 Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)\n |  | \n31.1 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Executive Officer\n | \n31.2 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Financial Officer\n | \n32.1 |  | \u2014 | Section 1350 Certification of Chief Executive Officer\n | \n32.2 |  | \u2014 | Section 1350 Certification of Chief Financial Officer\n | \n101.INS | \u2014 | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.\n |  | \n101.SCH | \u2014 | XBRL Taxonomy Extension Schema Document.\n |  | \n101.CAL | \u2014 | XBRL Taxonomy Extension Calculation Linkbase Document.\n |  | \n101.DEF | \u2014 | XBRL Taxonomy Extension Definition Linkbase Document.\n |  | \n101.LAB | \u2014 | XBRL Taxonomy Extension Label Linkbase Document.\n |  | \n101.PRE | \u2014 | XBRL Taxonomy Extension Presentation Linkbase Document.\n |  | \n104 |  | \u2014 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).  |  |  |  |  |  |  |  | \n |  | MERCK & CO., INC.\n |  | \nDate:  May 5, 2023 |  | /s/ Jennifer Zachary\n |  | JENNIFER ZACHARY\n |  | Executive Vice President and General Counsel\n |  | \nDate:  May 5, 2023 |  | /s/ Rita A. Karachun\n |  | RITA A. KARACHUN\n |  | Senior Vice President Finance - Global Controller"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Merck, in 2023 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  | \n  |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n |   |  |  |  |  |  |  |  | \nNew Jersey | 22-1918501\n(State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.)\n | \n126 East Lincoln Avenue\nRahway | New Jersey | 07065\n(Address of principal executive offices) (zip code)  |  |  |  |  |  |  |  | \n | Not Applicable | \n(Former name, former address and former fiscal year, if changed since last report.)  |  |  |  |  |  |  |  | \nSecurities Registered pursuant to Section\u00a012(b) of the Act:\nTitle of each class | Trading Symbol(s) | Name of each exchange on which registered\nCommon Stock ($0.50\u00a0par value) | MRK | New York Stock Exchange\n0.500% Notes due 2024 | MRK 24 | New York Stock Exchange\n1.875% Notes due 2026 | MRK/26 | New York Stock Exchange\n2.500% Notes due 2034 | MRK/34 | New York Stock Exchange\n1.375% Notes due 2036 | MRK 36A | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 | Accelerated filer | \u2610\n |  |  | \nNon-accelerated filer | \u2610 | Smaller reporting company | \u2610\n |  |  | \n |  | Emerging growth company | \u2610  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page No.\nPART I | FINANCIAL INFORMATION | 3\n |  | \nItem 1. | Financial Statements | 3\n | Condensed Consolidated Statement of Operations | 3\n | Condensed Consolidated Statement of Comprehensive(Loss)Income | 3\n | Condensed Consolidated Balance Sheet | 4\n | Condensed Consolidated Statement of Cash Flows | 5\n | Notes to Condensed Consolidated Financial Statements | 6\n |  | \nItem 2. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 29\n |  | \nItem 3. | Quantitative and Qualitative Disclosures about Market Risk | 42\n |  | \nItem 4. | Controls and Procedures | 42\n |  | \n | Cautionary Factors That May Affect Future Results | 42\n |  | \nPART II | OTHER INFORMATION | 43\n |  | \nItem 1. | Legal Proceedings | 43\n |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 43\n |  |  |  | \nItem 5. | Other Information | 43\n |  |  |  | \nItem 6. | Exhibits | 44\n |  | \n | Signatures |  |  | 45  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nSales | $ | 15,035 |  |  | $ | 14,593 |  |  | $ | 29,522 |  |  | $ | 30,494 | \nCosts, Expenses and Other |  |  |  |  |  |  | \nCost of sales | 4,024 |  |  | 4,216 |  |  | 7,951 |  |  | 9,596 | \nSelling, general and administrative | 2,702 |  |  | 2,512 |  |  | 5,182 |  |  | 4,834 | \nResearch and development | 13,321 |  |  | 2,798 |  |  | 17,597 |  |  | 5,374 | \nRestructuring costs | 151 |  |  | 142 |  |  | 218 |  |  | 194 | \nOther (income) expense, net | 172 |  |  | 438 |  |  | 259 |  |  | 1,148 | \n | 20,370 |  |  | 10,106 |  |  | 31,207 |  |  | 21,146 | \n(Loss) Income Before Taxes | (5,335) |  |  | 4,487 |  |  | (1,685) |  |  | 9,348 | \nIncome Tax Provision | 637 |  |  | 538 |  |  | 1,462 |  |  | 1,092 | \nNet (Loss) Income | (5,972) |  |  | 3,949 |  |  | (3,147) |  |  | 8,256 | \nLess: Net Income Attributable to Noncontrolling Interests | 3 |  |  | 5 |  |  | 7 |  |  | 2 | \nNet (Loss) Income Attributable to Merck & Co., Inc. | $ | (5,975) |  |  | $ | 3,944 |  |  | $ | (3,154) |  |  | $ | 8,254 | \nBasic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | $ | (2.35) |  |  | $ | 1.56 |  |  | $ | (1.24) |  |  | $ | 3.26 | \n(Loss) Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | $ | (2.35) |  |  | $ | 1.55 |  |  | $ | (1.24) |  |  | $ | 3.25 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nNet (Loss) Income Attributable to Merck\u00a0& Co., Inc. | $ | (5,975) |  |  | $ | 3,944 |  |  | $ | (3,154) |  |  | $ | 8,254 | \nOther Comprehensive (Loss) Income Net of Taxes: |  |  |  |  |  |  | \nNet unrealized gain on derivatives, net of reclassifications | 145 |  |  | 183 |  |  | 12 |  |  | 246 | \nBenefit plan net (loss) gain and prior service (cost) credit, net of amortization | (25) |  |  | 246 |  |  | (75) |  |  | 278 | \nCumulative translation adjustment | (137) |  |  | (387) |  |  | (69) |  |  | (422) | \n | (17) |  |  | 42 |  |  | (132) |  |  | 102 | \nComprehensive (Loss) Income Attributable to Merck\u00a0& Co., Inc. | $ | (5,992) |  |  | $ | 3,986 |  |  | $ | (3,286) |  |  | $ | 8,356 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\nAssets |  |  | \nCurrent Assets |  |  | \nCash and cash equivalents | $ | 5,660 |  |  | $ | 12,694 | \nShort-term investments | 718 |  |  | 498 | \nAccounts receivable (net of allowance for doubtful accounts of $86in 2023and $72in 2022) | 11,030 |  |  | 9,450 | \nInventories (excludes inventories of $3,220in 2023 and $2,938in 2022classified in Other assets - see Note\u00a07) | 5,930 |  |  | 5,911 | \nOther current assets | 6,639 |  |  | 7,169 | \nTotal current assets | 29,977 |  |  | 35,722 | \nInvestments | 1,214 |  |  | 1,015 | \nProperty, Plant and Equipment, at cost, net of accumulated depreciation of $18,432in 2023 and $17,985in 2022 | 22,231 |  |  | 21,422 | \nGoodwill | 21,195 |  |  | 21,204 | \nOther Intangibles, Net | 19,665 |  |  | 20,269 | \nOther Assets | 10,187 |  |  | 9,528 | \n | $ | 104,469 |  |  | $ | 109,160 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nLoans payable and current portion of long-term debt | $ | 2,839 |  |  | $ | 1,946 | \nTrade accounts payable | 3,442 |  |  | 4,264 | \nAccrued and other current liabilities | 13,747 |  |  | 14,159 | \nIncome taxes payable | 1,489 |  |  | 1,986 | \nDividends payable | 1,877 |  |  | 1,884 | \nTotal current liabilities | 23,394 |  |  | 24,239 | \nLong-Term Debt | 34,072 |  |  | 28,745 | \nDeferred Income Taxes | 996 |  |  | 1,795 | \nOther Noncurrent Liabilities | 7,265 |  |  | 8,323 | \nMerck\u00a0& Co., Inc. Stockholders\u2019 Equity |  |  | \nCommon stock, $0.50par valueAuthorized -6,500,000,000sharesIssued -3,577,103,522shares in 2023 and 2022 | 1,788 |  |  | 1,788 | \nOther paid-in capital | 44,219 |  |  | 44,379 | \nRetained earnings | 54,198 |  |  | 61,081 | \nAccumulated other comprehensive loss | (4,900) |  |  | (4,768) | \n | 95,305 |  |  | 102,480 | \nLess treasury stock, at cost:1,037,678,033shares in 2023 and1,039,269,638shares in 2022 | 56,612 |  |  | 56,489 | \nTotal Merck\u00a0& Co., Inc. stockholders\u2019 equity | 38,693 |  |  | 45,991 | \nNoncontrolling Interests | 49 |  |  | 67 | \nTotal equity | 38,742 |  |  | 46,058 | \n | $ | 104,469 |  |  | $ | 109,160 |   |  |  |  |  |  |  |  |  |  |  | \n | Six Months EndedJune 30,\n | 2023 |  | 2022\nCash Flows from Operating Activities |  |  | \nNet (loss) income | $ | (3,147) |  |  | $ | 8,256 | \nAdjustments to reconcile net (loss) income to net cash provided by operating activities: |  |  | \nAmortization | 1,020 |  |  | 1,163 | \nDepreciation | 874 |  |  | 895 | \n(Income) loss from investments in equity securities, net | (274) |  |  | 991 | \nCharge for the acquisition of Prometheus Biosciences, Inc. | 10,217 |  |  | \u2014 | \nCharge for the acquisition of Imago BioSciences, Inc. | 1,192 |  |  | \u2014 | \nDeferred income taxes | (632) |  |  | (600) | \nShare-based compensation | 314 |  |  | 257 | \nOther | 5 |  |  | 799 | \nNet changes in assets and liabilities | (4,526) |  |  | (2,698) | \nNet Cash Provided by Operating Activities | 5,043 |  |  | 9,063 | \nCash Flows from Investing Activities |  |  | \nCapital expenditures | (1,972) |  |  | (2,113) | \nPurchases of securities and other investments | (587) |  |  | (705) | \nProceeds from sales of securities and other investments | 785 |  |  | 374 | \nAcquisition of Prometheus Biosciences, Inc., net of cash acquired | (10,705) |  |  | \u2014 | \nAcquisition of Imago BioSciences, Inc., net of cash acquired | (1,327) |  |  | \u2014 | \nOther | 4 |  |  | 194 | \nNet Cash Used in Investing Activities | (13,802) |  |  | (2,250) | \nCash Flows from Financing Activities |  |  | \nNet change in short-term borrowings | 1,937 |  |  | \u2014 | \nProceeds from issuance of debt | 5,946 |  |  | \u2014 | \nPayments on debt | (1,751) |  |  | (1,250) | \nPurchases of treasury stock | (487) |  |  | \u2014 | \nDividends paid to stockholders | (3,738) |  |  | (3,515) | \nProceeds from exercise of stock options | 112 |  |  | 109 | \nOther | (315) |  |  | (207) | \nNet Cash Provided by (Used in) Financing Activities | 1,704 |  |  | (4,863) | \nEffect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | (6) |  |  | (364) | \nNet (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash | (7,061) |  |  | 1,586 | \nCash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of$79and $71at January 1, 2023 and 2022, respectively, included inOther current assets) | 12,773 |  |  | 8,167 | \nCash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $52and $78at June\u00a030, 2023 and 2022, respectively, included inOther current assets) | $ | 5,712 |  |  | $ | 9,753 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nAlliance revenue - Lynparza | $ | 310 |  |  | $ | 275 |  |  | $ | 585 |  |  | $ | 541 | \nAlliance revenue - Koselugo | 25 |  |  | 24 |  |  | 48 |  |  | 33 | \nTotal alliance revenue | $ | 335 |  |  | $ | 299 |  |  | $ | 633 |  |  | $ | 574 | \n |  |  |  |  |  |  | \nCost of sales(1) | 78 |  |  | 62 |  |  | 148 |  |  | 361 | \nSelling, general and administrative | 51 |  |  | 46 |  |  | 98 |  |  | 90 | \nResearch and development | 22 |  |  | 25 |  |  | 43 |  |  | 51 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | June 30, 2023 |  | December 31, 2022\nReceivables from AstraZeneca included inOther current assets |  |  |  |  | $ | 332 |  |  | $ | 303 | \nPayables to AstraZeneca included inAccrued and other current liabilities(2) |  |  |  |  | 260 |  |  | 123 | \nPayables to AstraZeneca included inOther Noncurrent Liabilities(2) |  |  |  |  | 600 |  |  | 600 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nAlliance revenue - Lenvima | $ | 242 |  |  | $ | 231 |  |  | $ | 474 |  |  | $ | 459 | \n |  |  |  |  |  |  | \nCost of sales(1) | 57 |  |  | 53 |  |  | 183 |  |  | 106 | \nSelling, general and administrative | 48 |  |  | 42 |  |  | 99 |  |  | 73 | \nResearch and development | 17 |  |  | 47 |  |  | 56 |  |  | 104 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | June 30, 2023 |  | December 31, 2022\nReceivables from Eisai included inOther current assets |  |  |  |  | $ | 242 |  |  | $ | 214 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nAlliance revenue - Adempas/Verquvo | $ | 68 |  |  | $ | 98 |  |  | $ | 167 |  |  | $ | 170 | \nNet sales of Adempas recorded by Merck | 65 |  |  | 63 |  |  | 125 |  |  | 124 | \nNet sales of Verquvo recorded by Merck | 9 |  |  | 6 |  |  | 16 |  |  | 9 | \nTotal sales | $ | 142 |  |  | $ | 167 |  |  | $ | 308 |  |  | $ | 303 | \n |  |  |  |  |  |  | \nCost of sales(1) | 56 |  |  | 54 |  |  | 113 |  |  | 103 | \nSelling, general and administrative | 34 |  |  | 42 |  |  | 67 |  |  | 65 | \nResearch and development | 25 |  |  | 17 |  |  | 50 |  |  | 34 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | June 30, 2023 |  | December 31, 2022\nReceivables from Bayer included inOther current assets |  |  |  |  | $ | 144 |  |  | $ | 143 | \nPayables to Bayer included inAccrued and other current liabilities |  |  |  |  | 82 |  |  | 80 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nNet sales ofLagevriorecorded by Merck | $ | 203 |  |  | $ | 1,177 |  |  | $ | 595 |  |  | $ | 4,424 | \n |  |  |  |  |  |  | \nCost of sales(1)(2) | 193 |  |  | 615 |  |  | 414 |  |  | 2,341 | \nSelling, general and administrative(2) | 24 |  |  | 34 |  |  | 51 |  |  | 69 | \nResearch and development(2) | 10 |  |  | 30 |  |  | 26 |  |  | 56 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | June 30, 2023 |  | December 31, 2022\nReceivables from Ridgeback included inOther current assets(3) |  |  |  |  | $ | 51 |  |  | $ | \u2014 | \nPayables to Ridgeback included inAccrued and other current liabilities(4) |  |  |  |  | 30 |  |  | 348 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, 2023 |  | Six Months Ended June 30, 2023\n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nCost of sales | $ | \u2014 |  |  | $ | 22 |  |  | $ | 10 |  |  | $ | 32 |  |  | $ | \u2014 |  |  | $ | 43 |  |  | $ | 18 |  |  | $ | 61 | \nSelling, general and administrative | \u2014 |  |  | \u2014 |  |  | 52 |  |  | 52 |  |  | \u2014 |  |  | \u2014 |  |  | 53 |  |  | 53 | \nResearch and development | \u2014 |  |  | \u2014 |  |  | 1 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  | 1 |  |  | 1 | \nRestructuring costs | 110 |  |  | \u2014 |  |  | 41 |  |  | 151 |  |  | 151 |  |  | \u2014 |  |  | 67 |  |  | 218 | \n | $ | 110 |  |  | $ | 22 |  |  | $ | 104 |  |  | $ | 236 |  |  | $ | 151 |  |  | $ | 43 |  |  | $ | 139 |  |  | $ | 333 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, 2022 |  | Six Months Ended June 30, 2022\n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nCost of sales | $ | \u2014 |  |  | $ | 17 |  |  | $ | 50 |  |  | $ | 67 |  |  | $ | \u2014 |  |  | $ | 35 |  |  | $ | 78 |  |  | $ | 113 | \nSelling, general and administrative | \u2014 |  |  | 8 |  |  | 19 |  |  | 27 |  |  | \u2014 |  |  | 12 |  |  | 36 |  |  | 48 | \nResearch and development | \u2014 |  |  | 22 |  |  | \u2014 |  |  | 22 |  |  | \u2014 |  |  | 29 |  |  | \u2014 |  |  | 29 | \nRestructuring costs | 106 |  |  | \u2014 |  |  | 36 |  |  | 142 |  |  | 132 |  |  | \u2014 |  |  | 62 |  |  | 194 | \n | $ | 106 |  |  | $ | 47 |  |  | $ | 105 |  |  | $ | 258 |  |  | $ | 132 |  |  | $ | 76 |  |  | $ | 176 |  |  | $ | 384 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nRestructuring reserves January\u00a01, 2023 | $ | 479 |  |  | $ | \u2014 |  |  | $ | 34 |  |  | $ | 513 | \nExpenses | 151 |  |  | 43 |  |  | 139 |  |  | 333 | \n(Payments) receipts, net | (84) |  |  | \u2014 |  |  | (74) |  |  | (158) | \nNon-cash activity | \u2014 |  |  | (43) |  |  | (68) |  |  | (111) | \nRestructuring reserves June\u00a030, 2023(1) | $ | 546 |  |  | $ | \u2014 |  |  | $ | 31 |  |  | $ | 577 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income(1) |  | Amount of Pretax (Gain) Loss Recognized inOther (income) expense, netfor Amounts Excluded from Effectiveness Testing\n | Three Months Ended June 30, |  | Six Months Ended June 30, |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022\nNet Investment Hedging Relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | $ | \u2014 |  |  | $ | (31) |  |  | $ | 1 |  |  | $ | (46) |  |  | $ | \u2014 |  |  | $ | (1) |  |  | $ | 1 |  |  | $ | (2) | \nEuro-denominated notes | 21 |  |  | (128) |  |  | 73 |  |  | (181) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30, 2023 |  | December 31, 2022\n |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional\n($ in millions) |  | Asset |  | Liability |  | Asset |  | Liability | \nDerivatives Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Other current assets | $ | 200 |  |  | $ | \u2014 |  |  | $ | 5,976 |  |  | $ | 220 |  |  | $ | \u2014 |  |  | $ | 4,824 | \nForeign exchange contracts | Other Assets | 43 |  |  | \u2014 |  |  | 1,750 |  |  | 27 |  |  | \u2014 |  |  | 1,609 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 62 |  |  | 2,245 |  |  | \u2014 |  |  | 101 |  |  | 2,691 | \nForeign exchange contracts | Other Noncurrent Liabilities | \u2014 |  |  | 1 |  |  | 328 |  |  | \u2014 |  |  | 1 |  |  | 91 | \n |  | $ | 243 |  |  | $ | 63 |  |  | $ | 10,299 |  |  | $ | 247 |  |  | $ | 102 |  |  | $ | 9,215 | \nDerivatives Not Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Other current assets | $ | 222 |  |  | $ | \u2014 |  |  | $ | 8,838 |  |  | $ | 186 |  |  | $ | \u2014 |  |  | $ | 8,540 | \n |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 181 |  |  | 10,112 |  |  | \u2014 |  |  | 307 |  |  | 10,926 | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  | $ | 222 |  |  | $ | 181 |  |  | $ | 18,950 |  |  | $ | 186 |  |  | $ | 307 |  |  | $ | 19,466 | \n |  | $ | 465 |  |  | $ | 244 |  |  | $ | 29,249 |  |  | $ | 433 |  |  | $ | 409 |  |  | $ | 28,681 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\n($ in millions) | Asset |  | Liability |  | Asset |  | Liability\nGross amounts recognized in the condensed consolidated balance sheet | $ | 465 |  |  | $ | 244 |  |  | $ | 433 |  |  | $ | 409 | \nGross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet | (180) |  |  | (180) |  |  | (220) |  |  | (220) | \nCash collateral received/posted | (102) |  |  | \u2014 |  |  | (66) |  |  | (19) | \nNet amounts | $ | 183 |  |  | $ | 64 |  |  | $ | 147 |  |  | $ | 170 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022\nFinancial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are Recorded | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss) |  | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss)\n | $ | 15,035 |  |  | $ | 14,593 |  |  | $ | 172 |  |  | $ | 438 |  |  | $ | (17) |  |  | $ | 42 |  |  | $ | 29,522 |  |  | $ | 30,494 |  |  | $ | 259 |  |  | $ | 1,148 |  |  | $ | (132) |  |  | $ | 102 | \n(Gain) loss on fair value hedging relationships: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHedged items | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (14) |  |  | \u2014 |  |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | \u2014 |  |  | \u2014 | \nImpact of cash flow hedging relationships: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 194 |  |  | 403 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 128 |  |  | 551 | \nIncrease inSalesas a result ofAOCLreclassifications | 24 |  |  | 172 |  |  | \u2014 |  |  | \u2014 |  |  | (24) |  |  | (172) |  |  | 125 |  |  | 239 |  |  | \u2014 |  |  | \u2014 |  |  | (125) |  |  | (239) | \nInterest rate contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOther (income) expense, neton derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |  |  | \u2014 |  |  | \u2014 | \nAmount of gain (loss) recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 13 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 13 |  |  | (1) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Amount of Derivative Pretax (Gain) Loss Recognized in Income\n |  |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n($ in millions) |  |  | 2023 |  | 2022 |  | 2023 |  | 2022\nDerivatives Not Designated as Hedging Instruments | Income Statement Caption |  |  |  |  |  |  |  | \nForeign exchange contracts(1) | Other (income) expense, net |  | $ | (41) |  |  | $ | (64) |  |  | $ | (28) |  |  | $ | (36) | \nForeign exchange contracts(2) | Sales |  | (5) |  |  | (36) |  |  | (3) |  |  | (38) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\n | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue |  | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue\n($ in millions) | Gains |  | Losses |  | Gains |  | Losses | \nCommercial paper | $ | 561 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 561 |  |  | $ | 498 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 498 | \nU.S. government and agency securities | 256 |  |  | \u2014 |  |  | \u2014 |  |  | 256 |  |  | 68 |  |  | \u2014 |  |  | \u2014 |  |  | 68 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 3 |  |  | \u2014 |  |  | \u2014 |  |  | 3 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal debt securities | $ | 821 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 821 |  |  | $ | 569 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 569 | \nPublicly traded equity securities(1) |  |  |  |  |  |  | 1,520 |  |  |  |  |  |  |  |  | 1,284 | \nTotal debt and publicly traded equity securities |  |  |  |  |  |  | $ | 2,341 |  |  |  |  |  |  |  |  | $ | 1,853 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair Value Measurements Using |  | Fair Value Measurements Using\n | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |  | Total\n($ in millions) | June 30, 2023 |  | December 31, 2022\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCommercial paper | $ | \u2014 |  |  | $ | 561 |  |  | $ | \u2014 |  |  | $ | 561 |  |  | $ | \u2014 |  |  | $ | 498 |  |  | $ | \u2014 |  |  | $ | 498 | \nU.S. government and agency securities | \u2014 |  |  | 187 |  |  | \u2014 |  |  | 187 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPublicly traded equity securities | 1,184 |  |  | \u2014 |  |  | \u2014 |  |  | 1,184 |  |  | 1,015 |  |  | \u2014 |  |  | \u2014 |  |  | 1,015 | \n | 1,184 |  |  | 748 |  |  | \u2014 |  |  | 1,932 |  |  | 1,015 |  |  | 498 |  |  | \u2014 |  |  | 1,513 | \nOther assets(1) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | 69 |  |  | \u2014 |  |  | \u2014 |  |  | 69 |  |  | 68 |  |  | \u2014 |  |  | \u2014 |  |  | 68 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 3 |  |  | \u2014 |  |  | \u2014 |  |  | 3 | \nPublicly traded equity securities | 336 |  |  | \u2014 |  |  | \u2014 |  |  | 336 |  |  | 269 |  |  | \u2014 |  |  | \u2014 |  |  | 269 | \n | 409 |  |  | \u2014 |  |  | \u2014 |  |  | 409 |  |  | 340 |  |  | \u2014 |  |  | \u2014 |  |  | 340 | \nDerivative assets(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 316 |  |  | \u2014 |  |  | 316 |  |  | \u2014 |  |  | 218 |  |  | \u2014 |  |  | 218 | \nPurchased currency options | \u2014 |  |  | 149 |  |  | \u2014 |  |  | 149 |  |  | \u2014 |  |  | 215 |  |  | \u2014 |  |  | 215 | \n | \u2014 |  |  | 465 |  |  | \u2014 |  |  | 465 |  |  | \u2014 |  |  | 433 |  |  | \u2014 |  |  | 433 | \nTotal assets | $ | 1,593 |  |  | $ | 1,213 |  |  | $ | \u2014 |  |  | $ | 2,806 |  |  | $ | 1,355 |  |  | $ | 931 |  |  | $ | \u2014 |  |  | $ | 2,286 | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nContingent consideration | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 349 |  |  | $ | 349 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 456 |  |  | $ | 456 | \nDerivative liabilities(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 235 |  |  | \u2014 |  |  | 235 |  |  | \u2014 |  |  | 402 |  |  | \u2014 |  |  | 402 | \nWritten currency options | \u2014 |  |  | 9 |  |  | \u2014 |  |  | 9 |  |  | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 | \n | \u2014 |  |  | 244 |  |  | \u2014 |  |  | 244 |  |  | \u2014 |  |  | 409 |  |  | \u2014 |  |  | 409 | \nTotal liabilities | $ | \u2014 |  |  | $ | 244 |  |  | $ | 349 |  |  | $ | 593 |  |  | $ | \u2014 |  |  | $ | 409 |  |  | $ | 456 |  |  | $ | 865 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022\nFair value January 1 | $ | 456 |  |  | $ | 777 | \nChanges in estimated fair value(1) | 10 |  |  | (114) | \nPayments | (117) |  |  | (119) | \nOther | \u2014 |  |  | (2) | \nFair value June 30(2) | $ | 349 |  |  | $ | 542 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | June 30, 2023 |  | December 31, 2022\nFinished goods | $ | 1,841 |  |  | $ | 1,841 | \nRaw materials and work in process | 7,453 |  |  | 7,063 | \nSupplies | 269 |  |  | 238 | \nTotal | 9,563 |  |  | 9,142 | \nDecrease to LIFO cost | (413) |  |  | (293) | \n | $ | 9,150 |  |  | $ | 8,849 | \nRecognized as: |  |  | \nInventories | $ | 5,930 |  |  | $ | 5,911 | \nOther Assets | 3,220 |  |  | 2,938 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at April 1, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,275 |  | $ | 56,252 |  | $ | (4,369) |  | 1,049 |  | $ | (57,063) |  | $ | 70 |  | $ | 40,953 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 3,944 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3,944 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 42 |  | \u2014 |  | \u2014 |  | \u2014 |  | 42 | \nCash dividends declared on common stock ($0.69per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,759) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,759) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (160) |  | \u2014 |  | \u2014 |  | (5) |  | 293 |  | \u2014 |  | 133 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 5 |  | 5 | \n |  |  |  |  |  |  |  |  | \nBalance at June 30, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,115 |  | $ | 58,437 |  | $ | (4,327) |  | 1,044 |  | $ | (56,770) |  | $ | 75 |  | $ | 43,318 | \nBalance at April 1, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,467 |  | $ | 62,039 |  | $ | (4,883) |  | 1,040 |  | $ | (56,577) |  | $ | 71 |  | $ | 46,905 | \nNet loss attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | (5,975) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (5,975) | \nOther comprehensive loss, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (17) |  | \u2014 |  | \u2014 |  | \u2014 |  | (17) | \nCash dividends declared on common stock ($0.73per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,866) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,866) | \nTreasury stock shares purchased | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3 |  | (338) |  | \u2014 |  | (338) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (248) |  | \u2014 |  | \u2014 |  | (5) |  | 303 |  | \u2014 |  | 55 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3 |  | 3 | \nDistributions attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (25) |  | (25) | \nBalance at June 30, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,219 |  | $ | 54,198 |  | $ | (4,900) |  | 1,038 |  | $ | (56,612) |  | $ | 49 |  | $ | 38,742 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at January\u00a01, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,238 |  | $ | 53,696 |  | $ | (4,429) |  | 1,049 |  | $ | (57,109) |  | $ | 73 |  | $ | 38,257 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 8,254 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 8,254 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 102 |  | \u2014 |  | \u2014 |  | \u2014 |  | 102 | \nCash dividends declared on common stock ($1.38per share) | \u2014 |  | \u2014 |  | \u2014 |  | (3,513) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (3,513) | \n |  |  |  |  |  |  |  |  | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (123) |  | \u2014 |  | \u2014 |  | (5) |  | 339 |  | \u2014 |  | 216 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 2 |  | 2 | \n |  |  |  |  |  |  |  |  | \nBalance at June 30, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,115 |  | $ | 58,437 |  | $ | (4,327) |  | 1,044 |  | $ | (56,770) |  | $ | 75 |  | $ | 43,318 | \nBalance at January\u00a01, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,379 |  | $ | 61,081 |  | $ | (4,768) |  | 1,039 |  | $ | (56,489) |  | $ | 67 |  | $ | 46,058 | \nNet loss attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | (3,154) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (3,154) | \nOther comprehensive loss, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (132) |  | \u2014 |  | \u2014 |  | \u2014 |  | (132) | \nCash dividends declared on common stock ($1.46per share) | \u2014 |  | \u2014 |  | \u2014 |  | (3,729) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (3,729) | \nTreasury stock shares purchased | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 4 |  | (487) |  | \u2014 |  | (487) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (160) |  | \u2014 |  | \u2014 |  | (5) |  | 364 |  | \u2014 |  | 204 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 7 |  | 7 | \nDistributions attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (25) |  | (25) | \nBalance at June 30, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,219 |  | $ | 54,198 |  | $ | (4,900) |  | 1,038 |  | $ | (56,612) |  | $ | 49 |  | $ | 38,742 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\n($ in millions) | U.S. |  | International |  | U.S. |  | International |  | U.S. |  | International |  | U.S. |  | International\nService cost | $ | 76 |  |  | $ | 50 |  |  | $ | 99 |  |  | $ | 72 |  |  | $ | 152 |  |  | $ | 99 |  |  | $ | 198 |  |  | $ | 147 | \nInterest cost | 133 |  |  | 75 |  |  | 103 |  |  | 37 |  |  | 266 |  |  | 149 |  |  | 206 |  |  | 75 | \nExpected return on plan assets | (185) |  |  | (130) |  |  | (197) |  |  | (98) |  |  | (372) |  |  | (257) |  |  | (393) |  |  | (199) | \nAmortization of unrecognized prior service cost (credit) | \u2014 |  |  | 16 |  |  | (8) |  |  | (3) |  |  | (1) |  |  | 12 |  |  | (16) |  |  | (7) | \nNet (gain) loss amortization | \u2014 |  |  | (1) |  |  | 56 |  |  | 25 |  |  | \u2014 |  |  | (2) |  |  | 112 |  |  | 50 | \nTermination benefits | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 | \nCurtailments | 2 |  |  | \u2014 |  |  | 4 |  |  | \u2014 |  |  | 5 |  |  | \u2014 |  |  | 8 |  |  | \u2014 | \nSettlements | 5 |  |  | \u2014 |  |  | 101 |  |  | \u2014 |  |  | 26 |  |  | \u2014 |  |  | 101 |  |  | \u2014 | \n | $ | 32 |  |  | $ | 10 |  |  | $ | 159 |  |  | $ | 33 |  |  | $ | 77 |  |  | $ | 1 |  |  | $ | 217 |  |  | $ | 66 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nService cost | $ | 8 |  |  | $ | 12 |  |  | $ | 17 |  |  | $ | 25 | \nInterest cost | 16 |  |  | 11 |  |  | 31 |  |  | 23 | \nExpected return on plan assets | (16) |  |  | (21) |  |  | (32) |  |  | (43) | \nAmortization of unrecognized prior service credit | (12) |  |  | (14) |  |  | (25) |  |  | (29) | \nNet gain amortization | (11) |  |  | (11) |  |  | (21) |  |  | (21) | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n | $ | (15) |  |  | $ | (23) |  |  | $ | (30) |  |  | $ | (45) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nInterest income | $ | (109) |  |  | $ | (15) |  |  | $ | (221) |  |  | $ | (22) | \nInterest expense | 277 |  |  | 240 |  |  | 519 |  |  | 483 | \nExchange losses | 62 |  |  | 86 |  |  | 122 |  |  | 124 | \nLoss (income) from investments in equity securities, net(1) | 175 |  |  | 284 |  |  | (274) |  |  | 991 | \nNet periodic defined benefit plan (credit) cost other than service cost | (111) |  |  | (27) |  |  | (226) |  |  | (148) | \nOther, net | (122) |  |  | (130) |  |  | 339 |  |  | (280) | \n | $ | 172 |  |  | $ | 438 |  |  | $ | 259 |  |  | $ | 1,148 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ and shares in millions except per share amounts) | 2023 |  | 2022 |  | 2023 |  | 2022\nNet (Loss) Income Attributable to Merck\u00a0& Co., Inc. | $ | (5,975) |  |  | $ | 3,944 |  |  | $ | (3,154) |  |  | $ | 8,254 | \nAverage common shares outstanding | 2,539 |  |  | 2,531 |  |  | 2,539 |  |  | 2,529 | \nCommon shares issuable(1) | \u2014 |  |  | 9 |  |  | \u2014 |  |  | 9 | \nAverage common shares outstanding assuming dilution | 2,539 |  |  | 2,540 |  |  | 2,539 |  |  | 2,538 | \nBasic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | $ | (2.35) |  |  | $ | 1.56 |  |  | $ | (1.24) |  |  | $ | 3.26 | \n(Loss) Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | $ | (2.35) |  |  | $ | 1.55 |  |  | $ | (1.24) |  |  | $ | 3.25 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance April 1, 2022, net of taxes | $ | 207 |  |  | $ | (2,711) |  |  | $ | (1,865) |  |  | $ | (4,369) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 403 |  |  | 168 |  |  | (365) |  |  | 206 | \nTax | (85) |  |  | (35) |  |  | (22) |  |  | (142) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 318 |  |  | 133 |  |  | (387) |  |  | 64 | \nReclassification adjustments, pretax | (171) |  | (1) | 144 |  | (2) | \u2014 |  |  | (27) | \nTax | 36 |  |  | (31) |  |  | \u2014 |  |  | 5 | \nReclassification adjustments, net of taxes | (135) |  |  | 113 |  |  | \u2014 |  |  | (22) | \nOther comprehensive income (loss), net of taxes | 183 |  |  | 246 |  |  | (387) |  |  | 42 | \nBalance June 30, 2022, net of taxes | $ | 390 |  |  | $ | (2,465) |  |  | $ | (2,252) |  |  | $ | (4,327) | \nBalance April 1, 2023, net of taxes | $ | (60) |  |  | $ | (2,458) |  |  | $ | (2,365) |  |  | $ | (4,883) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 194 |  |  | (6) |  |  | (115) |  |  | 73 | \nTax | (41) |  |  | 1 |  |  | (22) |  |  | (62) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 153 |  |  | (5) |  |  | (137) |  |  | 11 | \nReclassification adjustments, pretax | (11) |  | (1) | (23) |  | (2) | \u2014 |  |  | (34) | \nTax | 3 |  |  | 3 |  |  | \u2014 |  |  | 6 | \nReclassification adjustments, net of taxes | (8) |  |  | (20) |  |  | \u2014 |  |  | (28) | \nOther comprehensive income (loss), net of taxes | 145 |  |  | (25) |  |  | (137) |  |  | (17) | \nBalance June 30, 2023, net of taxes | $ | 85 |  |  | $ | (2,483) |  |  | $ | (2,502) |  |  | $ | (4,900) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance January 1, 2022, net of taxes | $ | 144 |  |  | $ | (2,743) |  |  | $ | (1,830) |  |  | $ | (4,429) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 551 |  |  | 169 |  |  | (383) |  |  | 337 | \nTax | (116) |  |  | (37) |  |  | (39) |  |  | (192) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 435 |  |  | 132 |  |  | (422) |  |  | 145 | \nReclassification adjustments, pretax | (239) |  | (1) | 189 |  | (2) | \u2014 |  |  | (50) | \nTax | 50 |  |  | (43) |  |  | \u2014 |  |  | 7 | \nReclassification adjustments, net of taxes | (189) |  |  | 146 |  |  | \u2014 |  |  | (43) | \nOther comprehensive income (loss), net of taxes | 246 |  |  | 278 |  |  | (422) |  |  | 102 | \nBalance June 30, 2022, net of taxes | $ | 390 |  |  | $ | (2,465) |  |  | $ | (2,252) |  |  | $ | (4,327) | \nBalance January 1, 2023, net of taxes | $ | 73 |  |  | $ | (2,408) |  |  | $ | (2,433) |  |  | $ | (4,768) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 128 |  |  | (53) |  |  | (36) |  |  | 39 | \nTax | (27) |  |  | 3 |  |  | (42) |  |  | (66) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 101 |  |  | (50) |  |  | (78) |  |  | (27) | \nReclassification adjustments, pretax | (113) |  | (1) | (30) |  | (2) | 9 |  |  | (134) | \nTax | 24 |  |  | 5 |  |  | \u2014 |  |  | 29 | \nReclassification adjustments, net of taxes | (89) |  |  | (25) |  |  | 9 |  |  | (105) | \nOther comprehensive income (loss), net of taxes | 12 |  |  | (75) |  |  | (69) |  |  | (132) | \nBalance June 30, 2023, net of taxes | $ | 85 |  |  | $ | (2,483) |  |  | $ | (2,502) |  |  | $ | (4,900) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\n($ in millions) | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total\nPharmaceutical: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nKeytruda | $ | 3,863 |  |  | $ | 2,408 |  |  | $ | 6,271 |  |  | $ | 3,197 |  |  | $ | 2,055 |  |  | $ | 5,252 |  |  | $ | 7,348 |  |  | $ | 4,718 |  |  | $ | 12,065 |  |  | $ | 5,976 |  |  | $ | 4,085 |  |  | $ | 10,061 | \nAlliance revenue-Lynparza(1) | 144 |  |  | 166 |  |  | 310 |  |  | 143 |  |  | 132 |  |  | 275 |  |  | 286 |  |  | 299 |  |  | 585 |  |  | 283 |  |  | 257 |  |  | 541 | \nAlliance revenue-Lenvima(1) | 163 |  |  | 79 |  |  | 242 |  |  | 128 |  |  | 103 |  |  | 231 |  |  | 316 |  |  | 158 |  |  | 474 |  |  | 284 |  |  | 175 |  |  | 459 | \nWelireg | 49 |  |  | 2 |  |  | 50 |  |  | 27 |  |  | \u2014 |  |  | 27 |  |  | 90 |  |  | 3 |  |  | 92 |  |  | 45 |  |  | \u2014 |  |  | 45 | \nAlliance revenue-Reblozyl(2) | 36 |  |  | 11 |  |  | 47 |  |  | 28 |  |  | 5 |  |  | 33 |  |  | 66 |  |  | 24 |  |  | 90 |  |  | 55 |  |  | 30 |  |  | 86 | \nVaccines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | 464 |  |  | 1,994 |  |  | 2,458 |  |  | 428 |  |  | 1,245 |  |  | 1,674 |  |  | 880 |  |  | 3,550 |  |  | 4,430 |  |  | 846 |  |  | 2,287 |  |  | 3,133 | \nProQuad/M-M-RII/Varivax | 447 |  |  | 135 |  |  | 582 |  |  | 434 |  |  | 143 |  |  | 578 |  |  | 868 |  |  | 242 |  |  | 1,109 |  |  | 805 |  |  | 243 |  |  | 1,047 | \nRotaTeq | 93 |  |  | 37 |  |  | 131 |  |  | 98 |  |  | 75 |  |  | 173 |  |  | 273 |  |  | 155 |  |  | 428 |  |  | 273 |  |  | 116 |  |  | 389 | \nVaxneuvance | 147 |  |  | 20 |  |  | 168 |  |  | 11 |  |  | \u2014 |  |  | 12 |  |  | 241 |  |  | 33 |  |  | 274 |  |  | 16 |  |  | 1 |  |  | 16 | \nPneumovax23 | 23 |  |  | 69 |  |  | 92 |  |  | 94 |  |  | 59 |  |  | 153 |  |  | 63 |  |  | 125 |  |  | 188 |  |  | 212 |  |  | 114 |  |  | 325 | \nVaqta | 29 |  |  | 13 |  |  | 42 |  |  | 16 |  |  | 19 |  |  | 35 |  |  | 59 |  |  | 23 |  |  | 82 |  |  | 45 |  |  | 25 |  |  | 71 | \nHospital Acute Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBridion | 299 |  |  | 203 |  |  | 502 |  |  | 237 |  |  | 190 |  |  | 426 |  |  | 576 |  |  | 413 |  |  | 989 |  |  | 432 |  |  | 389 |  |  | 821 | \nPrevymis | 61 |  |  | 82 |  |  | 143 |  |  | 47 |  |  | 56 |  |  | 103 |  |  | 116 |  |  | 157 |  |  | 273 |  |  | 87 |  |  | 110 |  |  | 197 | \nDificid | 68 |  |  | 8 |  |  | 76 |  |  | 63 |  |  | 3 |  |  | 66 |  |  | 130 |  |  | 11 |  |  | 141 |  |  | 113 |  |  | 6 |  |  | 119 | \nPrimaxin | (2) |  |  | 56 |  |  | 53 |  |  | \u2014 |  |  | 64 |  |  | 64 |  |  | 2 |  |  | 132 |  |  | 133 |  |  | 1 |  |  | 122 |  |  | 122 | \nNoxafil | 11 |  |  | 45 |  |  | 55 |  |  | 16 |  |  | 45 |  |  | 60 |  |  | 25 |  |  | 91 |  |  | 116 |  |  | 25 |  |  | 92 |  |  | 118 | \nZerbaxa | 30 |  |  | 24 |  |  | 54 |  |  | 22 |  |  | 24 |  |  | 46 |  |  | 57 |  |  | 47 |  |  | 104 |  |  | 40 |  |  | 36 |  |  | 76 | \nCardiovascular |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue-Adempas/Verquvo(3) | 70 |  |  | (2) |  |  | 68 |  |  | 88 |  |  | 10 |  |  | 98 |  |  | 153 |  |  | 14 |  |  | 167 |  |  | 159 |  |  | 11 |  |  | 170 | \nAdempas | \u2014 |  |  | 65 |  |  | 65 |  |  | \u2014 |  |  | 63 |  |  | 63 |  |  | \u2014 |  |  | 125 |  |  | 125 |  |  | \u2014 |  |  | 124 |  |  | 124 | \nVirology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLagevrio | 2 |  |  | 201 |  |  | 203 |  |  | \u2014 |  |  | 1,177 |  |  | 1,177 |  |  | \u2014 |  |  | 595 |  |  | 595 |  |  | 1,523 |  |  | 2,901 |  |  | 4,424 | \nIsentress/IsentressHD | 56 |  |  | 80 |  |  | 136 |  |  | 67 |  |  | 80 |  |  | 147 |  |  | 108 |  |  | 151 |  |  | 259 |  |  | 128 |  |  | 177 |  |  | 305 | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBelsomra | 21 |  |  | 42 |  |  | 63 |  |  | 19 |  |  | 50 |  |  | 69 |  |  | 37 |  |  | 82 |  |  | 119 |  |  | 39 |  |  | 98 |  |  | 137 | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSimponi | \u2014 |  |  | 180 |  |  | 180 |  |  | \u2014 |  |  | 181 |  |  | 181 |  |  | \u2014 |  |  | 359 |  |  | 359 |  |  | \u2014 |  |  | 366 |  |  | 366 | \nRemicade | \u2014 |  |  | 48 |  |  | 48 |  |  | \u2014 |  |  | 53 |  |  | 53 |  |  | \u2014 |  |  | 99 |  |  | 99 |  |  | \u2014 |  |  | 114 |  |  | 114 | \nDiabetes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nJanuvia | 243 |  |  | 267 |  |  | 511 |  |  | 301 |  |  | 455 |  |  | 756 |  |  | 514 |  |  | 548 |  |  | 1,062 |  |  | 626 |  |  | 909 |  |  | 1,535 | \nJanumet | 82 |  |  | 272 |  |  | 354 |  |  | 105 |  |  | 371 |  |  | 476 |  |  | 138 |  |  | 544 |  |  | 683 |  |  | 168 |  |  | 762 |  |  | 931 | \nOther pharmaceutical(4) | 171 |  |  | 382 |  |  | 553 |  |  | 157 |  |  | 372 |  |  | 528 |  |  | 342 |  |  | 793 |  |  | 1,138 |  |  | 317 |  |  | 814 |  |  | 1,131 | \nTotal Pharmaceutical segment sales | 6,570 |  |  | 6,887 |  |  | 13,457 |  |  | 5,726 |  |  | 7,030 |  |  | 12,756 |  |  | 12,688 |  |  | 13,491 |  |  | 26,179 |  |  | 12,498 |  |  | 14,364 |  |  | 26,863 | \nAnimal Health: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLivestock | 165 |  |  | 643 |  |  | 807 |  |  | 164 |  |  | 662 |  |  | 826 |  |  | 338 |  |  | 1,318 |  |  | 1,656 |  |  | 335 |  |  | 1,322 |  |  | 1,658 | \nCompanion Animal | 310 |  |  | 339 |  |  | 649 |  |  | 313 |  |  | 328 |  |  | 641 |  |  | 618 |  |  | 673 |  |  | 1,291 |  |  | 616 |  |  | 676 |  |  | 1,291 | \nTotal Animal Health segment sales | 475 |  |  | 982 |  |  | 1,456 |  |  | 477 |  |  | 990 |  |  | 1,467 |  |  | 956 |  |  | 1,991 |  |  | 2,947 |  |  | 951 |  |  | 1,998 |  |  | 2,949 | \nTotal segment sales | 7,045 |  |  | 7,869 |  |  | 14,913 |  |  | 6,203 |  |  | 8,020 |  |  | 14,223 |  |  | 13,644 |  |  | 15,482 |  |  | 29,126 |  |  | 13,449 |  |  | 16,362 |  |  | 29,812 | \nOther(5) | (27) |  |  | 149 |  |  | 122 |  |  | 35 |  |  | 335 |  |  | 370 |  |  | 32 |  |  | 364 |  |  | 396 |  |  | 128 |  |  | 555 |  |  | 682 | \n | $ | 7,018 |  |  | $ | 8,018 |  |  | $ | 15,035 |  |  | $ | 6,238 |  |  | $ | 8,355 |  |  | $ | 14,593 |  |  | $ | 13,676 |  |  | $ | 15,846 |  |  | $ | 29,522 |  |  | $ | 13,577 |  |  | $ | 16,917 |  |  | $ | 30,494 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nUnited States | $ | 7,018 |  |  | $ | 6,238 |  |  | $ | 13,676 |  |  | $ | 13,577 | \nEurope, Middle East and Africa | 3,348 |  |  | 3,582 |  |  | 6,651 |  |  | 7,942 | \nChina | 1,913 |  |  | 1,372 |  |  | 3,628 |  |  | 2,515 | \nAsia Pacific (other than China and Japan) | 848 |  |  | 1,008 |  |  | 1,694 |  |  | 1,938 | \nJapan | 675 |  |  | 1,114 |  |  | 1,434 |  |  | 2,103 | \nLatin America | 742 |  |  | 642 |  |  | 1,403 |  |  | 1,249 | \nOther | 491 |  |  | 637 |  |  | 1,036 |  |  | 1,170 | \n | $ | 15,035 |  |  | $ | 14,593 |  |  | $ | 29,522 |  |  | $ | 30,494 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nSegment profits: |  |  |  |  |  |  | \nPharmaceutical segment | $ | 9,854 |  |  | $ | 9,173 |  |  | $ | 18,993 |  |  | $ | 18,673 | \nAnimal Health segment | 467 |  |  | 571 |  |  | 1,032 |  |  | 1,156 | \nTotal segment profits | 10,321 |  |  | 9,744 |  |  | 20,025 |  |  | 19,829 | \nOther profits | 19 |  |  | 260 |  |  | 184 |  |  | 454 | \nUnallocated: |  |  |  |  |  |  | \nInterest income | 109 |  |  | 15 |  |  | 221 |  |  | 22 | \nInterest expense | (277) |  |  | (240) |  |  | (519) |  |  | (483) | \nAmortization | (477) |  |  | (463) |  |  | (1,020) |  |  | (1,163) | \nDepreciation | (376) |  |  | (431) |  |  | (775) |  |  | (809) | \nResearch and development | (13,194) |  |  | (2,652) |  |  | (17,341) |  |  | (5,097) | \nRestructuring costs | (151) |  |  | (142) |  |  | (218) |  |  | (194) | \nCharge for Zetia antitrust litigation settlements | \u2014 |  |  | \u2014 |  |  | (573) |  |  | \u2014 | \nOther unallocated, net | (1,309) |  |  | (1,604) |  |  | (1,669) |  |  | (3,211) | \n | $ | (5,335) |  |  | $ | 4,487 |  |  | $ | (1,685) |  |  | $ | 9,348 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nUnited States | $ | 7,018 |  |  | $ | 6,238 |  |  | 12 | % |  | 12 | % |  | $ | 13,676 |  |  | $ | 13,577 |  |  | 1 | % |  | 1 | %\nInternational | 8,018 |  |  | 8,355 |  |  | (4) | % |  | 2 | % |  | 15,846 |  |  | 16,917 |  |  | (6) | % |  | \u2014 | %\nTotal | $ | 15,035 |  |  | $ | 14,593 |  |  | 3 | % |  | 7 | % |  | $ | 29,522 |  |  | $ | 30,494 |  |  | (3) | % |  | \u2014 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nKeytruda | $ | 6,271 |  |  | $ | 5,252 |  |  | 19 | % |  | 21 | % |  | $ | 12,065 |  |  | $ | 10,061 |  |  | 20 | % |  | 23 | %\nAlliance Revenue - Lynparza(1) | 310 |  |  | 275 |  |  | 13 | % |  | 15 | % |  | 585 |  |  | 541 |  |  | 8 | % |  | 12 | %\nAlliance Revenue-Lenvima(1) | 242 |  |  | 231 |  |  | 5 | % |  | 6 | % |  | 474 |  |  | 459 |  |  | 3 | % |  | 5 | %\nWelireg | 50 |  |  | 27 |  |  | 89 | % |  | 89 | % |  | 92 |  |  | 45 |  |  | * |  | *\nAlliance Revenue-Reblozyl(2) | 47 |  |  | 33 |  |  | 41 | % |  | 41 | % |  | 90 |  |  | 86 |  |  | 4 | % |  | 4 | %  |  |  |  |  | \nDate | Approval\nJanuary 2023 | U.S. Food and Drug Administration (FDA) approval as a single agent for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a \u22654 cm), II, or IIIA NSCLC, based on the KEYNOTE-091 trial.\nMarch 2023 | FDA full approval for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. The conversion from an accelerated to a full (regular) approval is based on the KEYNOTE-158, KEYNOTE-164 and KEYNOTE-051 trials.\nApril 2023 | FDA accelerated approval in combination with enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy, based on the KEYNOTE-869 trial dose escalation cohort, Cohort A and Cohort K, which was conducted in collaboration with Seagen and Astellas.\nJune 2023 | Japan\u2019s Ministry of Health, Labor and Welfare (MHLW) approval for the treatment of patients with relapsed or refractory PMBCL, based on the KEYNOTE-170 and the KEYNOTE-A33 studies.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nGardasil/Gardasil9 | $ | 2,458 |  |  | $ | 1,674 |  |  | 47 | % |  | 53 | % |  | $ | 4,430 |  |  | $ | 3,133 |  |  | 41 | % |  | 48 | %\nProQuad | 222 |  |  | 214 |  |  | 4 | % |  | 4 | % |  | 412 |  |  | 376 |  |  | 10 | % |  | 10 | %\nM-M-RII | 104 |  |  | 103 |  |  | 2 | % |  | 2 | % |  | 207 |  |  | 206 |  |  | \u2014 | % |  | 1 | %\nVarivax | 255 |  |  | 261 |  |  | (2) | % |  | (2) | % |  | 491 |  |  | 465 |  |  | 5 | % |  | 6 | %\nRotaTeq | 131 |  |  | 173 |  |  | (25) | % |  | (24) | % |  | 428 |  |  | 389 |  |  | 10 | % |  | 13 | %\nVaxneuvance | 168 |  |  | 12 |  |  | * |  | * |  | 274 |  |  | 16 |  |  | * |  | *\nPneumovax 23 | 92 |  |  | 153 |  |  | (40) | % |  | (38) | % |  | 188 |  |  | 325 |  |  | (42) | % |  | (39) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nBridion | $ | 502 |  |  | $ | 426 |  |  | 18 | % |  | 19 | % |  | $ | 989 |  |  | $ | 821 |  |  | 21 | % |  | 23 | %\nPrevymis | 143 |  |  | 103 |  |  | 39 | % |  | 42 | % |  | 273 |  |  | 197 |  |  | 39 | % |  | 43 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nAlliance Revenue - Adempas/Verquvo(1) | $ | 68 |  |  | $ | 98 |  |  | (31) | % |  | (31) | % |  | $ | 167 |  |  | $ | 170 |  |  | (2) | % |  | (2) | %\nAdempas | 65 |  |  | 63 |  |  | 3 | % |  | 5 | % |  | 125 |  |  | 124 |  |  | \u2014 | % |  | 5 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nLagevrio | $ | 203 |  |  | $ | 1,177 |  |  | (83) | % |  | (82) | % |  | $ | 595 |  |  | $ | 4,424 |  |  | (87) | % |  | (85) | %\nIsentress/Isentress HD | 136 |  |  | 147 |  |  | (7) | % |  | (4) | % |  | 259 |  |  | 305 |  |  | (15) | % |  | (12) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nJanuvia/Janumet | $ | 864 |  |  | $ | 1,233 |  |  | (30) | % |  | (28) | % |  | $ | 1,744 |  |  | $ | 2,466 |  |  | (29) | % |  | (26) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nLivestock | $ | 807 |  |  | $ | 826 |  |  | (2) | % |  | 2 | % |  | $ | 1,656 |  |  | $ | 1,658 |  |  | \u2014 | % |  | 5 | %\nCompanion Animal | 649 |  |  | 641 |  |  | 1 | % |  | 2 | % |  | 1,291 |  |  | 1,291 |  |  | \u2014 | % |  | 2 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | Six Months EndedJune 30, |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  | 2023 |  | 2022 |  | % Change\nCost of sales | $ | 4,024 |  |  | $ | 4,216 |  |  | (5) | % |  | $ | 7,951 |  |  | $ | 9,596 |  |  | (17) | %\nSelling, general and administrative | 2,702 |  |  | 2,512 |  |  | 8 | % |  | 5,182 |  |  | 4,834 |  |  | 7 | %\nResearch and development | 13,321 |  |  | 2,798 |  |  | * |  | 17,597 |  |  | 5,374 |  |  | *\nRestructuring costs | 151 |  |  | 142 |  |  | 6 | % |  | 218 |  |  | 194 |  |  | 12 | %\nOther (income) expense, net | 172 |  |  | 438 |  |  | (61) | % |  | 259 |  |  | 1,148 |  |  | (77) | %\n | $ | 20,370 |  |  | $ | 10,106 |  |  | * |  | $ | 31,207 |  |  | $ | 21,146 |  |  | 48 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSegment Profits |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nPharmaceutical segment profits | $ | 9,854 |  |  | $ | 9,173 |  |  | $ | 18,993 |  |  | $ | 18,673 | \nAnimal Health segment profits | 467 |  |  | 571 |  |  | 1,032 |  |  | 1,156 | \nOther | (15,656) |  |  | (5,257) |  |  | (21,710) |  |  | (10,481) | \n(Loss) Income Before Taxes | $ | (5,335) |  |  | $ | 4,487 |  |  | $ | (1,685) |  |  | $ | 9,348 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions except per share amounts) | 2023 |  | 2022 |  | 2023 |  | 2022\n(Loss) income before taxes as reported under GAAP | $ | (5,335) |  |  | $ | 4,487 |  |  | $ | (1,685) |  |  | $ | 9,348 | \nIncrease (decrease) for excluded items: |  |  |  |  |  |  | \nAcquisition- and divestiture-related costs | 498 |  |  | 530 |  |  | 1,088 |  |  | 1,168 | \nRestructuring costs | 236 |  |  | 258 |  |  | 333 |  |  | 384 | \nLoss (income) from investments in equity securities, net | 194 |  |  | 234 |  |  | (235) |  |  | 918 | \nOther items: |  |  |  |  |  |  | \nCharge for Zetia antitrust litigation settlements | \u2014 |  |  | \u2014 |  |  | 573 |  |  | \u2014 | \nNon-GAAP (loss) income before taxes | (4,407) |  |  | 5,509 |  |  | 74 |  |  | 11,818 | \nIncome tax provision as reported under GAAP | 637 |  |  | 538 |  |  | 1,462 |  |  | 1,092 | \nEstimated tax benefit on excluded items(1) | 173 |  |  | 223 |  |  | 261 |  |  | 552 | \nNon-GAAP income tax provision | 810 |  |  | 761 |  |  | 1,723 |  |  | 1,644 | \nNon-GAAP net (loss) income | (5,217) |  |  | 4,748 |  |  | (1,649) |  |  | 10,174 | \nLess: Net income attributable to noncontrolling interests as reported under GAAP | 3 |  |  | 5 |  |  | 7 |  |  | 2 | \nNon-GAAP net (loss) income attributable to Merck\u00a0& Co., Inc. | $ | (5,220) |  |  | $ | 4,743 |  |  | $ | (1,656) |  |  | $ | 10,172 | \nEPS assuming dilution as reported under GAAP(2) | $ | (2.35) |  |  | $ | 1.55 |  |  | $ | (1.24) |  |  | $ | 3.25 | \nEPS difference | 0.29 |  |  | 0.32 |  |  | 0.59 |  |  | 0.76 | \nNon-GAAP EPS assuming dilution(2) | $ | (2.06) |  |  | $ | 1.87 |  |  | $ | (0.65) |  |  | $ | 4.01 |   |  |  |  |  |  |  |  | \nPhase 2\nCancerMK-0482(2)Non-Small-Cell LungMK-1308 (quavonlimab)(2)Non-Small-Cell LungMK-1308A (quavonlimab+pembrolizumab)ColorectalHepatocellularMelanomaSmall-Cell LungMK-2140 (zilovertamab vedotin)BladderBreastGastricHematological MalignanciesNon-Small-Cell LungOvarianPancreaticMK-2870(1)(3)Neoplasm MalignantMK-3475KeytrudaAdvanced Solid TumorsProstateMK-3543 (bomedemstat)Myeloproliferative DisordersMK-4280 (favezelimab)(2)Non-Small-Cell LungMK-4280A (favezelimab+pembrolizumab)BladderEsophagealMelanomaRenal CellSmall-Cell LungMK-4830(2)ColorectalEsophagealMelanomaNon-Small-Cell LungOvarianRenal CellSmall-Cell Lung | CancerMK-5684(1)ProstateMK-5890 (boserolimab)(2)Non-Small-Cell LungSmall-Cell LungMK-6482Welireg(3)BiliaryColorectalEndometrialEsophagealHepatocellularPancreaticRare cancersVon Hippel-Lindau Disease-Associated Tumors (EU)MK-7119 Tukysa(1)Advanced Solid TumorsBiliaryBladderCervicalEndometrialGastricNon-Small-Cell LungMK-7339 Lynparza(1)(3)Advanced Solid TumorsMK-7684A (vibostolimab+pembrolizumab)BiliaryBladderBreastCervicalColorectalEndometrialEsophagealGastricHead and NeckHematological MalignanciesHepatocellularOvarianProstate | CancerMK-7902 Lenvima(1)(2)BiliaryPancreaticProstateSmall-Cell LungDengue Fever Virus VaccineV181HIV-1 InfectionMK-8591B (islatravir+MK-8507)(4)MK-8591D (islatravir+lenacapavir)(1)(5)HypercholesterolemiaMK-0616Nonalcoholic Steatohepatitis (NASH)MK-6024 (efinopegdutide)Pulmonary Arterial HypertensionMK-5475Pulmonary Hypertension Due To Left Heart DiseaseMK-7962 (sotatercept)SchizophreniaMK-8189(6)ThrombosisMK-2060Treatment Resistant DepressionMK-1942Ulcerative ColitisMK-7240  |  |  |  |  |  |  |  | \nPhase 3 (Phase 3 entry date) | Under Review\nAntiviral COVID-19MK-4482Lagevrio(U.S.) (May 2021)(1)(7)CancerMK-1026 (nemtabrutinib)Hematological Malignancies (March 2023)MK-1308A (quavonlimab+pembrolizumab)Renal Cell (April 2021)MK-3475KeytrudaCutaneous Squamous Cell (August 2019) (EU)Hepatocellular (May 2016) (EU)Mesothelioma (May 2018)Ovarian (December 2018)Small-Cell Lung (May 2017)MK-3475A (pembrolizumab+hyaluronidase subcutaneous)Non-Small-Cell Lung (February 2023)MK-4280A (favezelimab+pembrolizumab)Colorectal (November 2021)Hematological Malignancies (October 2022)MK-6482Welireg(3)Renal Cell (February 2020)MK-7119 Tukysa(1)Breast (October 2019)Colorectal (August 2022)MK-7339 Lynparza(2)Non-Small-Cell Lung (June 2019)Small-Cell Lung (December 2020)MK-7684A (vibostolimab+pembrolizumab)Melanoma (January 2023)Non-Small-Cell Lung (April 2021)Small-Cell Lung (March 2022)MK-7902 Lenvima(1)(2)Esophageal (July 2021)Gastric (December 2020)Head and Neck (February 2020)Non-Small-Cell Lung (March 2019)V940(1)(2)Melanoma (July 2023)HIV-1 InfectionMK-8591A (doravirine+islatravir) (February 2020)(5)Pneumococcal Vaccine AdultV116 (July 2022)Pulmonary Arterial HypertensionMK-7962 (sotatercept) (January 2021)Respiratory Syncytial VirusMK-1654 (clesrovimab) (November 2021) | New Molecular EntitiesCoughMK-7264 (gefapixant) (U.S.)(8)(EU) | Certain Supplemental FilingsCancerMK-3475Keytruda\u2022    Second-Line Hepatocellular Carcinoma(KEYNOTE-394) (U.S.)\u2022    Locally Advanced or Metastatic Merkel Cell Carcinoma(KEYNOTE-913) (U.S.)\u2022    First-Line Advanced or Unresectable Biliary Tract Cancer(KEYNOTE-966) (U.S.) (EU) (JPN)\u2022    First-Line HER2 Negative Locally Advanced Unresectable or Metastatic Gastric Cancer(KEYNOTE-859) (U.S.) (EU) (JPN)\u2022    Resectable Stage II, IIIA or IIIB NSCLC(KEYNOTE-671) (U.S.) (EU)\u2022    Adjuvant Non-Small-Cell Lung Cancer(KEYNOTE-091) (EU)\u2022    Metastatic HER2+ Gastric Cancer(KEYNOTE-811) (EU)MK-7339 Lynparza(1)\u2022    First-Line Metastatic Prostate Cancer(PROpel) (JPN)\nFootnotes:(1)Being developed in a collaboration.(2)Being developed in combination withKeytruda.(3)Being developed as monotherapy and/or in combination withKeytruda.(4)On FDA clinical hold.(5)On FDA partial clinical hold for higher doses than those used in current clinical trials.(6)Phase 2b development costs are being co-funded.(7)Available in the U.S. under Emergency Use Authorization.(8)In July 2023, the FDA accepted Merck\u2019s resubmission of the NDA for gefapixant following the Company\u2019s response to the CRL received in January 2022.  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | June 30, 2023 |  | December 31, 2022\nCash and investments | $ | 7,592 |  |  | $ | 14,207 | \nWorking capital | 6,583 |  |  | 11,483 | \nTotal debt to total liabilities and equity | 35.3 | % |  | 28.1 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | ($\u00a0in\u00a0millions)\nPeriod | Total\u00a0Numberof SharesPurchased(1) |  | Average\u00a0PricePaid PerShare |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0SharesThat May Yet Be PurchasedUnder the Plans or Programs(1)\nApril 1 - April 30 | 376,898 |  |  | $110.51 |  | 376,898 |  |  | $4,856\nMay 1 - May 31 | 907,404 |  |  | $114.76 |  | 907,404 |  |  | $4,752\nJune 1 - June 30 | 1,734,532 |  |  | $110.72 |  | 1,734,532 |  |  | $4,560\nTotal | 3,018,834 |  |  | $111.91 |  | 3,018,834 |  |  |   |  |  |  |  |  |  |  | \nNumber |  | Description\n | \n3.1 | \u2014 | Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) \u2013 Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on November\u00a04, 2009 (No. 1-6571)\n | \n3.2 | \u2014 | By-Laws of Merck & Co., Inc. (effective March 22, 2022) \u2013 Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)\n |  | \n31.1 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Executive Officer\n | \n31.2 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Financial Officer\n | \n32.1 |  | \u2014 | Section 1350 Certification of Chief Executive Officer\n | \n32.2 |  | \u2014 | Section 1350 Certification of Chief Financial Officer\n | \n101.INS | \u2014 | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.\n |  | \n101.SCH | \u2014 | XBRL Taxonomy Extension Schema Document.\n |  | \n101.CAL | \u2014 | XBRL Taxonomy Extension Calculation Linkbase Document.\n |  | \n101.DEF | \u2014 | XBRL Taxonomy Extension Definition Linkbase Document.\n |  | \n101.LAB | \u2014 | XBRL Taxonomy Extension Label Linkbase Document.\n |  | \n101.PRE | \u2014 | XBRL Taxonomy Extension Presentation Linkbase Document.\n |  | \n104 |  | \u2014 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).  |  |  |  |  |  |  |  | \n |  | MERCK & CO., INC.\n |  | \nDate:  August 7, 2023 |  | /s/ Jennifer Zachary\n |  | JENNIFER ZACHARY\n |  | Executive Vice President and General Counsel\n |  | \nDate:  August 7, 2023 |  | /s/ Rita A. Karachun\n |  | RITA A. KARACHUN\n |  | Senior Vice President Finance - Global Controller"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Merck, in 2023 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  | \n  |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n |   |  |  |  |  |  |  |  | \nNew Jersey | 22-1918501\n(State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.)\n | \n126 East Lincoln Avenue\nRahway | New Jersey | 07065\n(Address of principal executive offices) (zip code)  |  |  |  |  |  |  |  | \n | Not Applicable | \n(Former name, former address and former fiscal year, if changed since last report.)  |  |  |  |  |  |  |  | \nSecurities Registered pursuant to Section\u00a012(b) of the Act:\nTitle of each class | Trading Symbol(s) | Name of each exchange on which registered\nCommon Stock ($0.50\u00a0par value) | MRK | New York Stock Exchange\n0.500% Notes due 2024 | MRK 24 | New York Stock Exchange\n1.875% Notes due 2026 | MRK/26 | New York Stock Exchange\n2.500% Notes due 2034 | MRK/34 | New York Stock Exchange\n1.375% Notes due 2036 | MRK 36A | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 | Accelerated filer | \u2610\n |  |  | \nNon-accelerated filer | \u2610 | Smaller reporting company | \u2610\n |  |  | \n |  | Emerging growth company | \u2610  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page No.\nPART I | FINANCIAL INFORMATION | 3\n |  | \nItem 1. | Financial Statements | 3\n | Condensed Consolidated Statement of Income | 3\n | Condensed Consolidated Statement of Comprehensive Income | 3\n | Condensed Consolidated Balance Sheet | 4\n | Condensed Consolidated Statement of Cash Flows | 5\n | Notes to Condensed Consolidated Financial Statements | 6\n |  | \nItem 2. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 31\n |  | \nItem 3. | Quantitative and Qualitative Disclosures about Market Risk | 45\n |  | \nItem 4. | Controls and Procedures | 45\n |  | \n | Cautionary Factors That May Affect Future Results | 45\n |  | \nPART II | OTHER INFORMATION | 46\n |  | \nItem 1. | Legal Proceedings | 46\n |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 46\n |  |  |  | \nItem 5. | Other Information | 46\n |  |  |  | \nItem 6. | Exhibits | 47\n |  | \n | Signatures |  |  | 48  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nSales | $ | 15,962 |  |  | $ | 14,959 |  |  | $ | 45,485 |  |  | $ | 45,453 | \nCosts, Expenses and Other |  |  |  |  |  |  | \nCost of sales | 4,264 |  |  | 3,934 |  |  | 12,214 |  |  | 13,530 | \nSelling, general and administrative | 2,519 |  |  | 2,520 |  |  | 7,700 |  |  | 7,355 | \nResearch and development | 3,307 |  |  | 4,399 |  |  | 20,904 |  |  | 9,773 | \nRestructuring costs | 126 |  |  | 94 |  |  | 344 |  |  | 288 | \nOther (income) expense, net | 126 |  |  | 429 |  |  | 388 |  |  | 1,576 | \n | 10,342 |  |  | 11,376 |  |  | 41,550 |  |  | 32,522 | \nIncome Before Taxes | 5,620 |  |  | 3,583 |  |  | 3,935 |  |  | 12,931 | \nTaxes on Income | 870 |  |  | 330 |  |  | 2,332 |  |  | 1,423 | \nNet Income | 4,750 |  |  | 3,253 |  |  | 1,603 |  |  | 11,508 | \nLess: Net Income Attributable to Noncontrolling Interests | 5 |  |  | 5 |  |  | 12 |  |  | 6 | \nNet Income Attributable to Merck & Co., Inc. | $ | 4,745 |  |  | $ | 3,248 |  |  | $ | 1,591 |  |  | $ | 11,502 | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | $ | 1.87 |  |  | $ | 1.28 |  |  | $ | 0.63 |  |  | $ | 4.55 | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | $ | 1.86 |  |  | $ | 1.28 |  |  | $ | 0.62 |  |  | $ | 4.53 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,745 |  |  | $ | 3,248 |  |  | $ | 1,591 |  |  | $ | 11,502 | \nOther Comprehensive Loss Net of Taxes: |  |  |  |  |  |  | \nNet unrealized gain on derivatives, net of reclassifications | 159 |  |  | 338 |  |  | 171 |  |  | 584 | \nBenefit plan net (loss) gain and prior service (cost) credit, net of amortization | \u2014 |  |  | (186) |  |  | (75) |  |  | 92 | \nCumulative translation adjustment | (175) |  |  | (568) |  |  | (244) |  |  | (990) | \n | (16) |  |  | (416) |  |  | (148) |  |  | (314) | \nComprehensive Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,729 |  |  | $ | 2,832 |  |  | $ | 1,443 |  |  | $ | 11,188 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\nAssets |  |  | \nCurrent Assets |  |  | \nCash and cash equivalents | $ | 8,605 |  |  | $ | 12,694 | \nShort-term investments | 168 |  |  | 498 | \nAccounts receivable (net of allowance for doubtful accounts of $85in 2023and $72in 2022) | 10,394 |  |  | 9,450 | \nInventories (excludes inventories of $3,151in 2023 and $2,938in 2022classified in Other assets - see Note\u00a07) | 6,131 |  |  | 5,911 | \nOther current assets | 6,656 |  |  | 7,169 | \nTotal current assets | 31,954 |  |  | 35,722 | \nInvestments | 1,306 |  |  | 1,015 | \nProperty, Plant and Equipment, at cost, net of accumulated depreciation of $18,446in 2023 and $17,985in 2022 | 22,526 |  |  | 21,422 | \nGoodwill | 21,183 |  |  | 21,204 | \nOther Intangibles, Net | 19,199 |  |  | 20,269 | \nOther Assets | 10,559 |  |  | 9,528 | \n | $ | 106,727 |  |  | $ | 109,160 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nLoans payable and current portion of long-term debt | $ | 887 |  |  | $ | 1,946 | \nTrade accounts payable | 3,509 |  |  | 4,264 | \nAccrued and other current liabilities | 14,840 |  |  | 14,159 | \nIncome taxes payable | 1,981 |  |  | 1,986 | \nDividends payable | 1,877 |  |  | 1,884 | \nTotal current liabilities | 23,094 |  |  | 24,239 | \nLong-Term Debt | 33,972 |  |  | 28,745 | \nDeferred Income Taxes | 1,018 |  |  | 1,795 | \nOther Noncurrent Liabilities | 7,343 |  |  | 8,323 | \nMerck\u00a0& Co., Inc. Stockholders\u2019 Equity |  |  | \nCommon stock, $0.50par valueAuthorized -6,500,000,000sharesIssued -3,577,103,522shares in 2023 and 2022 | 1,788 |  |  | 1,788 | \nOther paid-in capital | 44,358 |  |  | 44,379 | \nRetained earnings | 57,082 |  |  | 61,081 | \nAccumulated other comprehensive loss | (4,916) |  |  | (4,768) | \n | 98,312 |  |  | 102,480 | \nLess treasury stock, at cost:1,041,809,729shares in 2023 and1,039,269,638shares in 2022 | 57,066 |  |  | 56,489 | \nTotal Merck\u00a0& Co., Inc. stockholders\u2019 equity | 41,246 |  |  | 45,991 | \nNoncontrolling Interests | 54 |  |  | 67 | \nTotal equity | 41,300 |  |  | 46,058 | \n | $ | 106,727 |  |  | $ | 109,160 |   |  |  |  |  |  |  |  |  |  |  | \n | Nine Months EndedSeptember 30,\n | 2023 |  | 2022\nCash Flows from Operating Activities |  |  | \nNet income | $ | 1,603 |  |  | $ | 11,508 | \nAdjustments to reconcile net income to net cash provided by operating activities: |  |  | \nAmortization | 1,582 |  |  | 1,623 | \nDepreciation | 1,326 |  |  | 1,394 | \nIntangible asset impairment charges | 13 |  |  | 910 | \n(Income) loss from investments in equity securities, net | (240) |  |  | 1,361 | \nCharge for the acquisition of Prometheus Biosciences, Inc. | 10,217 |  |  | \u2014 | \nCharge for the acquisition of Imago BioSciences, Inc. | 1,192 |  |  | \u2014 | \nDeferred income taxes | (968) |  |  | (1,261) | \nShare-based compensation | 478 |  |  | 396 | \nOther | (94) |  |  | 1,169 | \nNet changes in assets and liabilities | (2,349) |  |  | (2,435) | \nNet Cash Provided by Operating Activities | 12,760 |  |  | 14,665 | \nCash Flows from Investing Activities |  |  | \nCapital expenditures | (2,874) |  |  | (3,239) | \nPurchases of securities and other investments | (704) |  |  | (710) | \nProceeds from sales of securities and other investments | 1,489 |  |  | 709 | \nAcquisition of Prometheus Biosciences, Inc., net of cash acquired | (10,705) |  |  | \u2014 | \nAcquisition of Imago BioSciences, Inc., net of cash acquired | (1,327) |  |  | \u2014 | \nOther acquisitions, net of cash acquired | \u2014 |  |  | (121) | \nOther | (15) |  |  | 149 | \nNet Cash Used in Investing Activities | (14,136) |  |  | (3,212) | \nCash Flows from Financing Activities |  |  | \n |  |  | \nProceeds from issuance of debt | 5,939 |  |  | \u2014 | \nPayments on debt | (1,752) |  |  | (2,250) | \nPurchases of treasury stock | (953) |  |  | \u2014 | \nDividends paid to stockholders | (5,593) |  |  | (5,262) | \nProceeds from exercise of stock options | 119 |  |  | 119 | \nOther | (325) |  |  | (172) | \nNet Cash Used in Financing Activities | (2,565) |  |  | (7,565) | \nEffect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | (163) |  |  | (776) | \nNet (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash | (4,104) |  |  | 3,112 | \nCash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of$79and $71at January 1, 2023 and 2022, respectively, included inOther current assets) | 12,773 |  |  | 8,167 | \nCash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $64and $134at September\u00a030, 2023 and 2022, respectively, included inOther current assets) | $ | 8,669 |  |  | $ | 11,279 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nAlliance revenue - Lynparza | $ | 299 |  |  | $ | 284 |  |  | $ | 884 |  |  | $ | 825 | \nAlliance revenue - Koselugo | 26 |  |  | 10 |  |  | 74 |  |  | 43 | \nTotal alliance revenue | $ | 325 |  |  | $ | 294 |  |  | $ | 958 |  |  | $ | 868 | \n |  |  |  |  |  |  | \nCost of sales(1) | 82 |  |  | 64 |  |  | 230 |  |  | 425 | \nSelling, general and administrative | 44 |  |  | 45 |  |  | 143 |  |  | 135 | \nResearch and development | 23 |  |  | 28 |  |  | 65 |  |  | 79 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | September 30, 2023 |  | December 31, 2022\nReceivables from AstraZeneca included inOther current assets |  |  |  |  | $ | 337 |  |  | $ | 303 | \nPayables to AstraZeneca included inAccrued and other current liabilities(2) |  |  |  |  | 257 |  |  | 123 | \nPayables to AstraZeneca included inOther Noncurrent Liabilities(2) |  |  |  |  | 600 |  |  | 600 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nAlliance revenue - Lenvima | $ | 260 |  |  | $ | 202 |  |  | $ | 734 |  |  | $ | 660 | \n |  |  |  |  |  |  | \nCost of sales(1) | 137 |  |  | 53 |  |  | 320 |  |  | 159 | \nSelling, general and administrative | 46 |  |  | 42 |  |  | 145 |  |  | 115 | \nResearch and development | 5 |  |  | 24 |  |  | 61 |  |  | 128 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | September 30, 2023 |  | December 31, 2022\nReceivables from Eisai included inOther current assets |  |  |  |  | $ | 260 |  |  | $ | 214 | \nPayables to Eisai included inAccrued and other current liabilities(2) |  |  |  |  | 125 |  |  | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nAlliance revenue - Adempas/Verquvo | $ | 92 |  |  | $ | 88 |  |  | $ | 259 |  |  | $ | 258 | \nNet sales of Adempas recorded by Merck | 65 |  |  | 57 |  |  | 189 |  |  | 181 | \nNet sales of Verquvo recorded by Merck | 8 |  |  | 6 |  |  | 24 |  |  | 15 | \nTotal sales | $ | 165 |  |  | $ | 151 |  |  | $ | 472 |  |  | $ | 454 | \n |  |  |  |  |  |  | \nCost of sales(1) | 53 |  |  | 55 |  |  | 165 |  |  | 158 | \nSelling, general and administrative | 33 |  |  | 42 |  |  | 100 |  |  | 107 | \nResearch and development | 26 |  |  | 18 |  |  | 76 |  |  | 52 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | September 30, 2023 |  | December 31, 2022\nReceivables from Bayer included inOther current assets |  |  |  |  | $ | 157 |  |  | $ | 143 | \nPayables to Bayer included inAccrued and other current liabilities |  |  |  |  | 82 |  |  | 80 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nNet sales ofLagevriorecorded by Merck | $ | 640 |  |  | $ | 436 |  |  | $ | 1,236 |  |  | $ | 4,859 | \n |  |  |  |  |  |  | \nCost of sales(1)(2) | 348 |  |  | 244 |  |  | 762 |  |  | 2,586 | \nSelling, general and administrative(2) | 21 |  |  | 48 |  |  | 72 |  |  | 117 | \nResearch and development(2) | 8 |  |  | 18 |  |  | 33 |  |  | 74 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | September 30, 2023 |  | December 31, 2022\nPayables to Ridgeback included inAccrued and other current liabilities(3) |  |  |  |  | $ | 242 |  |  | $ | 348 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, 2023 |  | Nine Months Ended September 30, 2023\n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nCost of sales | $ | \u2014 |  |  | $ | 31 |  |  | $ | 2 |  |  | $ | 33 |  |  | $ | \u2014 |  |  | $ | 74 |  |  | $ | 20 |  |  | $ | 94 | \nSelling, general and administrative | \u2014 |  |  | 5 |  |  | 35 |  |  | 40 |  |  | \u2014 |  |  | 5 |  |  | 88 |  |  | 93 | \nResearch and development | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1 |  |  | 1 | \nRestructuring costs | 95 |  |  | \u2014 |  |  | 31 |  |  | 126 |  |  | 246 |  |  | \u2014 |  |  | 98 |  |  | 344 | \n | $ | 95 |  |  | $ | 36 |  |  | $ | 68 |  |  | $ | 199 |  |  | $ | 246 |  |  | $ | 79 |  |  | $ | 207 |  |  | $ | 532 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, 2022 |  | Nine Months Ended September 30, 2022\n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nCost of sales | $ | \u2014 |  |  | $ | 16 |  |  | $ | 38 |  |  | $ | 54 |  |  | $ | \u2014 |  |  | $ | 51 |  |  | $ | 116 |  |  | $ | 167 | \nSelling, general and administrative | \u2014 |  |  | 5 |  |  | 21 |  |  | 26 |  |  | \u2014 |  |  | 17 |  |  | 57 |  |  | 74 | \nResearch and development | \u2014 |  |  | \u2014 |  |  | 1 |  |  | 1 |  |  | \u2014 |  |  | 29 |  |  | 1 |  |  | 30 | \nRestructuring costs | 65 |  |  | \u2014 |  |  | 29 |  |  | 94 |  |  | 197 |  |  | \u2014 |  |  | 91 |  |  | 288 | \n | $ | 65 |  |  | $ | 21 |  |  | $ | 89 |  |  | $ | 175 |  |  | $ | 197 |  |  | $ | 97 |  |  | $ | 265 |  |  | $ | 559 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nRestructuring reserves January\u00a01, 2023 | $ | 479 |  |  | $ | \u2014 |  |  | $ | 34 |  |  | $ | 513 | \nExpenses | 246 |  |  | 79 |  |  | 207 |  |  | 532 | \n(Payments) receipts, net | (191) |  |  | \u2014 |  |  | (103) |  |  | (294) | \nNon-cash activity | \u2014 |  |  | (79) |  |  | (105) |  |  | (184) | \nRestructuring reserves September\u00a030, 2023(1) | $ | 534 |  |  | $ | \u2014 |  |  | $ | 33 |  |  | $ | 567 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income(1) |  | Amount of Pretax (Gain) Loss Recognized inOther (income) expense, netfor Amounts Excluded from Effectiveness Testing\n | Three Months Ended September 30, |  | Nine Months Ended September 30, |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022\nNet Investment Hedging Relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | $ | (1) |  |  | $ | (1) |  |  | $ | \u2014 |  |  | $ | (47) |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 1 |  |  | $ | (2) | \nEuro-denominated notes | (100) |  |  | (250) |  |  | (26) |  |  | (431) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023\n($ in millions) | Par Value of Debt |  | Number of Interest Rate Swaps Held |  | Total Swap Notional Amount\n4.50% notes due 2033 | $ | 1,500 |  |  | 3 |  |  | $ | 750 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Carrying Amount of Hedged Liabilities |  | Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount\n($ in millions) | September 30, 2023 |  | December 31, 2022 |  | September 30, 2023 |  | December 31, 2022\nBalance Sheet Line Item in which Hedged Item is Included |  |  |  |  |  |  | \nLong-Term Debt | $ | 743 |  |  | $ | \u2014 |  |  | $ | (7) |  |  | $ | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30, 2023 |  | December 31, 2022\n |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional\n($ in millions) |  | Asset |  | Liability |  | Asset |  | Liability | \nDerivatives Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts | Other Noncurrent Liabilities | $ | \u2014 |  |  | $ | 8 |  |  | $ | 750 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nForeign exchange contracts | Other current assets | 321 |  |  | \u2014 |  |  | 8,059 |  |  | 220 |  |  | \u2014 |  |  | 4,824 | \nForeign exchange contracts | Other Assets | 51 |  |  | \u2014 |  |  | 1,746 |  |  | 27 |  |  | \u2014 |  |  | 1,609 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 4 |  |  | 680 |  |  | \u2014 |  |  | 101 |  |  | 2,691 | \nForeign exchange contracts | Other Noncurrent Liabilities | \u2014 |  |  | 1 |  |  | 178 |  |  | \u2014 |  |  | 1 |  |  | 91 | \n |  | $ | 372 |  |  | $ | 13 |  |  | $ | 11,413 |  |  | $ | 247 |  |  | $ | 102 |  |  | $ | 9,215 | \nDerivatives Not Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Other current assets | $ | 229 |  |  | $ | \u2014 |  |  | $ | 8,485 |  |  | $ | 186 |  |  | $ | \u2014 |  |  | $ | 8,540 | \n |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 163 |  |  | 9,910 |  |  | \u2014 |  |  | 307 |  |  | 10,926 | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  | $ | 229 |  |  | $ | 163 |  |  | $ | 18,395 |  |  | $ | 186 |  |  | $ | 307 |  |  | $ | 19,466 | \n |  | $ | 601 |  |  | $ | 176 |  |  | $ | 29,808 |  |  | $ | 433 |  |  | $ | 409 |  |  | $ | 28,681 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\n($ in millions) | Asset |  | Liability |  | Asset |  | Liability\nGross amounts recognized in the condensed consolidated balance sheet | $ | 601 |  |  | $ | 176 |  |  | $ | 433 |  |  | $ | 409 | \nGross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet | (138) |  |  | (138) |  |  | (220) |  |  | (220) | \nCash collateral received/posted | (143) |  |  | \u2014 |  |  | (66) |  |  | (19) | \nNet amounts | $ | 320 |  |  | $ | 38 |  |  | $ | 147 |  |  | $ | 170 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022\nFinancial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are Recorded | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss) |  | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss)\n | $ | 15,962 |  |  | $ | 14,959 |  |  | $ | 126 |  |  | $ | 429 |  |  | $ | (16) |  |  | $ | (416) |  |  | $ | 45,485 |  |  | $ | 45,453 |  |  | $ | 388 |  |  | $ | 1,576 |  |  | $ | (148) |  |  | $ | (314) | \n(Gain) loss on fair value hedging relationships: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHedged items | \u2014 |  |  | \u2014 |  |  | (7) |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (7) |  |  | (13) |  |  | \u2014 |  |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  |  | \u2014 |  |  | 8 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 8 |  |  | 4 |  |  | \u2014 |  |  | \u2014 | \nImpact of cash flow hedging relationships: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 247 |  |  | 682 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 375 |  |  | 1,233 | \nIncrease inSalesas a result ofAOCLreclassifications | 45 |  |  | 253 |  |  | \u2014 |  |  | \u2014 |  |  | (45) |  |  | (253) |  |  | 170 |  |  | 491 |  |  | \u2014 |  |  | \u2014 |  |  | (170) |  |  | (491) | \nInterest rate contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOther (income) expense, neton derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (2) |  |  | \u2014 |  |  | \u2014 | \nAmount of (loss) gain recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 13 |  |  | (2) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Amount of Derivative Pretax (Gain) Loss Recognized in Income\n |  |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n($ in millions) |  |  | 2023 |  | 2022 |  | 2023 |  | 2022\nDerivatives Not Designated as Hedging Instruments | Income Statement Caption |  |  |  |  |  |  |  | \nForeign exchange contracts(1) | Other (income) expense, net |  | $ | 60 |  |  | $ | (41) |  |  | $ | 32 |  |  | $ | (77) | \nForeign exchange contracts(2) | Sales |  | \u2014 |  |  | (4) |  |  | (3) |  |  | (42) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\n | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue |  | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue\n($ in millions) | Gains |  | Losses |  | Gains |  | Losses | \nCommercial paper | $ | 168 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 168 |  |  | $ | 498 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 498 | \nU.S. government and agency securities | 67 |  |  | \u2014 |  |  | \u2014 |  |  | 67 |  |  | 68 |  |  | \u2014 |  |  | \u2014 |  |  | 68 | \nCorporate notes and bonds | 12 |  |  | \u2014 |  |  | \u2014 |  |  | 12 |  |  | 3 |  |  | \u2014 |  |  | \u2014 |  |  | 3 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal debt securities | $ | 247 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 247 |  |  | $ | 569 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 569 | \nPublicly traded equity securities(1) |  |  |  |  |  |  | 1,746 |  |  |  |  |  |  |  |  | 1,284 | \nTotal debt and publicly traded equity securities |  |  |  |  |  |  | $ | 1,993 |  |  |  |  |  |  |  |  | $ | 1,853 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair Value Measurements Using |  | Fair Value Measurements Using\n | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |  | Total\n($ in millions) | September 30, 2023 |  | December 31, 2022\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCommercial paper | $ | \u2014 |  |  | $ | 168 |  |  | $ | \u2014 |  |  | $ | 168 |  |  | $ | \u2014 |  |  | $ | 498 |  |  | $ | \u2014 |  |  | $ | 498 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPublicly traded equity securities | 1,306 |  |  | \u2014 |  |  | \u2014 |  |  | 1,306 |  |  | 1,015 |  |  | \u2014 |  |  | \u2014 |  |  | 1,015 | \n | 1,306 |  |  | 168 |  |  | \u2014 |  |  | 1,474 |  |  | 1,015 |  |  | 498 |  |  | \u2014 |  |  | 1,513 | \nOther assets(1) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | 67 |  |  | \u2014 |  |  | \u2014 |  |  | 67 |  |  | 68 |  |  | \u2014 |  |  | \u2014 |  |  | 68 | \nCorporate notes and bonds | 12 |  |  | \u2014 |  |  | \u2014 |  |  | 12 |  |  | 3 |  |  | \u2014 |  |  | \u2014 |  |  | 3 | \nPublicly traded equity securities(2) | 440 |  |  | \u2014 |  |  | \u2014 |  |  | 440 |  |  | 269 |  |  | \u2014 |  |  | \u2014 |  |  | 269 | \n | 519 |  |  | \u2014 |  |  | \u2014 |  |  | 519 |  |  | 340 |  |  | \u2014 |  |  | \u2014 |  |  | 340 | \nDerivative assets(3) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 431 |  |  | \u2014 |  |  | 431 |  |  | \u2014 |  |  | 218 |  |  | \u2014 |  |  | 218 | \nPurchased currency options | \u2014 |  |  | 170 |  |  | \u2014 |  |  | 170 |  |  | \u2014 |  |  | 215 |  |  | \u2014 |  |  | 215 | \n | \u2014 |  |  | 601 |  |  | \u2014 |  |  | 601 |  |  | \u2014 |  |  | 433 |  |  | \u2014 |  |  | 433 | \nTotal assets | $ | 1,825 |  |  | $ | 769 |  |  | $ | \u2014 |  |  | $ | 2,594 |  |  | $ | 1,355 |  |  | $ | 931 |  |  | $ | \u2014 |  |  | $ | 2,286 | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nContingent consideration | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 345 |  |  | $ | 345 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 456 |  |  | $ | 456 | \nDerivative liabilities(3) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 160 |  |  | \u2014 |  |  | 160 |  |  | \u2014 |  |  | 402 |  |  | \u2014 |  |  | 402 | \nWritten currency options | \u2014 |  |  | 8 |  |  | \u2014 |  |  | 8 |  |  | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 | \nInterest rate swaps | \u2014 |  |  | 8 |  |  | \u2014 |  |  | 8 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \n | \u2014 |  |  | 176 |  |  | \u2014 |  |  | 176 |  |  | \u2014 |  |  | 409 |  |  | \u2014 |  |  | 409 | \nTotal liabilities | $ | \u2014 |  |  | $ | 176 |  |  | $ | 345 |  |  | $ | 521 |  |  | $ | \u2014 |  |  | $ | 409 |  |  | $ | 456 |  |  | $ | 865 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022\nFair value January 1 | $ | 456 |  |  | $ | 777 | \nChanges in estimated fair value(1) | 6 |  |  | (156) | \nPayments | (117) |  |  | (119) | \nOther | \u2014 |  |  | (3) | \nFair value September 30(2) | $ | 345 |  |  | $ | 499 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | September 30, 2023 |  | December 31, 2022\nFinished goods | $ | 1,840 |  |  | $ | 1,841 | \nRaw materials and work in process | 7,630 |  |  | 7,063 | \nSupplies | 281 |  |  | 238 | \nTotal | 9,751 |  |  | 9,142 | \nDecrease to LIFO cost | (469) |  |  | (293) | \n | $ | 9,282 |  |  | $ | 8,849 | \nRecognized as: |  |  | \nInventories | $ | 6,131 |  |  | $ | 5,911 | \nOther Assets | 3,151 |  |  | 2,938 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at July 1, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,115 |  | $ | 58,437 |  | $ | (4,327) |  | 1,044 |  | $ | (56,770) |  | $ | 75 |  | $ | 43,318 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 3,248 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3,248 | \nOther comprehensive loss, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (416) |  | \u2014 |  | \u2014 |  | \u2014 |  | (416) | \nCash dividends declared on common stock ($0.69per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,757) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,757) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 128 |  | \u2014 |  | \u2014 |  | \u2014 |  | 12 |  | \u2014 |  | 140 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 5 |  | 5 | \nDistributions attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (14) |  | (14) | \nBalance at September 30, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,243 |  | $ | 59,928 |  | $ | (4,743) |  | 1,044 |  | $ | (56,758) |  | $ | 66 |  | $ | 44,524 | \nBalance at July 1, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,219 |  | $ | 54,198 |  | $ | (4,900) |  | 1,038 |  | $ | (56,612) |  | $ | 49 |  | $ | 38,742 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 4,745 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 4,745 | \nOther comprehensive loss, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (16) |  | \u2014 |  | \u2014 |  | \u2014 |  | (16) | \nCash dividends declared on common stock ($0.73per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,861) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,861) | \nTreasury stock shares purchased | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 4 |  | (466) |  | \u2014 |  | (466) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 139 |  | \u2014 |  | \u2014 |  | \u2014 |  | 12 |  | \u2014 |  | 151 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 5 |  | 5 | \n |  |  |  |  |  |  |  |  | \nBalance at September 30, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,358 |  | $ | 57,082 |  | $ | (4,916) |  | 1,042 |  | $ | (57,066) |  | $ | 54 |  | $ | 41,300 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at January\u00a01, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,238 |  | $ | 53,696 |  | $ | (4,429) |  | 1,049 |  | $ | (57,109) |  | $ | 73 |  | $ | 38,257 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 11,502 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 11,502 | \nOther comprehensive loss, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (314) |  | \u2014 |  | \u2014 |  | \u2014 |  | (314) | \nCash dividends declared on common stock ($2.07per share) | \u2014 |  | \u2014 |  | \u2014 |  | (5,270) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (5,270) | \n |  |  |  |  |  |  |  |  | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 5 |  | \u2014 |  | \u2014 |  | (5) |  | 351 |  | \u2014 |  | 356 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 6 |  | 6 | \nDistributions attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (13) |  | (13) | \nBalance at September 30, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,243 |  | $ | 59,928 |  | $ | (4,743) |  | 1,044 |  | $ | (56,758) |  | $ | 66 |  | $ | 44,524 | \nBalance at January\u00a01, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,379 |  | $ | 61,081 |  | $ | (4,768) |  | 1,039 |  | $ | (56,489) |  | $ | 67 |  | $ | 46,058 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 1,591 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1,591 | \nOther comprehensive loss, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (148) |  | \u2014 |  | \u2014 |  | \u2014 |  | (148) | \nCash dividends declared on common stock ($2.19per share) | \u2014 |  | \u2014 |  | \u2014 |  | (5,590) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (5,590) | \nTreasury stock shares purchased | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 9 |  | (953) |  | \u2014 |  | (953) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (21) |  | \u2014 |  | \u2014 |  | (6) |  | 376 |  | \u2014 |  | 355 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 12 |  | 12 | \nDistributions attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (25) |  | (25) | \nBalance at September 30, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,358 |  | $ | 57,082 |  | $ | (4,916) |  | 1,042 |  | $ | (57,066) |  | $ | 54 |  | $ | 41,300 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\n($ in millions) | U.S. |  | International |  | U.S. |  | International |  | U.S. |  | International |  | U.S. |  | International\nService cost | $ | 88 |  |  | $ | 48 |  |  | $ | 91 |  |  | $ | 66 |  |  | $ | 239 |  |  | $ | 148 |  |  | $ | 289 |  |  | $ | 213 | \nInterest cost | 130 |  |  | 76 |  |  | 123 |  |  | 35 |  |  | 396 |  |  | 225 |  |  | 330 |  |  | 110 | \nExpected return on plan assets | (182) |  |  | (131) |  |  | (182) |  |  | (93) |  |  | (553) |  |  | (390) |  |  | (576) |  |  | (292) | \nAmortization of unrecognized prior service (credit) cost | \u2014 |  |  | (6) |  |  | (8) |  |  | (3) |  |  | (1) |  |  | 5 |  |  | (24) |  |  | (10) | \nNet (gain) loss amortization | \u2014 |  |  | (1) |  |  | 10 |  |  | 24 |  |  | \u2014 |  |  | (2) |  |  | 122 |  |  | 73 | \nTermination benefits | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 2 |  |  | 1 | \nCurtailments | \u2014 |  |  | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 5 |  |  | \u2014 |  |  | 11 |  |  | \u2014 | \nSettlements | \u2014 |  |  | \u2014 |  |  | 79 |  |  | \u2014 |  |  | 26 |  |  | \u2014 |  |  | 180 |  |  | \u2014 | \n | $ | 37 |  |  | $ | (14) |  |  | $ | 117 |  |  | $ | 29 |  |  | $ | 114 |  |  | $ | (14) |  |  | $ | 334 |  |  | $ | 95 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nService cost | $ | 8 |  |  | $ | 11 |  |  | $ | 24 |  |  | $ | 36 | \nInterest cost | 16 |  |  | 11 |  |  | 47 |  |  | 34 | \nExpected return on plan assets | (16) |  |  | (21) |  |  | (48) |  |  | (64) | \nAmortization of unrecognized prior service credit | (12) |  |  | (14) |  |  | (37) |  |  | (42) | \nNet gain amortization | (11) |  |  | (11) |  |  | (31) |  |  | (32) | \n |  |  |  |  |  |  | \nCurtailments | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) | \n | $ | (15) |  |  | $ | (24) |  |  | $ | (46) |  |  | $ | (69) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nInterest income | $ | (73) |  |  | $ | (40) |  |  | $ | (295) |  |  | $ | (62) | \nInterest expense | 317 |  |  | 244 |  |  | 836 |  |  | 727 | \nExchange losses | 85 |  |  | 96 |  |  | 208 |  |  | 220 | \nLoss (income) from investments in equity securities, net(1) | 33 |  |  | 371 |  |  | (240) |  |  | 1,361 | \nNet periodic defined benefit plan (credit) cost other than service cost | (138) |  |  | (60) |  |  | (364) |  |  | (208) | \nOther, net | (98) |  |  | (182) |  |  | 243 |  |  | (462) | \n | $ | 126 |  |  | $ | 429 |  |  | $ | 388 |  |  | $ | 1,576 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ and shares in millions except per share amounts) | 2023 |  | 2022 |  | 2023 |  | 2022\nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,745 |  |  | $ | 3,248 |  |  | $ | 1,591 |  |  | $ | 11,502 | \nAverage common shares outstanding | 2,537 |  |  | 2,533 |  |  | 2,538 |  |  | 2,531 | \nCommon shares issuable(1) | 9 |  |  | 9 |  |  | 11 |  |  | 9 | \nAverage common shares outstanding assuming dilution | 2,546 |  |  | 2,542 |  |  | 2,549 |  |  | 2,540 | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | $ | 1.87 |  |  | $ | 1.28 |  |  | $ | 0.63 |  |  | $ | 4.55 | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | $ | 1.86 |  |  | $ | 1.28 |  |  | $ | 0.62 |  |  | $ | 4.53 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance July 1, 2022, net of taxes | $ | 390 |  |  | $ | (2,465) |  |  | $ | (2,252) |  |  | $ | (4,327) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 682 |  |  | (294) |  |  | (618) |  |  | (230) | \nTax | (143) |  |  | 62 |  |  | 50 |  |  | (31) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 539 |  |  | (232) |  |  | (568) |  |  | (261) | \nReclassification adjustments, pretax | (254) |  | (1) | 77 |  | (2) | \u2014 |  |  | (177) | \nTax | 53 |  |  | (31) |  |  | \u2014 |  |  | 22 | \nReclassification adjustments, net of taxes | (201) |  |  | 46 |  |  | \u2014 |  |  | (155) | \nOther comprehensive income (loss), net of taxes | 338 |  |  | (186) |  |  | (568) |  |  | (416) | \nBalance September 30, 2022, net of taxes | $ | 728 |  |  | $ | (2,651) |  |  | $ | (2,820) |  |  | $ | (4,743) | \nBalance July 1, 2023, net of taxes | $ | 85 |  |  | $ | (2,483) |  |  | $ | (2,502) |  |  | $ | (4,900) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 247 |  |  | 29 |  |  | (252) |  |  | 24 | \nTax | (52) |  |  | (7) |  |  | 77 |  |  | 18 | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 195 |  |  | 22 |  |  | (175) |  |  | 42 | \nReclassification adjustments, pretax | (45) |  | (1) | (27) |  | (2) | \u2014 |  |  | (72) | \nTax | 9 |  |  | 5 |  |  | \u2014 |  |  | 14 | \nReclassification adjustments, net of taxes | (36) |  |  | (22) |  |  | \u2014 |  |  | (58) | \nOther comprehensive income (loss), net of taxes | 159 |  |  | \u2014 |  |  | (175) |  |  | (16) | \nBalance September 30, 2023, net of taxes | $ | 244 |  |  | $ | (2,483) |  |  | $ | (2,677) |  |  | $ | (4,916) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance January 1, 2022, net of taxes | $ | 144 |  |  | $ | (2,743) |  |  | $ | (1,830) |  |  | $ | (4,429) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 1,233 |  |  | (125) |  |  | (1,001) |  |  | 107 | \nTax | (259) |  |  | 25 |  |  | 11 |  |  | (223) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 974 |  |  | (100) |  |  | (990) |  |  | (116) | \nReclassification adjustments, pretax | (493) |  | (1) | 266 |  | (2) | \u2014 |  |  | (227) | \nTax | 103 |  |  | (74) |  |  | \u2014 |  |  | 29 | \nReclassification adjustments, net of taxes | (390) |  |  | 192 |  |  | \u2014 |  |  | (198) | \nOther comprehensive income (loss), net of taxes | 584 |  |  | 92 |  |  | (990) |  |  | (314) | \nBalance September 30, 2022, net of taxes | $ | 728 |  |  | $ | (2,651) |  |  | $ | (2,820) |  |  | $ | (4,743) | \nBalance January 1, 2023, net of taxes | $ | 73 |  |  | $ | (2,408) |  |  | $ | (2,433) |  |  | $ | (4,768) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 375 |  |  | (24) |  |  | (288) |  |  | 63 | \nTax | (79) |  |  | (4) |  |  | 35 |  |  | (48) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 296 |  |  | (28) |  |  | (253) |  |  | 15 | \nReclassification adjustments, pretax | (158) |  | (1) | (57) |  | (2) | 9 |  |  | (206) | \nTax | 33 |  |  | 10 |  |  | \u2014 |  |  | 43 | \nReclassification adjustments, net of taxes | (125) |  |  | (47) |  |  | 9 |  |  | (163) | \nOther comprehensive income (loss), net of taxes | 171 |  |  | (75) |  |  | (244) |  |  | (148) | \nBalance September 30, 2023, net of taxes | $ | 244 |  |  | $ | (2,483) |  |  | $ | (2,677) |  |  | $ | (4,916) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\n($ in millions) | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total\nPharmaceutical: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nKeytruda | $ | 3,795 |  |  | $ | 2,543 |  |  | $ | 6,338 |  |  | $ | 3,331 |  |  | $ | 2,095 |  |  | $ | 5,426 |  |  | $ | 11,142 |  |  | $ | 7,261 |  |  | $ | 18,403 |  |  | $ | 9,307 |  |  | $ | 6,180 |  |  | $ | 15,487 | \nAlliance revenue-Lynparza(1) | 153 |  |  | 146 |  |  | 299 |  |  | 144 |  |  | 140 |  |  | 284 |  |  | 439 |  |  | 445 |  |  | 884 |  |  | 427 |  |  | 397 |  |  | 825 | \nAlliance revenue-Lenvima(1) | 160 |  |  | 100 |  |  | 260 |  |  | 142 |  |  | 60 |  |  | 202 |  |  | 476 |  |  | 258 |  |  | 734 |  |  | 426 |  |  | 235 |  |  | 660 | \nWelireg | 51 |  |  | 3 |  |  | 54 |  |  | 38 |  |  | \u2014 |  |  | 38 |  |  | 141 |  |  | 6 |  |  | 146 |  |  | 83 |  |  | \u2014 |  |  | 83 | \nAlliance revenue-Reblozyl(2) | 43 |  |  | 10 |  |  | 52 |  |  | 32 |  |  | 7 |  |  | 39 |  |  | 108 |  |  | 33 |  |  | 142 |  |  | 87 |  |  | 37 |  |  | 124 | \nVaccines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | 838 |  |  | 1,746 |  |  | 2,585 |  |  | 957 |  |  | 1,337 |  |  | 2,294 |  |  | 1,718 |  |  | 5,297 |  |  | 7,015 |  |  | 1,803 |  |  | 3,624 |  |  | 5,428 | \nProQuad/M-M-RII/Varivax | 567 |  |  | 146 |  |  | 713 |  |  | 532 |  |  | 136 |  |  | 668 |  |  | 1,435 |  |  | 388 |  |  | 1,823 |  |  | 1,337 |  |  | 379 |  |  | 1,716 | \nRotaTeq | 108 |  |  | 48 |  |  | 156 |  |  | 154 |  |  | 102 |  |  | 256 |  |  | 381 |  |  | 203 |  |  | 584 |  |  | 427 |  |  | 218 |  |  | 644 | \nVaxneuvance | 182 |  |  | 33 |  |  | 214 |  |  | 15 |  |  | 1 |  |  | 16 |  |  | 423 |  |  | 65 |  |  | 488 |  |  | 31 |  |  | 1 |  |  | 32 | \nPneumovax23 | 42 |  |  | 98 |  |  | 140 |  |  | 68 |  |  | 63 |  |  | 131 |  |  | 105 |  |  | 223 |  |  | 327 |  |  | 280 |  |  | 177 |  |  | 457 | \nVaqta | 32 |  |  | 37 |  |  | 69 |  |  | 27 |  |  | 36 |  |  | 64 |  |  | 91 |  |  | 60 |  |  | 151 |  |  | 72 |  |  | 62 |  |  | 134 | \nHospital Acute Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBridion | 265 |  |  | 159 |  |  | 424 |  |  | 233 |  |  | 190 |  |  | 423 |  |  | 841 |  |  | 572 |  |  | 1,413 |  |  | 665 |  |  | 579 |  |  | 1,244 | \nPrevymis | 70 |  |  | 87 |  |  | 157 |  |  | 49 |  |  | 64 |  |  | 114 |  |  | 186 |  |  | 244 |  |  | 430 |  |  | 136 |  |  | 174 |  |  | 310 | \nDificid | 69 |  |  | 5 |  |  | 74 |  |  | 72 |  |  | 6 |  |  | 77 |  |  | 199 |  |  | 16 |  |  | 215 |  |  | 184 |  |  | 12 |  |  | 196 | \nPrimaxin | \u2014 |  |  | 41 |  |  | 41 |  |  | \u2014 |  |  | 63 |  |  | 63 |  |  | 2 |  |  | 173 |  |  | 174 |  |  | 1 |  |  | 185 |  |  | 185 | \nNoxafil | 4 |  |  | 47 |  |  | 51 |  |  | 13 |  |  | 49 |  |  | 62 |  |  | 29 |  |  | 138 |  |  | 167 |  |  | 39 |  |  | 141 |  |  | 180 | \nZerbaxa | 29 |  |  | 24 |  |  | 53 |  |  | 24 |  |  | 19 |  |  | 43 |  |  | 86 |  |  | 71 |  |  | 157 |  |  | 64 |  |  | 55 |  |  | 120 | \nCardiovascular |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue-Adempas/Verquvo(3) | 96 |  |  | (4) |  |  | 92 |  |  | 85 |  |  | 3 |  |  | 88 |  |  | 249 |  |  | 10 |  |  | 259 |  |  | 244 |  |  | 14 |  |  | 258 | \nAdempas | \u2014 |  |  | 65 |  |  | 65 |  |  | \u2014 |  |  | 57 |  |  | 57 |  |  | \u2014 |  |  | 189 |  |  | 189 |  |  | \u2014 |  |  | 181 |  |  | 181 | \nVirology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLagevrio | \u2014 |  |  | 640 |  |  | 640 |  |  | \u2014 |  |  | 436 |  |  | 436 |  |  | \u2014 |  |  | 1,236 |  |  | 1,236 |  |  | 1,523 |  |  | 3,336 |  |  | 4,859 | \nIsentress/IsentressHD | 58 |  |  | 61 |  |  | 119 |  |  | 68 |  |  | 93 |  |  | 161 |  |  | 165 |  |  | 212 |  |  | 377 |  |  | 196 |  |  | 270 |  |  | 466 | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBelsomra | 23 |  |  | 35 |  |  | 58 |  |  | 20 |  |  | 42 |  |  | 62 |  |  | 60 |  |  | 117 |  |  | 176 |  |  | 60 |  |  | 139 |  |  | 199 | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSimponi | \u2014 |  |  | 179 |  |  | 179 |  |  | \u2014 |  |  | 173 |  |  | 173 |  |  | \u2014 |  |  | 539 |  |  | 539 |  |  | \u2014 |  |  | 540 |  |  | 540 | \nRemicade | \u2014 |  |  | 45 |  |  | 45 |  |  | \u2014 |  |  | 49 |  |  | 49 |  |  | \u2014 |  |  | 144 |  |  | 144 |  |  | \u2014 |  |  | 163 |  |  | 163 | \nDiabetes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nJanuvia | 328 |  |  | 252 |  |  | 581 |  |  | 332 |  |  | 385 |  |  | 717 |  |  | 842 |  |  | 800 |  |  | 1,642 |  |  | 958 |  |  | 1,294 |  |  | 2,252 | \nJanumet | 43 |  |  | 211 |  |  | 255 |  |  | 90 |  |  | 327 |  |  | 417 |  |  | 182 |  |  | 755 |  |  | 937 |  |  | 258 |  |  | 1,089 |  |  | 1,347 | \nOther pharmaceutical(4) | 197 |  |  | 353 |  |  | 549 |  |  | 194 |  |  | 410 |  |  | 603 |  |  | 540 |  |  | 1,147 |  |  | 1,690 |  |  | 511 |  |  | 1,225 |  |  | 1,736 | \nTotal Pharmaceutical segment sales | 7,153 |  |  | 7,110 |  |  | 14,263 |  |  | 6,620 |  |  | 6,343 |  |  | 12,963 |  |  | 19,840 |  |  | 20,602 |  |  | 40,442 |  |  | 19,119 |  |  | 20,707 |  |  | 39,826 | \nAnimal Health: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLivestock | 205 |  |  | 669 |  |  | 874 |  |  | 186 |  |  | 643 |  |  | 829 |  |  | 543 |  |  | 1,987 |  |  | 2,530 |  |  | 521 |  |  | 1,965 |  |  | 2,486 | \nCompanion Animal | 257 |  |  | 269 |  |  | 526 |  |  | 289 |  |  | 253 |  |  | 542 |  |  | 875 |  |  | 942 |  |  | 1,817 |  |  | 904 |  |  | 929 |  |  | 1,834 | \nTotal Animal Health segment sales | 462 |  |  | 938 |  |  | 1,400 |  |  | 475 |  |  | 896 |  |  | 1,371 |  |  | 1,418 |  |  | 2,929 |  |  | 4,347 |  |  | 1,425 |  |  | 2,894 |  |  | 4,320 | \nTotal segment sales | 7,615 |  |  | 8,048 |  |  | 15,663 |  |  | 7,095 |  |  | 7,239 |  |  | 14,334 |  |  | 21,258 |  |  | 23,531 |  |  | 44,789 |  |  | 20,544 |  |  | 23,601 |  |  | 44,146 | \nOther(5) | 100 |  |  | 199 |  |  | 299 |  |  | 227 |  |  | 398 |  |  | 625 |  |  | 135 |  |  | 561 |  |  | 696 |  |  | 383 |  |  | 925 |  |  | 1,307 | \n | $ | 7,715 |  |  | $ | 8,247 |  |  | $ | 15,962 |  |  | $ | 7,322 |  |  | $ | 7,637 |  |  | $ | 14,959 |  |  | $ | 21,393 |  |  | $ | 24,092 |  |  | $ | 45,485 |  |  | $ | 20,927 |  |  | $ | 24,526 |  |  | $ | 45,453 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nUnited States | $ | 7,715 |  |  | $ | 7,322 |  |  | $ | 21,393 |  |  | $ | 20,927 | \nEurope, Middle East and Africa | 3,327 |  |  | 3,286 |  |  | 9,978 |  |  | 11,228 | \nChina | 1,694 |  |  | 1,442 |  |  | 5,322 |  |  | 3,957 | \nJapan | 1,081 |  |  | 673 |  |  | 2,514 |  |  | 2,776 | \nAsia Pacific (other than China and Japan) | 781 |  |  | 854 |  |  | 2,475 |  |  | 2,792 | \nLatin America | 895 |  |  | 684 |  |  | 2,298 |  |  | 1,933 | \nOther | 469 |  |  | 698 |  |  | 1,505 |  |  | 1,840 | \n | $ | 15,962 |  |  | $ | 14,959 |  |  | $ | 45,485 |  |  | $ | 45,453 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nSegment profits: |  |  |  |  |  |  | \nPharmaceutical segment | $ | 10,407 |  |  | $ | 9,590 |  |  | $ | 29,400 |  |  | $ | 28,263 | \nAnimal Health segment | 421 |  |  | 515 |  |  | 1,453 |  |  | 1,672 | \nTotal segment profits | 10,828 |  |  | 10,105 |  |  | 30,853 |  |  | 29,935 | \nOther profits | 190 |  |  | 377 |  |  | 374 |  |  | 831 | \nUnallocated: |  |  |  |  |  |  | \nInterest income | 73 |  |  | 40 |  |  | 295 |  |  | 62 | \nInterest expense | (317) |  |  | (244) |  |  | (836) |  |  | (727) | \nAmortization | (562) |  |  | (460) |  |  | (1,582) |  |  | (1,623) | \nDepreciation | (401) |  |  | (448) |  |  | (1,175) |  |  | (1,257) | \nResearch and development | (3,183) |  |  | (4,277) |  |  | (20,523) |  |  | (9,374) | \nRestructuring costs | (126) |  |  | (94) |  |  | (344) |  |  | (288) | \nCharge for Zetia antitrust litigation settlements | \u2014 |  |  | \u2014 |  |  | (573) |  |  | \u2014 | \nOther unallocated, net | (882) |  |  | (1,416) |  |  | (2,554) |  |  | (4,628) | \n | $ | 5,620 |  |  | $ | 3,583 |  |  | $ | 3,935 |  |  | $ | 12,931 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange |  | Nine Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nUnited States | $ | 7,715 |  |  | $ | 7,322 |  |  | 5 | % |  | 5 | % |  | $ | 21,393 |  |  | $ | 20,927 |  |  | 2 | % |  | 2 | %\nInternational | 8,247 |  |  | 7,637 |  |  | 8 | % |  | 12 | % |  | 24,092 |  |  | 24,526 |  |  | (2) | % |  | 4 | %\nTotal | $ | 15,962 |  |  | $ | 14,959 |  |  | 7 | % |  | 9 | % |  | $ | 45,485 |  |  | $ | 45,453 |  |  | \u2014 | % |  | 3 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange |  | Nine Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nKeytruda | $ | 6,338 |  |  | $ | 5,426 |  |  | 17 | % |  | 17 | % |  | $ | 18,403 |  |  | $ | 15,487 |  |  | 19 | % |  | 21 | %\nAlliance Revenue - Lynparza(1) | 299 |  |  | 284 |  |  | 5 | % |  | 6 | % |  | 884 |  |  | 825 |  |  | 7 | % |  | 10 | %\nAlliance Revenue-Lenvima(1) | 260 |  |  | 202 |  |  | 29 | % |  | 30 | % |  | 734 |  |  | 660 |  |  | 11 | % |  | 13 | %\nWelireg | 54 |  |  | 38 |  |  | 43 | % |  | 43 | % |  | 146 |  |  | 83 |  |  | 77 | % |  | 77 | %\nAlliance Revenue-Reblozyl(2) | 52 |  |  | 39 |  |  | 35 | % |  | 35 | % |  | 142 |  |  | 124 |  |  | 14 | % |  | 14 | %  |  |  |  |  | \nDate | Approval\nJanuary 2023 | U.S. Food and Drug Administration (FDA) approval as a single agent for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a \u22654 cm), II, or IIIA NSCLC, based on the KEYNOTE-091 trial.\nMarch 2023 | FDA full approval for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. The conversion from an accelerated to a full (regular) approval is based on the KEYNOTE-158, KEYNOTE-164 and KEYNOTE-051 trials.\nApril 2023 | FDA accelerated approval in combination with enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy, based on the KEYNOTE-869 trial dose escalation cohort, Cohort A and Cohort K, which was conducted in collaboration with Seagen and Astellas.\nJune 2023 | Japan\u2019s Ministry of Health, Labor and Welfare (MHLW) approval for the treatment of patients with relapsed or refractory PMBCL, based on the KEYNOTE-170 and the KEYNOTE-A33 studies.\nAugust 2023 | European Commission (EC) approval in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or GEJ adenocarcinoma in adults whose tumors express PD-L1, based on the KEYNOTE-811 trial.\nOctober 2023 | EC approval as a monotherapy for the adjuvant treatment of adults with NSCLC who are at high risk of recurrence following complete resection and platinum-based chemotherapy, based on the KEYNOTE-091 trial.\nOctober 2023 | FDA approval for the treatment of patients with resectable (tumors >=4cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery, based on the KEYNOTE-671 trial.\nOctober 2023 | FDA full approval for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. The conversion from an accelerated to a full (regular) approval is based on the KEYNOTE-913 and KEYNOTE-017 trials.\nOctober 2023 | FDA approval in combination with gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer, based on the KEYNOTE-966 trial.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange |  | Nine Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nGardasil/Gardasil9 | $ | 2,585 |  |  | $ | 2,294 |  |  | 13 | % |  | 16 | % |  | $ | 7,015 |  |  | $ | 5,428 |  |  | 29 | % |  | 34 | %\nProQuad | 267 |  |  | 264 |  |  | 1 | % |  | 1 | % |  | 678 |  |  | 640 |  |  | 6 | % |  | 6 | %\nM-M-RII | 122 |  |  | 124 |  |  | (2) | % |  | (4) | % |  | 329 |  |  | 330 |  |  | \u2014 | % |  | (1) | %\nVarivax | 325 |  |  | 280 |  |  | 16 | % |  | 15 | % |  | 816 |  |  | 746 |  |  | 9 | % |  | 10 | %\nRotaTeq | 156 |  |  | 256 |  |  | (39) | % |  | (39) | % |  | 584 |  |  | 644 |  |  | (9) | % |  | (8) | %\nVaxneuvance | 214 |  |  | 16 |  |  | * |  | * |  | 488 |  |  | 32 |  |  | * |  | *\nPneumovax 23 | 140 |  |  | 131 |  |  | 6 | % |  | 4 | % |  | 327 |  |  | 457 |  |  | (28) | % |  | (27) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange |  | Nine Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nBridion | $ | 424 |  |  | $ | 423 |  |  | \u2014 | % |  | \u2014 | % |  | $ | 1,413 |  |  | $ | 1,244 |  |  | 14 | % |  | 15 | %\nPrevymis | 157 |  |  | 114 |  |  | 38 | % |  | 38 | % |  | 430 |  |  | 310 |  |  | 39 | % |  | 41 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange |  | Nine Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nAlliance Revenue - Adempas/Verquvo(1) | $ | 92 |  |  | $ | 88 |  |  | 5 | % |  | 5 | % |  | $ | 259 |  |  | $ | 258 |  |  | \u2014 | % |  | \u2014 | %\nAdempas | 65 |  |  | 57 |  |  | 15 | % |  | 11 | % |  | 189 |  |  | 181 |  |  | 5 | % |  | 7 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange |  | Nine Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nLagevrio | $ | 640 |  |  | $ | 436 |  |  | 47 | % |  | 51 | % |  | $ | 1,236 |  |  | $ | 4,859 |  |  | (75) | % |  | (73) | %\nIsentress/Isentress HD | 119 |  |  | 161 |  |  | (27) | % |  | (27) | % |  | 377 |  |  | 466 |  |  | (19) | % |  | (17) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange |  | Nine Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nJanuvia/Janumet | $ | 835 |  |  | $ | 1,133 |  |  | (26) | % |  | (25) | % |  | $ | 2,579 |  |  | $ | 3,599 |  |  | (28) | % |  | (26) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange |  | Nine Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nLivestock | $ | 874 |  |  | $ | 829 |  |  | 5 | % |  | 7 | % |  | $ | 2,530 |  |  | $ | 2,486 |  |  | 2 | % |  | 6 | %\nCompanion Animal | 526 |  |  | 542 |  |  | (3) | % |  | (4) | % |  | 1,817 |  |  | 1,834 |  |  | (1) | % |  | \u2014 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | Nine Months EndedSeptember 30, |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  | 2023 |  | 2022 |  | % Change\nCost of sales | $ | 4,264 |  |  | $ | 3,934 |  |  | 8 | % |  | $ | 12,214 |  |  | $ | 13,530 |  |  | (10) | %\nSelling, general and administrative | 2,519 |  |  | 2,520 |  |  | \u2014 | % |  | 7,700 |  |  | 7,355 |  |  | 5 | %\nResearch and development | 3,307 |  |  | 4,399 |  |  | (25) | % |  | 20,904 |  |  | 9,773 |  |  | *\nRestructuring costs | 126 |  |  | 94 |  |  | 34 | % |  | 344 |  |  | 288 |  |  | 19 | %\nOther (income) expense, net | 126 |  |  | 429 |  |  | (71) | % |  | 388 |  |  | 1,576 |  |  | (75) | %\n | $ | 10,342 |  |  | $ | 11,376 |  |  | (9) | % |  | $ | 41,550 |  |  | $ | 32,522 |  |  | 28 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSegment Profits |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nPharmaceutical segment profits | $ | 10,407 |  |  | $ | 9,590 |  |  | $ | 29,400 |  |  | $ | 28,263 | \nAnimal Health segment profits | 421 |  |  | 515 |  |  | 1,453 |  |  | 1,672 | \nOther | (5,208) |  |  | (6,522) |  |  | (26,918) |  |  | (17,004) | \nIncome Before Taxes | $ | 5,620 |  |  | $ | 3,583 |  |  | $ | 3,935 |  |  | $ | 12,931 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions except per share amounts) | 2023 |  | 2022 |  | 2023 |  | 2022\nIncome before taxes as reported under GAAP | $ | 5,620 |  |  | $ | 3,583 |  |  | $ | 3,935 |  |  | $ | 12,931 | \nIncrease (decrease) for excluded items: |  |  |  |  |  |  | \nAcquisition- and divestiture-related costs | 555 |  |  | 1,344 |  |  | 1,643 |  |  | 2,512 | \nRestructuring costs | 199 |  |  | 175 |  |  | 532 |  |  | 559 | \nLoss (income) from investments in equity securities, net | 17 |  |  | 350 |  |  | (218) |  |  | 1,268 | \nOther items: |  |  |  |  |  |  | \nCharge for Zetia antitrust litigation settlements | \u2014 |  |  | \u2014 |  |  | 573 |  |  | \u2014 | \nNon-GAAP income before taxes | 6,391 |  |  | 5,452 |  |  | 6,465 |  |  | 17,270 | \nIncome tax provision as reported under GAAP | 870 |  |  | 330 |  |  | 2,332 |  |  | 1,423 | \nEstimated tax benefit on excluded items(1) | 89 |  |  | 414 |  |  | 350 |  |  | 965 | \nNon-GAAP income tax provision | 959 |  |  | 744 |  |  | 2,682 |  |  | 2,388 | \nNon-GAAP net income | 5,432 |  |  | 4,708 |  |  | 3,783 |  |  | 14,882 | \nLess: Net income attributable to noncontrolling interests as reported under GAAP | 5 |  |  | 5 |  |  | 12 |  |  | 6 | \nNon-GAAP net income attributable to Merck\u00a0& Co., Inc. | $ | 5,427 |  |  | $ | 4,703 |  |  | $ | 3,771 |  |  | $ | 14,876 | \nEPS assuming dilution as reported under GAAP(2) | $ | 1.86 |  |  | $ | 1.28 |  |  | $ | 0.62 |  |  | $ | 4.53 | \nEPS difference | 0.27 |  |  | 0.57 |  |  | 0.86 |  |  | 1.33 | \nNon-GAAP EPS assuming dilution(2) | $ | 2.13 |  |  | $ | 1.85 |  |  | $ | 1.48 |  |  | $ | 5.86 |   |  |  |  |  |  |  |  | \nPhase 2\nCancerMK-1308 (quavonlimab)(2)Non-Small-Cell LungMK-1308A (quavonlimab+pembrolizumab)ColorectalSmall-Cell LungMK-2140 (zilovertamab vedotin)BladderBreastGastricHematological MalignanciesNon-Small-Cell LungOvarianPancreaticMK-2400 (ifinatamab deruxtecan)(1)Small-Cell LungMK-2870(1)(3)Neoplasm MalignantMK-3475KeytrudaAdvanced Solid TumorsProstateMK-3475A (pembrolizumab+hyaluronidase subcutaneous)Cutaneous Squamous CellMK-3543 (bomedemstat)Myeloproliferative DisordersMK-4280 (favezelimab)(2)Non-Small-Cell LungMK-4280A (favezelimab+pembrolizumab)BladderCutaneous Squamous CellEsophagealMelanomaRenal CellSmall-Cell LungMK-4830(2)ColorectalEsophagealMelanomaNon-Small-Cell LungOvarianRenal CellSmall-Cell Lung | CancerMK-5684(1)ProstateMK-5890 (boserolimab)(2)Non-Small-Cell LungSmall-Cell LungMK-6482Welireg(3)BiliaryColorectalEndometrialEsophagealHepatocellularPancreaticRare cancersVon Hippel-Lindau Disease-Associated Tumors (EU)MK-7119 Tukysa(1)Advanced Solid TumorsBiliaryBladderCervicalEndometrialGastricNon-Small-Cell LungMK-7339 Lynparza(1)(3)Advanced Solid TumorsMK-7684A (vibostolimab+pembrolizumab)BiliaryBladderBreastCervicalColorectalEndometrialEsophagealGastricHead and NeckHepatocellularOvarianProstate | CancerMK-7902 Lenvima(1)(2)BiliaryHead and NeckPancreaticProstateSmall-Cell LungDengue Fever Virus VaccineV181HIV-1 InfectionMK-8591B (islatravir+MK-8507)(4)MK-8591D (islatravir+lenacapavir)(1)(5)Nonalcoholic Steatohepatitis (NASH)MK-6024 (efinopegdutide)Pulmonary Arterial HypertensionMK-5475Pulmonary Hypertension Due To Left Heart DiseaseMK-7962 (sotatercept)SchizophreniaMK-8189(6)ThrombosisMK-2060  |  |  |  |  |  |  |  | \nPhase 3 (Phase 3 entry date) | Under Review\nAntiviral COVID-19MK-4482Lagevrio(U.S.) (May 2021)(1)(7)CancerMK-1022 (patritumab deruxtecan)(1)Non-Small-Cell Lung (May 2022)MK-1026 (nemtabrutinib)Hematological Malignancies (March 2023)MK-1308A (quavonlimab+pembrolizumab)Renal Cell (April 2021)MK-3475KeytrudaCutaneous Squamous Cell (August 2019) (EU)Hepatocellular (May 2016) (EU)Mesothelioma (May 2018)Ovarian (December 2018)Small-Cell Lung (May 2017)MK-3475A (pembrolizumab+hyaluronidase subcutaneous)Non-Small-Cell Lung (February 2023)MK-4280A (favezelimab+pembrolizumab)Colorectal (November 2021)Hematological Malignancies (October 2022)MK-6482Welireg(3)Renal Cell (EU) (February 2020)MK-7119 Tukysa(1)Breast (October 2019)Colorectal (August 2022)MK-7339 Lynparza(2)Non-Small-Cell Lung (June 2019)Small-Cell Lung (December 2020)MK-7684A (vibostolimab+pembrolizumab)Melanoma (January 2023)Non-Small-Cell Lung (April 2021)Small-Cell Lung (March 2022)MK-7902 Lenvima(1)(2)Esophageal (July 2021)Gastric (December 2020)V940(1)(2)Melanoma (July 2023)HIV-1 InfectionMK-8591A (doravirine+islatravir) (February 2020)(5)HypercholesterolemiaMK-0616 (August 2023)Pneumococcal Vaccine AdultV116 (July 2022)Pulmonary Arterial HypertensionMK-7962 (sotatercept) (EU) (January 2021)Respiratory Syncytial VirusMK-1654 (clesrovimab) (November 2021)Ulcerative ColitisMK-7240 (October 2023) | New Molecular EntitiesCoughMK-7264 (gefapixant) (U.S.)(8)Pulmonary Arterial HypertensionMK-7962 (sotatercept) U.S. | Certain Supplemental FilingsCancerMK-3475Keytruda\u2022    Second-Line Hepatocellular Carcinoma(KEYNOTE-394) (U.S.)\u2022    High-Risk Locally Advanced Cervical Cancer(KEYNOTE-A18) (U.S.)\u2022    First-Line HER2 Negative Locally Advanced Unresectable or Metastatic Gastric Cancer(KEYNOTE-859) (U.S.) (EU) (JPN)\u2022    First-Line Locally Advanced Unresectable or Metastatic Biliary Tract Cancer(KEYNOTE-966) (EU) (JPN)\u2022    Resectable Stage II, IIIA or IIIB NSCLC(KEYNOTE-671) (EU) (JPN)MK-6482Welireg\u2022    Previously Treated Advanced Renal Cell Carcinoma(LIGHTSPARK-005) (U.S.)\nFootnotes:(1)Being developed in a collaboration.(2)Being developed in combination withKeytruda.(3)Being developed as monotherapy and/or in combination withKeytruda.(4)On FDA clinical hold.(5)On FDA partial clinical hold for higher doses than those used in current clinical trials.(6)Phase 2b development costs are being co-funded.(7)Available in the U.S. under Emergency Use Authorization.(8)In July 2023, the FDA accepted Merck\u2019s resubmission of the NDA for gefapixant following the Company\u2019s response to the CRL received in January 2022.  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | September 30, 2023 |  | December 31, 2022\nCash and investments | $ | 10,079 |  |  | $ | 14,207 | \nWorking capital | 8,860 |  |  | 11,483 | \nTotal debt to total liabilities and equity | 32.7 | % |  | 28.1 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | ($\u00a0in\u00a0millions)\nPeriod | Total\u00a0Numberof SharesPurchased(1) |  | Average\u00a0PricePaid PerShare |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0SharesThat May Yet Be PurchasedUnder the Plans or Programs(1)\nJuly 1 - July 31 | 1,918,488 |  |  | $108.79 |  | 1,918,488 |  |  | $4,351\nAugust 1 - August 31 | 1,450,550 |  |  | $106.99 |  | 1,450,550 |  |  | $4,196\nSeptember 1 - September 30 | 950,239 |  |  | $107.33 |  | 950,239 |  |  | $4,094\nTotal | 4,319,277 |  |  | $107.86 |  | 4,319,277 |  |  |   |  |  |  |  |  |  |  | \nNumber |  | Description\n | \n3.1 | \u2014 | Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) \u2013 Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on November\u00a04, 2009 (No. 1-6571)\n | \n3.2 | \u2014 | By-Laws of Merck & Co., Inc. (effective March 22, 2022) \u2013 Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)\n |  | \n31.1 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Executive Officer\n | \n31.2 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Financial Officer\n | \n32.1 |  | \u2014 | Section 1350 Certification of Chief Executive Officer\n | \n32.2 |  | \u2014 | Section 1350 Certification of Chief Financial Officer\n | \n101.INS | \u2014 | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.\n |  | \n101.SCH | \u2014 | XBRL Taxonomy Extension Schema Document.\n |  | \n101.CAL | \u2014 | XBRL Taxonomy Extension Calculation Linkbase Document.\n |  | \n101.DEF | \u2014 | XBRL Taxonomy Extension Definition Linkbase Document.\n |  | \n101.LAB | \u2014 | XBRL Taxonomy Extension Label Linkbase Document.\n |  | \n101.PRE | \u2014 | XBRL Taxonomy Extension Presentation Linkbase Document.\n |  | \n104 |  | \u2014 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).  |  |  |  |  |  |  |  | \n |  | MERCK & CO., INC.\n |  | \nDate:  November 3, 2023 |  | /s/ Jennifer Zachary\n |  | JENNIFER ZACHARY\n |  | Executive Vice President and General Counsel\n |  | \nDate:  November 3, 2023 |  | /s/ Rita A. Karachun\n |  | RITA A. KARACHUN\n |  | Senior Vice President Finance - Global Controller"}]}
